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Abstract 
Organophosphorus (OP) pesticides are widely used despite evidence they cause 
neurotoxicity after exposure. The primary target for OPs is acetylcholinesterase, but there 
is evidence they can inhibit other cellular proteins including cytoskeletal and axon growth 
associated proteins, which are implicated in nervous system development. Furthermore, 
little is known about the ability of OPs to cause genotoxicity.  
The objectives of this study were to evaluate the effects of selected OPs on neurite 
outgrowth, expression of cytoskeletal proteins and associated gene expression levels, and 
to investigate histone deacetylation (HDAC) activity in three types of differentiating cell 
models. The initial findings indicated that cell viability was unaffected by exposure to 1, 3 
and 10 µM CPF, CPO and PSP in N2a and C6 cells. A high content assay was sensitive 
enough to rapidly detect and quantify morphological changes, including inhibition of 
neurite number and length. 
Western blot and ELISA analysis in N2a and C6 cells revealed reduced levels of the 
selected cytoskeletal and associated regulatory proteins (MAP-2, Tau, βIII-tubulin, GAP-
43, NFH and GFAP) following the treatment with at least one concentration of CPF, CPO 
and PSP, which could be linked to the inhibition of neurite outgrowth. Using quantitative 
RT-PCR analysis on the total RNA of the genes MAP-2, TUBB3, MAPT, NEFH, GAP-43, 
and GFAP showed a good correlation between the altered protein expression and 
regulation of gene levels for most markers, which suggests these OPs can cause genotoxic 
effects. Increased levels of HDAC activity were observed for all OPs in rodent cell lines, 
suggesting that epigenetic effects may be at least partly involved in some gene expression 
changes.  
RT-PCR analysis of TUBB3, NEFH, and GFAP was also carried out in ReNcell CX cells, a 
co-culture of neuronal and glial cells, and showed down-regulation of gene levels for at 
least one concentration of all the OPs, as well as increasing the level of HDAC activity in a 
similar pattern to the results for N2a and C6 cells.  
Taken together, the data in this thesis suggest a novel action of OPs altering HDAC 
activity, which can be correlated to some of the observed changes in gene and protein 
levels of selected cytoskeletal and associated regulatory proteins that can be linked to the 
observed disruption of neurite outgrowth and neural development. Further work is needed 
to identify other molecular targets invoved in these phenomena, particularly when there is 
no correlation with HDAC activity changes. 
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1.1 Major cell types in the nervous system 
The nervous system in mammals is composed of two main cell types, the glial and neuronal 
cells, both of which play important roles in the regulation of neural function. Neuronal cells 
are involved in the transmission of information to neighbouring cells, which may be either 
neurons or effector cells, via electrical impulses that travel along axons (Alberts et al., 
1983). Glial cells do not play a direct role in such information processing; their main roles 
include providing structural, homeostatic, and defensive support to neurons (Barone et al., 
2000).  These functionally and morphologically distinct cells act together to sustain the 
correct functioning of the nervous system; it is therefore important to understand the basic 
properties of these cells in order to better understand the effects of neurotoxins in vivo 
(Brown, 1991).   
1.1.1 Neurons 
As neurons regulate neurotransmission, any effect of a neurotoxin on this cell type may 
have a large effect on the nervous system. Neurons are responsible for the perception of and 
response to stimuli, and they also transmit cellular signals to other neighbouring cells 
through synaptic transmission (Barres and Barde, 2000). Neurons are highly polarised cells 
that produce dendrites and axons upon differentiation. The structural and morphological 
features of axons reflect their role in neurotransmission and the need for a system to 
mediate axonal transport (Barres and Barde, 2000). 
The structure of the differentiated neuronal cells displays three key features: the growth 
cone, axon and cell body. Within the cell body are located the nucleus and the cytoplasmic 
organelles including ribosomes and the endomembrane system (Wilson and Hunt, 2014). 
The axon is a long projection that extends from the cell body; this structure is vital for 
neurotransmission and axonal transport. The actual length of the axon varies and can 
measure up to one thousand times longer than the cell body (Alberts et al., 1983). Further 
information about these morphological features can be determined by studying cultured 
neuronal cells induced to differentiate in a controlled environment (Henschler et al., 1992; 
Flaskos et al., 1994; 1998; Schmuck and Ahr, 1997). 
1.1.2 Glial cells 
The second most important type of cells, and the most numerous in the nervous system is 
the glial cell. Glial cells include all neural cells that do not transmit electrical signals 
(Compston et al., 1997). They are not directly involved in signal transduction, but the 
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interest in glia has increased due to their multiple roles, including providing defensive, 
homeostatic, structural, and nutritional support to neurons (Barone et al., 2000). The actual 
number of glial cells in the nervous system is much greater than neuronal cells; 
approximately 90 % of the cells in the human brain are glial cells (Allen and Barres, 2009).  
Glia comprises a heterogenous array of cell types from different origins that have specific 
functions and morphologies (Compston et al., 1997). The cell types include microglia, 
oligodendrocytes and astrocytes in the central nervous system (CNS), and enteric glia and 
Schwann cells in the peripheral nervous system (PNS) (Figure 1.1) (Allen and Barres, 
2009).  
Glial cells, except microglia, originate from the neuroectoderm, and mainly develop after 
neurogenesis. Microglial cells are derived from the immune system and reach the brain via 
blood circulation during development (Allen and Barres, 2009). Astrocytes and 
oligodendrocytes can be found in differentiating neural stem cell cultures, which allows 
them to be studied in vitro (Compston et al., 1997; Rice and Barone, 2000). 
In the PNS, Schwann cells consist of two types, myelinating and non-myelinating cells. The 
myelinating cells have a similar function and structure to oligodendrocytes in the CNS; 
they produce an insulating sheath around axons. The non-myelinating Schwann cells 
provide metabolic and mechanical support for neurons. Enteric glia have an essential role in 
synaptic transmission and are located in the autonomic ganglia (Jessen, 2004). 
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Figure 1.1. Schematic representation of neural cell types.  
The interaction between glia cells and neurons with blood vessels. Adopted from Allen and Barres 
(2009). 
1.1.2.1 Microglia 
Microglia is prenatally derived from mesodermal (myeloid) tissue (Chan et al., 2007). They 
have a protective role as specialised brain macrophages, in that they clean up cellular 
debris, check the brain for damage or infections, eliminate inadequate synapsis and digest 
dead neurons that have undergone apoptosis (Compston et al., 1997; Allen and Barres, 
2009).  
In some neurodegenerative disorders, for example Alzheimer's disease (AD), microglia 
become activated, which changes the phenotype to amoeboid and this increases their 
phagocytic function (de la Torre, 2002; Grammas et al., 2002; Nakamura, 2002; Allen and 
Barres, 2009). 
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1.1.2.2 Oligodendrocytes 
Oligodendrocytes synthesise the myelin sheath around axons, which is an insulating 
membrane that provides support and improves electrical signal transmission efficiency and 
speed (Compston et al., 1997; Allen and Barres, 2009). Due to their important role, any 
toxicity towards these cells could greatly affect the development of insulated neurons in 
mammals (Sachana et al., 2008). In some neurodegenerative disorders, such as multiple 
sclerosis (MS), the myelin sheath produced by the oligodendrocyte undergoes an 
autoimmune attack, resulting in demyelination of the axons (Antel, 2006). Other studies 
have suggested that loss of this type of glial cell can be linked to clinical depression (Allen 
and Barres, 2009). 
1.1.2.3 Astrocytes 
Originally, it was thought the main function of astrocytes was to regulate the levels of 
extracellular potassium ions in neurons (Orkand et al., 1966). However, it is now known 
that astrocytes carry out several important roles that support the functionality of neurons; 
they can guide neuronal migration, differentiation and proliferation, help in assembly and 
formation of synapses during central nervous development, neurite outgrowth generation, 
supply the neurons with energy, guidance for axons, and help to maintain the trophic and 
ionic balance of neurons and the extracellular environment (Guerri and Renau-Piqueras, 
1997; Aschner et al., 1999; Allen and Barres, 2009). Astrocytes also help to regulate the 
formation of the blood-brain barrier and they can respond to neural injury by secreting 
neurotrophic factors, including glial-derived neurotrophic factor (GDNF) (Barres and 
Barde, 2000).  
Astrocytes can also act as physical barriers; they separate synaptic connections between 
neighbouring neurons, and they can recycle neurotransmitters, which protects the neurons 
from excitotoxicity (Hassel et al., 1997; Hertz et al., 1999). Astrocytes are in contact with 
neurons and blood vessels, which means that the calcium response that activates the 
astrocytes after neuronal activity, can be used to modulate the ability of blood vessels to 
regulate blood flow (Zonta et al., 2003). This allows for more oxygen and glucose to be 
transported to the neurons (Allen and Barres, 2009). The intake of glutamate by astrocytes 
can induce glycolysis leading to elevated lactate production, which can be used by neurons 
as an energy source (Tsacopoulos and Magistretti, 1996). Astrocytes can also protect 
neurons from oxidative stress by releasing antioxidants including glutathione (Sagara et al., 
1993). Thus, the different types of neuronal and glial cells act cooperatively in the 
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regulation of neural function and the targeting of any one of them by neurotoxins such as 
organophosphates could have a detrimental effect on the nervous system. 
1.2 Historical overview of organophosphates 
Organophosphorous compounds (OPs) are a group of synthetic chemical compounds 
formed by a reaction between a phosphoric acid and alcohol. They were first synthesised in 
the 19th century (Singh and Khurana, 2009). Historically, OPs have been used in a range of 
agricultural, industrial and domestic settings, with a wide range of applications, but as more 
investigations were carried out it became clear that these types of compounds were toxic to 
mammals, causing different levels of neurotoxicity depending on the dose, age and route of 
exposure. OPs were developed as insecticides and pesticides in 1940 when Schrader’s 
group developed around 2000 compounds, including chemical warfare agents like sarin and 
tabun and pesticides such as parathion (Antonijevic and Sojiljkovic, 2007).  
1.3 Organophosphorus insecticides and pesticides 
Pesticides are mainly used to control insect damage in agricultural crops; they are mixtures 
of chemicals and the OP insecticides are the most widely used (Gupta, 2006; Gennari et al., 
2015). The worldwide consumption of pesticides is significant; it is estimated to be more 
than five billion pounds per year (Gupta, 2006; Gennari et al., 2015).  
Although the main use of OPs is in agriculture, they are not restricted to this category; they 
are also used in many residential, medical, and industrial settings, including use as solvents, 
lubricants, and fire retardants as well as insecticides (Hargreaves, 2012). In the year 2005, it 
was estimated that 2 billion tonnes of OP insecticides, including chlorpyrifos (CPF), were 
applied to agricultural fields across the world; only a small proportion of this actually 
targeted pests, and the rest ended up polluting the environment (Gavrilescu et al., 2015).  
A European study has helped to highlight how widespread the problem of OP pollution is; 
it is reported that different food products including processed food and baby food were 
contaminated with more than 250 different OPs (EC, 2005). In addition, the study found 
that approximately 50 % of the cereals, fruits, and vegetables from Europe contained OP 
residues (EC, 2005). These findings of overuse and pollution were supported by a study 
from the USA, which reported that in 1995, approximately 11 million kg of OP compounds 
(primarily diazinon, malathion, and CPF) were used to produce agricultural crops, with 
commercial and residential properties using 6 to 9 million kg of insecticidal OP compounds 
in the same year (Aspelin, 1997).  
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The widespread overuse of OPs and their potential adverse effects pose a significant risk to 
public health; it is not only agricultural workers that are at risk of exposure to these 
insecticides; due to pollution, the general population are also at risk (Mearns et al., 1994; 
Stephens et al., 1995). Different epidemiological studies have all shown that there is 
repeated exposure in the majority of people to low concentrations of OPs, due to interaction 
with the environment and also through food sources. Over the long-term this exposure may 
cause chronic nervous system damage (Mearns et al., 1994; Stephens et al., 1995). 
This prolonged low level exposure to OPs, together with increased reports of acute 
pesticide poisoning is a major public health concern. Globally, around three million people 
suffer accedental acute pesticide poisoning, which results in around 346,000 deaths per year 
(WHO, 2008). A report by the World Health Organisation (WHO) highlighted that each 
year there are 2 million cases of pesticide poisoning which results in approximately 
370,000 deaths worldwide (Gunnell et al., 2007). The US Sentinel Event Notification 
System for Occupational Risks (SENSOR) pesticide program has shown that nearly 50 % 
of the acute pesticide related illnesses were caused by OP insecticides (Calvert et al., 2004). 
The incidence of acute poisoning related deaths in the UK and other western countries is 
relatively low (Jamal, 1995), but this is in contrast to developing countries, where the rate is 
significantly higher, with estimates of over 300,000 deaths/year. The increased rate is 
influenced by the higher use of OP pesticides, combined with a lack of strict regulations, 
and limited knowledge of safety procedures in developing countries (Carlton et al., 2004; 
WHO, 2008). 
Due to their widespread use and potential impacts on public health, there have been 
suggestions by regulatory authorities in some developed countries that OP compounds 
should be tightly regulated, including imposition of restrictions or bans on their uses. For 
example, in the USA the Environmental Protection Agency (EPA) in 2000 completely 
banned CPF for domestic use due to its proven developmental neurotoxicity (EPA, 2000). 
The Advisory Committee of Pesticides (ACP) in the UK also raised concerns over the 
potential toxicity of CPF and its impact on public health and food safety (ACP, 2002). 
Based on these recommendations, the use of CPF in a household setting has been stopped 
and it was restricted to agricultural application only in some countries (Colborn, 2006). As 
mentioned previously, a recent study by the EPA recommended that the use of most of OPs 
should be banned not only in household but in agriculture as well due to the toxicity of OPs 
(EPA, 2016), but the suggested ban has not been carried out (EPA, 2017). Despite the 
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potential dangers to health and the imposed restrictions, CPF remains a popular pesticide to 
use especially in many developing countries (Salyha, 2010).  
1.4 Chlorpyrifos 
CPF was first synthesised and then manufactured commercially in 1965 by the Dow Elanco 
Company, and it is still one of the most extensively used OPs to control insects in homes, 
gardens and agricultural fields worldwide (Cox, 1994; Hargreaves, 2012). It has become 
widely distributed in the world market under different brand names, including Scout, 
Eradex, Empire, Brodan, Lorsban, Dursban, and Reldan (Salyha, 2010). In 1997, there were 
approximately 850 commercial CPF products registered in the USA, according to the EPA 
(EPA, 1999). Currently CPF use is still authorised in around 50 countries, including Japan, 
New Zealand, Australia, USA, France, UK, Canada, Spain, and Italy (Salyha, 2010). 
CPF has been used in many applications in different locations; within residential settings it 
has been used to control pests and insects including cockroaches, mosquitos, fleas, flies, 
and lice, whereas in farming and industrial settings it is applied directly to storage bins, 
farm buildings, golf courses, lawns, animal sites, and even sheep and turkeys (Eaton et al., 
2008; Salyha, 2010). One of the largest areas of use is arable farming; CPF is applied to 
several major crops, including corn, fruits, vegetables, tree nuts, wheat, soybeans, and 
citrus fruit (Eaton et al., 2008; Salyha, 2010). The National Centre for Food and 
Agriculture Policy (NCFAP), reported that the USA used approximately 1.4 million kg of 
CPF in the home and garden every year (NCFAP, 2000). This high level of use is also 
typical in other countries; for example, the annual usage of CPF in 2011 in China was 
approximately 20 million kg (AgroNews, 2013). 
CPF is classified as an EPA class II toxicant as it induces the same toxic effects as most 
acetylcholinesterase (AChE) inhibiting pesticides, but there are conflicting data on the 
carcinogenic and mutagenic potential of CPF in the literature (Dreiher et al., 2005; Cui et 
al., 2006). 
1.4.1 Chemical structure and physical properties 
OPs are phosphoric acid derived esters (Figure 1.2, panel A), which contain an X group 
(leaving group) and two lipophilic groups R1 and R2 (Eddleston et al., 2008; Hargreaves, 
2012). The X group is usually displaced when an OP binds forming a stable bond through 
an organophosphorylation reaction (Costa, 2006). The chemical name of CPF, which is one 
of the compounds of interest to the current study, is O,O-diethyl O-3,5,6-trichloropyridin-2-
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yl phosphonothioate, O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphothionate, 
chlorpyrifos-ethyl; it is normally found as a white to colourless crystalline solid, which 
gives off a strong mercaptan-like odour (Figure 1.2). CPF is the active ingredient in many 
insecticide formulations, available in different forms, including capsules, suspensions, 
granules, powder, gel-based products, and emulsifiable concentrates (Wauchope et al., 
1992). CPF is lipophilic meaning it is poorly soluble in water but it does dissolve into most 
organic solvents; therefore, before application on to crops or animals, it needs to be mixed 
with solvents, for example acetone, benzene, xylene, diethyl ether, methanol or carbon 
disulphide (Wauchope et al., 1992; Eaton et al., 2008). 
A. B.
 
Figure 1.2. Chemical structure of (A) general organophosphate structure, (B) 
chlorpyrifos.   
OPs contain a central phosphorus atom with a double bond to either sulphur or oxygen, R1 and R2 
groups that are typically (but not always) ethyl or methyl in structure, and a leaving group which is 
specific to the individual organophosphate. Adopted from Reigart and Roberts (1999). 
1.4.2 Routes of exposure to chlorpyrifos 
There are different routes that can lead to exposure CPF; it can enter the body through 
ingestion, dermal contact, or inhalation, and this leads to it being rapidly absorbed through 
the airways, oral mucosa, and skin (Karki et al., 2004; Munoz-Quezada et al., 2012). 
Common exposure routes in animals and humans are from inhaling contaminated dust, 
breathing polluted air, contact during application or preparation of OPs in the workplace, 
and eating or drinking food and water that are contaminated with OPs (WHO, 2001).  
In the USA one of the major sources of CPF exposure is application of pesticides and other 
insect treatments indoors; the EPA reported over 17,000 cases between 1993 and 1996 
(EPA, 1997), and between 1998 and 2002 there were 2,593 incidents of acute CPF 
poisoning reported in school children in the USA (Alarcon et al., 2005). Even after the 
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introduction of restrictions in CPF use, there were still more than 300 cases of acute CPF 
toxicity reported between 2002 and 2011 (EPA, 2013). 
Outside of the home, occupational exposure is one of the most common sources of CPF 
poisoning; CPF exposure affects agricultural workers, such as pesticide sprayers, sheep 
dippers, and farmers, and their families (Gupta, 2006; Munoz-Quezada et al., 2012). Even 
children and other people living on or near a farm that uses OP insecticides can be at risk of 
OP exposure due to the amounts of insecticides applied (Gupta, 2006; Munoz-Quezada et 
al., 2012). There is also a risk that the treatment of a workplace with insecticides, such as 
CPF, to remove termites or other insects could lead to significant exposure of the 
employees; indeed, over 1300 cases of workplace exposure to CPF were reported between 
1985 and 1992 to the US poison control centre (EPA, 1994). Another common source of 
CPF exposure is during manufacturing; a prospective cohort study evaluated the level of 
occupational exposure in manufacturing workers. The results of the study showed there was 
a significant increase in CPF metabolites in the urine of those workers tested, which raised 
major concerns about the guidelines for occupational exposure to CPF (Albers et al., 2004).  
One of the other key exposure routes is through inhalation of CPF contaminated air and 
water, with CPF contamination of groundwater having been reported in nine states in the 
USA (EPA, 1992), South Africa and Spain (Thoma and Nicholson, 1989). Significant CPF 
air contamination has been detected at application sites; studies that analysed air samples 
taken from approximately one metre above a cornfield that had been sprayed, showed that 
half of the CPF applied was vaporized, and that this contaminated the air for over 25 days 
(Whang et al., 1993). CPF can also be carried up into the atmosphere and move some 
distance away from the application site; for example, studies of air samples detected CPF 
contamination up to about 24 km away from the site of CPF application (Zabik and Seiber, 
1993). 
As soon as CPF is applied and is in the environment, it can be rapidly absorbed through all 
possible routes of exposure (oral, dermal, inhalation) due to the fact it is a lipophilic 
compound which crosses biological membranes, including the blood brain barrier and the 
placenta (Timchalk et al., 2002). As CPF enters the bloodstream it can distribute into the 
tissues at significant concentrations, which are able to inhibit AChE, a key enzyme in the 
regulation of cholinergic neuron activity, and induce neural damage (Timchalk et al., 
2002).  
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1.4.3 Metabolic pathway of chlorpyrifos to chlorpyrifos-oxon  
Within humans, many different enzymes contain polymorphisms which means that 
individuals can have variations in enzyme activity, and therefore will react differently after 
exposure to toxins such as OPs, resulting in differences in activation and detoxification of 
the xenobiotic in question (Costa et al., 2005). CPF is metabolically converted into its 
oxygen form chlorpyrifos oxon (CPO), by replacing the sulphur group with oxygen. CPF 
biotransformation is mostly mediated by cytochromes. Generally, CPF is oxidized by 
CYP450 to diethylthiophosphate (DETP) and 3,5,6-trichloro-2-pyridinol (TCP) formation 
(Figure 1.3). CYP450 are present in several isoforms in the liver; studies have shown 
CYP2B6 and CYP3A4 are the most effective enzymes for CPO formation from CPF 
(Mutch and Williams, 2006; Croom et al., 2010). Then, the metabolites are filtered through 
the kidneys to be excreted in the urine (Eaton et al., 2008).  In the liver, CPO is hydrolysed 
by diethylphosphate (DEP) and 3,5,6-trichloro-2-pyridinol (TCP) to become a less toxic 
product. CPO detoxification also involves plasma A-esterases, such as paraoxonase 1 
(PON1). It has been highlighted by several in vivo studies which showed that low levels of 
these enzymes can increase the OP neurotoxicity susceptibility (Costa et al., 2013). Studies 
in humans have shown that PON1 has a polymorphic distribution in plasma samples, which 
means there is a large variation in concentrations and activity in individuals (Costa et al., 
2013). 
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Figure 1.3. Representation of the metabolism of CPF. 
1.5 Phenyl saligenin phosphate 
Phenyl saligenin phosphate (PSP) is a structural analogue of saligenin cyclic-o-tolyl 
phosphate (SCOTP), which is the active metabolite of tri-ortho cresyl phosphate (TOCP) 
(Fowler et al., 2001). Studies of this non-pesticide OP and its ‘parent’ compound show that 
they produce their toxic effect by NTE organophosphorylation, which leads to inhibition of 
enzyme activity and can cause organophosphate-induced delayed neuropathy (OPIDN) 
(Nomeir and Abou-Donia, 1986; Zhao et al., 2006). Occupational exposure to toxic 
aerosols of TOCP via its use in aviation fluids, can result in cognitive dysfunction, 
neurodegenerative poisoning, and memory loss (Winder and Balouet, 2001; Michaelis, 
2011; Hargreaves, 2012). 
Studies of PSP have shown that it has several key targets within the body, such as 
neuropathy target esterase (NTE), mitogen-activated protein kinase (MAPK) signalling, 
cytoskeletal proteins, transglutaminase enzyme activity and neurotrophin receptors (Carlson 
and Ehrich, 2001; Harris et al., 2009a; Pomeroy-Black and Ehrich, 2012; Baker et al., 
2013). PSP is a classical inhibitor of NTE; after exposure to PSP, NTE is inhibited by 
organophosphorylation. In differentiating neuronal cells, this is followed by reduced neurite 
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outgrowth associated with modification of axonal morphology and neuronal degeneration, 
which are critical events in the development of OPIDN (Flaskos et al., 1994; Ehrich and 
Jortner, 2001). 
Studies investigating PSP-induced toxicity have focused on the effects of MAPK and 
phosphoinositide-3-kinase/protein kinase B (PI-3K/PKB) signalling, as these play a vital 
role in the neuronal response to OP exposure (Kaplan, 1995; Hargreaves et al., 2006; 
Pomeroy-Black and Ehrich, 2012). The studies found increased phosphorylation of PKB 
and MEK1/2 protein kinases in human SH-SY5Y neuroblastoma cells by low 
concentrations of PSP (e.g. 0.01-1.0 µM), and that 2.5 µM PSP for 4 h in mouse N2a 
neuroblastoma cells caused activation of extracellular-signal-regulated kinases 1/2 
(ERK1/2) associated with the inhibition of NTE and neurite outgrowth (Nostrandt et al., 
1992; Carlson et al., 2000; Hargreaves et al., 2006; Pomeroy-Black and Ehrich, 2012).  
Other studies have focused on the effects of PSP on cytoskeletal proteins and myelin basic 
protein; generally, the studies have found that sub-lethal concentrations of PSP induced NF 
and microtubule degradation, in association with in myelin degeneration, abnormal neurite 
growth and axonal damage (Abou-Donia and Lapadula, 1990; Ehrich and Jortner, 2001; 
Massicotte et al., 2003; Hargreaves et al., 2006; El-Fawal and McCain, 2008).  
Overall, these results indicate that PSP and TOCP can cause significant neurotoxicity by 
disrupting the activity of cytoskeletal proteins and MBP, but the molecular basis of these 
effects has not been fully investigated; therefore, further research is required to fully 
elucidate the mechanisms involved (Baker et al., 2013). 
1.6 The acute toxicity of organophosphates in the nervous system 
The enzyme AChE is the primary target of OPs in the nervous system, and its inhibition 
produces the best-known effect of OP acute toxicity. AChE is found at neuromuscular 
junctions, is involved in termination of neurotransmission, and is a serine hydrolase that 
catalyses the degradation of acetylcholine (ACh), a neurotransmitter that is present in the 
CNS and PNS, to produce acetate and choline (Campbell et al., 1997; Steevens and 
Benson, 1999; Ray and Richards, 2001). The inhibition of AChE results in the 
accumulation of ACh in the synaptic cleft, thereby overstimulating nicotinic and muscarinic 
receptors (Table 1.1) (Hasan et al., 1979; Pope, 1999; Costa, 2006). This overstimulation 
causes neurotoxic effects, for example neuromuscular paralysis (such as continuous muscle 
contraction), throughout the entire body (Gupta, 2006).  
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Table 1.1. Acetylcholine receptors, subtypes and location (Adopted from Tata et al., 
2014). 
ACh receptors  Subtypes  Location  
Nicotinic  
receptors  
N1 or Nm  Neuromuscular junction  
N2 or Nn Autonomic ganglia, central nervous system 
Muscarinic  
receptors  
M1  Cortex and hippocampus regions of the brain  
M2  Heart, brain, spinal cord, exocrine gland  
M3  Exocrine glands and smooth muscles  
M4  Central nervous system  
M5  Central nervous system  
OPs inhibit AChE by forming a covalent bond with a serine residue in the active site; as     
a consequence of this reaction, a transient intermediate complex is generated, which is 
partially hydrolysed through the loss of the X substituent group, resulting in the formation 
of a stable, organophosphorylated and inhibited AChE enzyme (Figure 1.4) (Betancourt 
and Carr, 2004; Eaton et al., 2008). CPF can target AChE both in the CNS and PNS, 
however in its non-oxidised state, it does not inhibit AChE very strongly in vivo, whereas 
the oxidised state (CPO) powerfully inhibits AChE. As mentioned previously, cytochrome 
P-450 catalyses the conversion of CPF to CPO through oxidative desulphuration, allowing 
CPF to become a powerful inhibitor of AChE in vivo (Betancourt and Carr, 2004; Eaton et 
al., 2008). 
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Figure 1.4. Inhibition of AChE by organophosphates. 
This leads to accumulation of ACh in the synaptic cleft which results in impeded neurotransmission. 
Obtained from Vargas-Bernal et al. (2012). 
Another vital target for some OPs is the serine hydrolase enzyme known as NTE. NTE is a 
B-esterase, and its inhibition and ageing (in a similar manner as AChE (Section 1.6) is 
associated with the onset of the disorder called OPIDN (Johnson, 1970; Costa, 2006). In 
vertebrates, NTE is an integral membrane protein which is expressed in the endoplasmic 
reticulum (ER) of all neuronal cells, and some non-neuronal tissues, such as testicles, 
kidney, and lymphocytes (Glynn et al., 1998; Glynn, 1999). NTE belongs to the esterase 
family of enzymes and plays a critical role in neural development.  
Other functions of NTE include the hydrolysis of lipids to form lysolecithin, a membrane 
phospholipid that possesses demyelination properties and is linked with cell signalling 
between glial cells and neurons in nervous system development (Glynn 1999; Costa, 2006). 
NTE expression increases in the early stages of embryo development, where it may be 
involved in nervous system development and signal transduction (Lotti and Moretto, 1993; 
Moser et al., 2000; Road, 2010). Genetic studies have suggested the absence of NTE in the 
brain causes neuronal degeneration as associated with the loss of ER, and vacuolation in 
cell bodies, which cause defects in cellular function (Van Tienhoven et al., 2002; 
Akassoglou et al., 2004). To date, the precise molecular mechanism underlying OPIDN has 
not been fully elucidated; it has been established that, besides inhibition and ageing of 
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NTE, some cytoskeletal rearrangements as well as disruption of calcium homeostasis, are 
involved in the disorder (El-Fawal and Ehrich, 1993; Hargreaves, 2012).  
The clinical manifestations that form as a result of CPF poisoning can be divided into four 
main categories, including acute cholinergic syndrome, intermediate syndrome, delayed 
neuropathy and other neurological disorders (Figure 1.5) (Abou-Donia, 2003). The 
development of the specific neurological syndromes is dependent on different factors, 
including the onset of clinical symptoms, the chemical nature of the compound, and time 
and extent of exposure (Abou-Donia, 2003). 
 
Figure 1.5. Classification of organophosphate toxicity.     
Representation of the pathways involved in forming the different types of OP toxicity. Adopted 
from Jones and Karalliedde (2006). 
1.7 Acute cholinergic syndrome 
The main cause of acute CPF toxicity in mammals is the bioactivation of CPF to CPO in 
the liver as, at the molecular level, the P=O moiety of CPO can act as a potent inhibitor of 
AChE, whereas the P=S moiety of CPF lacks the inhibitory effect (Richardson, 1995; 
Bjorling-Poulsen et al., 2008; Eaton et al., 2008). CPO binds to the active site of by 
forming a stable covalent bond between the hydroxyl group of the serine in AChE and the 
phosphate group of the OP compound, which usually remains stable for hours to weeks 
(Karalliedde, 1999). This organophosphorylation of AChE results in the inhibition of its 
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normal function, degrading the major neurotransmitter of ACh at the ending of cholinergic 
nerve in the CNS and PNS, which leads to accumulation of ACh (Koelle, 1992). 
The accumulation of excess ACh at the synapses in the PNS and CNS results in 
hyperstimulation of the cholinergic receptors and causes what is known as 'cholinergic 
syndrome' (Abou-Donia, 2003). It is characterised by different clinical symptoms 
depending on the site where ACh accumulation occurs; the excess ACh binds to muscarinic 
receptors and different muscarinic effects can develop depending on the route of toxic 
exposure, including visual disorders, miosis, bronchoconstriction, hypersalivation, 
hypotension, bronchorrhoea, increased sweating and lacrimation, diarrhoea, vomiting, 
increased gastrointestinal mobility, abdominal cramps, and lowered heart beat (Elersek and 
Filipic, 2011).  
After CPF exposure, development of acute cholinergic syndrome usually occurs within       
a few minutes or up to a few hours (Eaton et al., 2008; Hargreaves, 2012). The extent and 
severity of the symptoms depends on the nature of the OP and the level of OP-AChE 
binding (Chambers, 2004). During onset, nicotinic receptors are stimulated, which causes 
hypertension and uncontrolled muscle contractions subsequently leading to paralysis (Singh 
and Sharma, 2000; Elersek and Filipic, 2011). The well-established symptoms of 
cholinergic crisis occur when there is severe inhibition of AChE (i.e. > 70 % of the normal 
levels) (Clegg and van Germet, 1999a). After the development neuromuscular paralysis 
(such as neuromuscular block) in the body, death can occur within a short time, by 
respiratory-failure and/or cardiac arrest (Lauder and Schambra, 1999; Costa, 2006; Gupta, 
2006; Easton et al., 2008; Flaskos, 2012; Hargreaves, 2012). Different CNS symptoms can 
arise after severe CPF intoxication, including confusion, headache, blurred vision, spasms, 
speaking disorders, insomnia, ataxia, coma, and convulsions (Cleeg and van Garmet, 
1999b; Lotti and Moretto, 2005; Elersek and Filipic, 2011).  
The reactivation of AChE after inhibition by many different OP compounds usually occurs 
within several hours by the spontaneous hydrolysis of the AChE-OP bond (Abou-Donia 
and Lapadula, 1990). However, when the inhibition is caused by CPO, the AChE-CPO 
complex undergoes an 'ageing' mechanism where a non-enzymatic hydrolysis or 
dealkylation process results in loss of one or two of the alkoxy labile groups (R1, R2) 
(Figure 1.6). After this ageing process has occurred, the inhibition of AChE becomes 
irreversible as the enzyme is more resistant to reactivation, and this inhibition can only be 
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overcome by the synthesis of new enzyme molecules and clearance of the xenobiotic 
(Abou-Donia and Lapadula, 1990; Karalliedde, 1999; Costa, 2006).  
 
Figure 1.6. Representation of interactions between esterases and OPs. 
The first reaction (1) leads to reversible organophosphorylation of AChE; the second (2) to 
hydrolysed OP and spontaneous reactivation of AChE, and the third (3) forms the ‘aged’ 
organophosphorylated AChE which is inactive, stable and carries an increased negative charge. 
Adopted from Costa (2006). 
 
There are two main approaches to the treatment of acute CPF toxicity; the first is to block 
the over stimulation of the muscarinic receptors and the second is to reactivate AChE 
activity. The first of these aims can be achieved by administering atropine that is                 
a cholinergic muscarinic antagonistand prevents the ACh accumulation at the receptors. For 
the second approach, which promotes ACh breakdown, AChE enzyme reactivation is 
induced by the administration of an oxime, such as paraidoxime (Thiermann et al., 1999; 
Eaton et al., 2008; Eddleston et al., 2008). However, if the AChE-CPO complex has already 
undergone ageing, oximes are unable to reactivate the inhibited AChE (Eaton et al., 2008). 
Anticonvulsant drugs such as diazepam are another potential treatment for CPF 
intoxication; these drugs are used to relieve anxiety and the convulsions, which are caused 
by acute poisoning after the exposure to CPF (Thiermann et al., 1999; Eaton et al., 2008; 
Eddleston et al., 2008). 
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1.8 Intermediate syndrome 
Intermediate syndrome is another neurotoxic effect associated with OP toxicity, 
characterised by symptoms that begin with respiratory insufficiency, and continue to 
produce weakness in limbs, neck and respiratory muscles (Senanayake and Karalliedde, 
1987; Eaton et al., 2008). This condition develops after the symptoms of cholinergic 
syndrome, but prior to the signs of OPIDN (Senanayake and Karalliedde, 1987; Costa, 
2006). Following OP exposure, it is estimated that 20 % of people will go on to develop 
intermediate syndrome, and the symptoms usually occur within 24 to 96 hours after 
exposure (Karalliedde, 2006; Yang and Deng, 2007). This was seen in a clinical case study 
of intermediate syndrome described in a 16-month old child who ingested CPF and 
developed flaccid paralysis and respiratory arrest after 27 hours (Mattingly et al., 2003).  
The precise underlying mechanism for the development of intermediate syndrome remains 
unclear, but there have been a number of mechanisms proposed, including failure of ACh 
release at neuromuscular junctions, the down regulation of ACh receptors, damage to 
muscles (myopathy), and prolonged inhibition of AChE (Yang and Deng, 2007; Abdollahi 
and Karami-Mohajeri, 2012). 
The treatment of intermediate syndrome depends on the progression and symptoms 
involved; the clinical signs (e.g. severe respiratory muscle weakness) can be treated by 
monitoring respiratory functions and giving mechanical ventilation if necessary 
(Karalliedde, 2006). Other symptoms can be treated in a similar way to acute cholinergic 
syndrome by the administration of oximes; however, timing is critical, as these drugs were 
found to prevent myopathy in animal studies if they were administered immediately after 
CPF exposure, but they had no effect if they were administered more than two hours or 
more after poisoning (Karalliedde, 2006). 
1.9 Organophosphate-induced delayed neuropathy (OPIDN) 
OPIDN is another delayed peripheral neuropathy caused by OP poisoning. It is a rare 
neuropathic condition which can result following a single or repeated exposure to certain 
OPs such as diisopropylfluorophosphate, o-tolyl saligenin phosphate dioctyl dichlorovinyl 
phosphate, mipafox, and dibutyryl dichlorovinyl phosphate, (Abou-Donia and Lapadula, 
1990; Ehrich et al., 1997). OPIDN is characterised by shaking in hands and feet, an initial 
delay in the onset of ataxia, which is followed by degeneration of the distal end of long 
axons and large peripheral nerves, and finally there is degeneration of the myelin sheath in 
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both the CNS and PNS (Abou-Donia and Lapadula, 1990; Lotti, 1992; Ehrich and Jortner, 
2001). 
Studies into the prediction of the ability of OPs to induce OPIDN have been carried out in 
vitro in cell lines, and also in vivo using hens, as these have proved to be reliable animal 
model as they readily show lesions and other clinical signs of OPIDN (Glynn, 1999).  
Studies have shown that it is possible to use cell cultures to screen for OPIDN inducing 
OPs, as NTE activity is found in both human and mouse differentiated and undifferentiated 
neuronal cell lines (Fedalei and Nardone, 1983; Carrington et al., 1985). There have been 
several studies measuring NTE inhibition in cultured neuronal cells, with mixed results 
when compared to animal studies (Nostrandt and Ehrich, 1992; El-Fawal and Ehrich, 
1993). The majority of the early studies of OPIDN in cell cultures that measured parameters 
other than NTE, used the cell lines to try to predict the ability to induce OPIDN, instead of 
using them to investigate the underlying mechanism of OPIDN (Veronesi, 1992). By using 
a controlled environment such as a cell line it is possible to study how the molecular 
initiating and other key events occur, beginning with phosphorylation, then ‘ageing’ of NTE 
and finally the production of axonal degeneration, which has been described in vivo 
(Johnson, 1990; Abou-Donia et al., 1988; 1990; 1993). To investigate these important 
details, it is necessary to use a relevant cell model, which will allow for the clarification of 
the biochemical mechanisms involved in development of OPIDN, especially as this could 
lead to the identification of novel endpoints for applied testing purposes (Flaskos, 1995).  
After CPF exposure, OPIDN clinical effects usually manifest after cholinergic toxicity and 
intermediate syndrome, but the progression may not but immediate; clinical onset of 
OPIDN can occur 6 to 14 days after OP exposure (Abou-Donia, 2003; Eaton et al., 2008; 
Jokanovic et al., 2011). With some OPs, the clinical onset can take even longer to occur; for 
the poor AChE inhibitor TOCP, it can take several weeks for the metabolism to the active 
SCOTP to produce clinical symptoms of OPIDN (Nomeir and Abou-Donia, 1986; Abou-
Donia and Lapadula, 1990). The early signs of OPIDN in humans include vomiting and 
diarrhoea, which is followed by progressive weakness of the lower limbs after the latency 
period (Abou-Donia, 1981; Abou-Donia and Lapadula, 1990; Abou-Donia, 1993; Jokanovic 
et al., 2011). In the later stages of OPIDN, weakness of the limbs may affect the arms and 
hands, resulting in reflex deterioration of certain limbs and abnormal balance; OPIDN 
eventually causes a flaccid paralysis, which means there is nerve damage in the muscles 
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and this results in prolonged spasms (Abou-Donia, 1981; Abou-Donia and Lapadula, 1990; 
Abou-Donia, 1993; Jokanovic et al., 2011).  
Studies of the clinical onset of OPIDN in hens have revealed that this process occurs in two 
main steps; the first involves the inhibition of NTE enzymatic activity by phosphorylation, 
which significantly decreases enzyme hydrolysis, and the second step is the ageing of the 
phosphorylated NTE, which allows OPIDN to be initiated (Glynn, 1999). Studies have 
shown that the NTE inhibition alone is not associated with neural degeneration; OPs which 
can inhibit NTE but do not induce ageing of phosphorylated NTE cannot generate 
neuropathic effects (Costa, 2006). The NTE ageing process occurs when a negatively 
charged group of an OP covalently binds to the OH group in the side chain of the serine 
residue in the NTE active site. This ageing of the NTE means the enzyme’s activity 
becomes permanently (irreversibly) inhibited, and this allows OPIDN to occur (Johnson, 
1990; Glynn, 1999). The importance of NTE ageing has also been shown in the work of du 
Toit et al. (1981) and Johnson (1969), who demonstrated that NTE inhibition in the spinal 
cord resulted in only spinal syndrome with no associated neuropathy, whereas the 
development of an axonopathy such as OPIDN also required NTE ageing (Johnson, 1969; 
du Toit et al., 1981). This suggests that only OPs that can inhibit and age NTE enzymatic 
activity can induce OPIDN. After NTE inhibition and ageing, there are then several 
alterations in the peripheral nerves, including myelin sheath loss, degeneration of long 
axons, accumulation of macrophage in nerves, and proliferation of Schwan cells (Singh and 
Sharma, 2000). Studies have also suggested that the susceptibility of NTE towards different 
OPs is associated with the age of the subject, as younger animals have a higher resistance to 
OPs than adults (Peraica et al., 1993).  
Further work in hen experimental models has suggested that CPF can induce OPIDN if 
there was over 50 % inhibition of NTE activity (Johnson, 1990; Lotti, 1992), which agrees 
with the known CPF-induced OPIDN cases in humans, mainly from accidental exposure 
(Eaton et al., 2008). This can be seen in the study by Osterloh et al. (1983) which 
demonstrated there were only low levels of NTE activity and plasma cholinesterase in a 
patient who had ingested CPF; in addition the patient presented with minimal acute 
cholinergic syndrome, cardiac arrhythmia, coma, and they eventually died 30 h after 
poisoning (Osterloh et al., 1983; Lotti et al.,1986) studied a male patient who had 
accidental oral CPF poisoning (<300 mg/kg); the patient developed mild axonal neuropathy 
after 43 days, and the authors concluded that, in this case, CPF induced OPIDN with a 
lower inhibition of NTE than is usually required in animals (Lotti et al., 1986). 
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The administration of PSP has also been shown to induce OPIDN in animal models 
(Nomeir and Abou-Donia, 1986). Studies have shown that PSP exposure can cause an 
increase in phosphorylation of the neurofilament heavy chain and tubulin and inhibit 
neurite outgrowth (Hargreaves et al., 2006; Flaskos et al., 2006). This suggests the 
phosphorylation of cytoskeletal proteins is a crucial process in the development of OPIDN 
(Abou-Donia, 1993).  
1.10 Other chronic neurological conditions associated with OP exposure 
Alongside the classical neurological syndromes, certain OPs including CPF, are able to 
cause other long lasting, persistent, and chronic neuropsychiatric and neurobehavioral 
disorders, which are collectively known as chronic OP induced neuropsychiatric disorder 
(COPIND), and these are commonly observed after an acute single dose or repeated sub-
chronic exposure to an OP (Sanchez-Santed et al., 2004). The key characteristics of 
COPIND are behavioural changes, including irritability, confusion, anxiety, drowsiness, 
insomnia, depression, anorexia, fatigue, emotional lability, and lethargy (Salvi et al., 2003). 
Symptoms that could be classified as COPIND have been observed after accidental 
exposure of agricultural workers to a single dose of CPF; the workers had impaired 
cognitive functions, memory and attention deficits, and abnormalities in 
neuropsychological tests (Savage et al., 1988; Rosenstock et al., 1991; Steenland et al., 
1994). 
Studies of long term OP use have shown there are neurological changes in adults; for 
example, Stephens et al. (1995) studied the performance of farm workers after repeated OP 
exposure; they found in neurobehavioral tests that there was a relatively slow speed for 
information processing, memory problems, greater susceptibility to psychiatric disorders, 
and an impaired attention span. These results were supported by the work of Fiedler et al. 
(1997), who observed schizophrenia and dystonic reactions in people who had been 
exposed to CPF over long periods. Studies have also shown that low level exposure to CPF 
can induce neurobehavioral effects; there have been high levels of anxiety observed in 
insecticide sprayers, but these results were not found in farmers (Levin et al., 1976). This is 
further supported by studies which have shown there was impaired cognitive function after 
exposure of weaning rats to sub-acute doses of CPF (Jett et al., 2001). 
There have also been investigations into the impact of CPF insecticides on children to 
determine whether they cause cognitive defects; several epidemiological studies on children 
and adolescents that have worked as pesticide applicators on crops including cotton, have 
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established that they have a significantly lower neurobehavioral performance and more 
neurological symptoms compared to non-OP workers (Rohlman et al., 2001; 2005; Rasoul 
et al., 2008). The results of these studies confirm the previously detected association 
between the duration and period of CPF application in an agriculture setting and the extent 
of developmental and cognitive disorders, but research is yet to determine the precise 
mechanisms that cause COPIND clinical symptoms in humans (Kamel et al., 2003; 
Rohlman et al., 2007). 
1.11 Effects of OPs on cytoskeletal proteins  
Although there are many studies highlighting the fact that CPF can cause poisoning effects 
based on CPO mediated AChE activity inhibition, there are several other cellular proteins 
that are proposed targets for CPF, CPO and PSP neurotoxicity, including cytoskeletal 
proteins, axon growth associated proteins and those involved in cell signalling pathways 
(Flaskos, 2014).  
As the disruption of cytoskeletal proteins can result in serious damage at different phases of 
neural development, how these key proteins are involved will be considered in the next 
sections.  
1.11.1 Cellular and cytoskeletal proteins as molecular targets of CPF, CPO and PSP 
toxicity  
Some of the developmental processes of the nervous system are controlled by the neuronal 
cytoskeleton, including cell migration, proliferation, morphogenesis, differentiation, neurite 
outgrowth, branching of dendrites, elongation of axons, steering of growth cones, and also 
apoptosis (Hargreaves, 1997; Flaskos, 2014). Due to their involvement in all these 
processes, disruption of cytoskeletal proteins can result in serious damage to neural 
development (Flaskos, 2014). The cytoskeleton itself is a complex structure, which is made 
up of three main classes of filamentous proteins, microfilaments (MFs), microtubules 
(MTs), and intermediate filaments (IFs). These cytoskeletal networks play an important role 
in axon growth regulation and stability and so they represent potential targets of 
neurotoxicity (Hargreaves, 1997).  Different OPs produce a variety of effects on 
cytoskeleton filaments in human neuroblastoma cells, depending on the OP structure and 
potency (Carlson and Ehrich, 2001). Therefore, future studies need to focus on the 
identification of non-cholinergic targets of these OP compounds, as this will help to identify 
the molecular mechanisms involved in OP-induced toxicity. 
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1.11.2 Microtubules 
Microtubules (MTs) have been shown to have important roles in growth and physiology; 
they are cytoplasmic elements composed of tubulin heterodimers and microtubule 
associated proteins (MAPs); they are involved in the regulation of intracellular transport, 
neuronal morphology, and the outgrowth of dendrites and axons (Cambray-Deakin, 1991; 
Ginzburg, 1991; Lodish et al., 2000a). MTs are the largest cytoskeletal structures in 
diameter being made of hollow, straight cylindrical polymers that are made of a ring of 
thirteen protofilaments, with an internal diameter of approximately 14 nm, and an external 
diameter of approximately 25 nm (Figure 1.7) (Okabe and Hirokawa, 1988; Hargreaves, 
1997). Protofilaments are formed by the assembly of heterodimers of the two tubulin 
subunits (α- and β-tubulin) in a staggered fashion (Figure 1.7), assisted by the interaction 
with MAPs (Tilney et al., 1973; Hargeaves, 1997). The evidence for the presence of MAPs 
in MTs comes from the fact that they co-purify with tubulin in vitro, the ability of MAPs to 
stimulate MT assembly in vitro and the observation that MTs are stained by indirect 
immunofluorescence with anti-MAP antibodies (Shelanski et al., 1973; Murphy and 
Borisy, 1975; Sloboda, 1976; Lodish et al., 2000a). 
 
Figure 1.7. Microtubule structure and composition.  
Schematic diagram of a microtubule showing how the tubulin polypeptides pack together to form     
a cylindrical wall of protofilaments.  
 
MTs originate from specific regions in most mammalian cell types; these are called the 
centrosomes or microtubule organising centres (MTOCs) (Heidemann et al., 1981). They 
are organised in a polar orientation, with depolymerisation and polymerisation occurring at 
the ends of the structure (Heidemann et al., 1981). The name for the ends of the MTs are 
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defined by the rate of growth in vitro; the ‘minus end’ is known slow growing end and the 
‘plus end’ is known as the fast-growing end (Figure 1.7) (Heidemann et al., 1981). In 
neuronal cells, axonal MTs are oriented with their minus ends anchored at the MTOCs of 
the axon, with the plus end extending along the axon toward the tip (Heidemann et al., 
1981; Bamburg et al., 1986; Lodish et al., 2000b). In non-neuronal cells, for example glia, 
centrioles, basal bodies, and centrosomes of chromosomes, the MTOCs are associated with 
the minus ends, and it is from here that MTs assemble, which means the polarity of MTs 
become fixed with the plus end extending outwards to the extremities of the cell (Lodish et 
al., 2000b). In dendrites the polarity of the MTs is mixed, with both ends being distal to the 
cell body (Lodish et al., 2000a).  
1.11.2.1 Biochemical properties of MTs 
1.11.2.1.1 Tubulin 
Tubulin is the main component of MTs and it contains α- and β- subunits, with the 
molecular weight each subunit being approximately 50 kDa. Each tubulin subunit has 
several isoforms encoded by different genes. A third subunit, γ-tubulin, is not part of MTs 
but instead is present in the MTOC, where it plays an important role in MT polar 
orientation and nucleation (Martin et al., 1997; Tischfield and Engle, 2010). Tubulin is       
a highly acidic, conserved protein and can bind a variety of MAPs (Hargreaves, 1997). 
Both α- and β- tubulin isoforms play important roles during the development of the nervous 
system. For example, the class III β-tubulin isotype (βIII-tubulin) has an essential role in 
neurite growth and cell differentiation; it is almost exclusively distributed in neuronal cells 
and is also one of earliest cytoskeletal proteins expressed in neural development (Easter et 
al., 1993). 
The presence of a strongly acidic carboxyl terminal domain allows both α- and β-subunits 
of tubulin to bind a variety of MAPs (Hargreaves, 1997). Within this domain there is an 
acidic region of 40 amino acids that contains phosphorylation sites (serine resides) for 
regulation, and binding sites for calcium and proteins such as MAPs that stabilise the MTs 
(Cleveland, 1993) (Table 1.2).   
The regulation of tubulin polymer formation is also controlled by several post-translational 
modifications, including phosphorylation of a serine at residue 444 (Ser-444) in the β-
tubulin subunit, acetylation of the lysine at position 40 (Lys40) in α-tubulin, detryosination/ 
tyrosination (removal/addition) of C-terminal tyrosine (Tyr) residues  in α-subunits, and the 
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addition of multiple glutamate residues in both α- and β-subunits (LeDizet and Piperno, 
1987; Barra et al., 1989; Diaz-Nido et al., 1990; Alexander et al., 1991; Ludueña, 1993; 
Fourest-Lieuvin et al., 2006; Janke, 2014) (Table 1.2). Such modifications may affect MT 
stability and locations (Janke and Kneussel, 2010). 
Tubulin synthesis can also be auto-regulated by a pool of unpolymerized tubulin, which is 
used up during MT assembly and in turn, then stimulates tubulin synthesis to increase 
(Cleveland, 1993). 
Table 1.2. Major microtubule cytoskeleton proteins of the nervous system and their 
regulation (Adopted from Luduena, 1993). 
Protein Expression pattern and distribution 
Post-translational 
modification 
α-tubulin In all cells, but some isoforms preferentially 
expressed in brain 
Acetylation, tyrosination, 
polyglutamylation 
β-tubulin In all cells, but some isoforms preferentially 
expressed in brain 
Phosphorylation, 
polyglutamylation 
γ-tubulin In MTOC of all cells Phosphorylation 
MAP 1a Appears late, widely distributed Phosphorylation 
MAP 1b Appears early, then declines; enriched in axons Phosphorylation 
MAP 2a High molecular weight; expressed in dendrites 
in mature neurons 
Phosphorylation 
MAP 2b High molecular weight; expressed in dendrites Phosphorylation 
MAP 2c Low molecular weight; expressed in dendrites 
in developing neurons 
Phosphorylation 
Tau Enriched in axons Phosphorylation 
OPs have been found to target tubulin, interfering with assembly and causing impairment of 
MT function (Prendergast et al., 2007). Studies have shown low concentrations (0.005 and 
0.01 mM) of CPO bound to tubulin and prevented polymerization, and dichlorvos increased 
tubulin phosphorylation, which resulted in synaptic dysfunction and axon dissociation 
(Choudhary et al., 2006; Grigoryan and Lockridge, 2009). 
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1.11.2.1.2 Microtubule-associated proteins 
The stability and assembly of MTs has been shown to be strongly dependent upon MAPs, 
as they regulate the dynamics of tubulin heterodimer formation, and help determine the 
balance between plasticity and rigidity in neuronal processes (Doering, 1993; Lodish et al., 
2000a; 2000b). MAPs are known to modulate MT dynamics, assembly and disassembly 
and are also involved in the interaction of MTs with IFs, actin filaments and other 
organelles (Matus, 1988; Nixon et al., 1990; Hargreaves, 1997). The MAP family members 
which are important in central nervous system development include MAP 1, MAP 2, Tau 
and stathmin (Schoenfeld and Obar, 1994). The main function of these proteins during 
neuronal development are to maintain the growth cone’s stability, by precise modulation of 
axonal and dendritic MTdynamics (Schoenfeld and Obar, 1994). For example, MAP 1, 
MAP 2 and Tau stimulate MT assembly, cross-link MTs with other cytoskeletal elements, 
and modulate interactions of MTs with IFs and actin filaments (Murphy et al., 1977; 
Griffith and Pollard, 1978; Sattilaro et al., 1981; Leterrier et al., 1982; Olmsted, 1986; 
Nixon et al., 1990). Other groups of MAPs, for example dynein and kinesin, can function 
as motor proteins (ATPases) and drive the intracellular transport of proteins and organelles 
from the cell body to the extending synapses and axons (Vallee and Bloom, 1991).  
MAPs 1 and 2 have three different isoforms each (MAP 1a, 1b, 1c, and MAP 2a, 2b, 2c), 
which can be detected based on their molecular weights; MAP 1a, MAP 1b, and MAP 1c 
have molecular weights of 350 kDa, 330 kDa, and 230 kDa, respectively (Olmsted, 1986; 
Nixon et al., 1990). MAP 2a and 2b are thermostable, elongated molecules that are 
expressed through the life of the neuron (MAP 2b), or during synaptic formation (MAP 2a), 
have a molecular weight of 280 kDa, and an estimated length of 185 nm (Vallee, 1980; 
Caceres et al., 1984; De Camili et al., 1984; Olmstead, 1986). MAP 1 and 2 are found in 
neuronal cell bodies and dendrites (Table 1.2), where they protect radially from the MT 
surface and form cross-bridges between MTs and NFs (Vallee, 1980; Leterrier et al., 1982; 
Heimann et al., 1985).  
1.11.2.1.3 Kinesin 
Kinesins are important motor proteins that mediate the transport of organelles, vesicles and 
other cellular proteins through the axon along microtubules (Pernigo et al., 2013). Studies 
of OP toxicity have shown significant effects on axonal transport through inhibition of 
motor proteins such as kinesin, for example administration of 10 μM CPF and 0.59 nM 
diisopropylfluorophosphate in bovine brain cortex cells reduced kinesin function and 
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axonal transport and increased axonal swelling (Inui et al., 1993; Massicotte et al., 2003; 
Gearhart et al., 2007). Axonal swelling results in decreased transportation, resulting in 
protein aggregation along the axon (Abou-Donia, 1993). 
1.11.2.1.4 Tau 
Tau is primarily found in axons (Cleveland, 1993) (Table 1.2), so it is considered as an 
axonal marker (Binder et al., 1985). It is formed of several polypeptides with molecular 
weights ranging between 45-60 kDa (Nixon et al., 1990). These proteins have calmodulin 
binding sites and can be phosphorylated, which modulates their role in promoting assembly 
of MTs, and stabilizing MTs (Weingarten et al., 1975; Black and Greene, 1982; Drubin and 
Kirschner, 1986; Olmsted, 1986; Kosik et al., 1988). Evidence for these roles of Tau comes 
from the work of Drubin and Kirschner (1986); they microinjected Tau into fibroblasts and 
observed that Tau could stabilize existing MTs and induce assembly of new MTs, which fits 
with the proposed roles of Tau in axonal MTs stability (Drubin and Kirschner, 1986). 
Studies have also shown that Tau abnormalities strongly correlate to the pathophysiology of 
neurodegenerative diseases, including AD (Kolarova et al., 2012). 
MT assembly dynamics are controlled by processes such as treadmilling and dynamic 
instability which maintain a constant polymer mass (Margolis and Wilson, 1978; Kirschner 
and Mitchison, 1986; Kerssemakers et al., 2006). Treadmilling involves producing a net 
gain or loss at the plus end of the MTs, with the minus being stabilised at the MTOC 
(Bergen and Borisy, 1980). The growing end of an MT can be stabilized by different factors 
including MAP binding, the presence of a GTP cap, or interaction with other cytoskeletal 
membrane elements (Kirschner and Mitchison, 1986; Gelfand and Bershadsky, 1991). 
The stability and assembly of MTs is highly dependent upon MAPs, which help regulate 
the dynamics of the tubulin heterodimers (Lodish et al., 2000a; 2000b). MAPs can 
stimulate MT assembly and they are involved in the interaction of MTs with actin filaments 
and IFs (Cleveland, 1993).  
The ability of MTs to help organise axonal development and growth is well established; as 
the developing neurites begin to extend, MTs are assembled and begin to be modulated by 
specific post-translational modifications of the tubulin subunits (Cambray-Deakin, 1991). 
MAPs play essential roles in this process, as they help to maintain the structure, function, 
and orientation of MTs involved (Heidemann et al., 1981; Craig and Banker, 1994; 
Mandell and Banker, 1995).  Due to the important roles of MTs in different aspects of 
neuronal development and functions, any disruption or alterations to MT protein 
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phosphorylation by toxic agents can lead to problems with brain development, and these 
types of changes may also be involved in the pathophysiological mechanisms of some 
neurodegenerative diseases (Millecamps and Julien, 2013). 
A number of studies have investigated the ability of CPF and CPO to disrupt the MT 
cytoskeleton and therefore cause developmental neurotoxicity. One study exposed 
differentiating rat C6 glioma cells to sub-cytotoxic (1-10 µM) doses of CPF and CPO that 
inhibited neurite outgrowth, and these doses reduced the protein levels of α-tubulin and 
MAP 1b in this cell line (Sachana et al., 2008). These results are further supported by the in 
vivo work of Abou-Donia (1993), who found after exposure to OPs, hens exhibited 
increased phosphorylation of cytoskeletal proteins including MAPs and tubulin, which 
would result in lower active protein levels, and also an increase in autophosphorylation of 
calcium/calmodulin kinase II (Abou-Donia, 1993). In addition, work in cultured rat brain 
slices showed exposure to doses of CPO between 0.1 to 10 µM induced alterations in the 
MAP-2 immunoreactivity (Prendergast et al., 2007). All of this suggests that alterations to 
MTs could be a useful biomarker of CPF-induced neurodegeneration. 
1.11.3 Intermediate filaments 
Intermediate filaments (IFs) are important components of the eukaryotic cytoskeleton, and 
they are can be useful markers of cell differentiation (Omary et al., 2006). They include an 
array of proteins expressed in different cell types and are classified as type I to VI based on 
gene sequence homology (Table 1.3) (Lewis and Cowan, 1986; Osborn and Weber, 1986; 
Robson, 1989; Strelkov et al., 2003; Eriksson et al., 2009). IFs are more biochemically 
stable and smaller in diameter than MTs, which allows them to provide structural support to 
many different types of cells, including neurons (Omary et al., 2006).  
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Table 1.3. Intermediate filament classification. 
 (Lewis and Cowan, 1986; Osborn and Weber, 1986; reviewed by Robson, 1989; Strelkov et 
al., 2003; Eriksson et al., 2009). 
Type Name Tissue/Cell 
I Acidic cytokeratins Epithelial cells 
II Basic cytokeratins Epithelial cells 
III Vimentin 
Glial fibrillary acidic protein (GFAP) 
Desmin 
Paranemin 
Synemin 
Peripherin 
Mesenchymal cells 
Glial cells 
Muscle cells 
Muscle cells 
Muscle cells 
Neuronal cells 
IV Neurofilaments 
Internexin 
Nestins 
Syncoilin 
Neuronal cells 
Neuronal cells 
Pluripotent cells 
Muscle cells 
V Nuclear lamins All cell types 
VI Phakinin  
Filensin 
Eye lens cells 
Eye lens cells 
 
All IF proteins have a conserved α-helical rod domain, which is flanked by a carboxy-
terminal tail, and an amino-terminal hypersensitive head domain (Figure 1.8) (Cooper and 
Hausman, 2000). The central rod domain contains a highly homologous 310 aa residue 
region that is conserved amongst the main IF types, and the variations in molecular 
interactions and molecular weight of all the IF subunits are determined by the sequence of 
the two end domains (Cooper and Hausman, 2000). IFs are constructed initially from two 
polypeptide chains that are wound together in a parallel form that then make a helical 
coiled-coil dimer; two of these then form a staggered tetramer (two anti-parallel dimers), 
which then form octamers, then protofilaments, and finally large complex IFs that contain 
16 to 32 polypeptides (Lodish et al., 2000b). 
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Figure 1.8. Structure of intermediate filament protein subunits.  
The diagram demonstrates the structure of IF protein monomer that contains an α-helical rod 
domain composed of 310 amino acid residues, an amino-terminal head domain and the carboxy-
terminal domain at the tail.    
 
Within the family of IF proteins, more than 50 different proteins have been identified that 
can be classified into six main groups based on aa sequence homology (Cooper and 
Hausman, 2000). There are types classes of IFs specific to the nervous system and these 
include neurofilament (NF) proteins, glial fibrillary acidic proteins (GFAP) and nestins, 
which are mainly expressed in astroglial and neuronal cells, respectively (Cooper and 
Hausman, 2000; Eriksson et al., 2009).  
1.11.3.1 Neurofilaments  
The axonal cytoskeleton contains MTs, MFs and NFs that form ordered networks of 
interconnected filaments linked by cross-bridges (Black and Lasek, 1980). After synthesis, 
NFs are initially assembled and transported from the neuronal cell body into the axonal 
space slowly, in a non-diffuse manner, then they are rapidly incorporated into the axonal 
cytoskeleton (Black and Lasek, 1980).  
NFs are made of three polypeptides chains called neurofilament light (NFL), medium 
(NFM), and heavy (NFH) chains, that can be categorised based on their molecular weights, 
which are approximately 70, 145 and 200 kDa, respectively (Ackerley et al., 2003). In 
mammals, these three protein types are found in mature neurons, and they are also highly 
expressed in axons (Lee and Cleveland, 1994). During axonal extension NFs can provide 
support, and they also have major roles in the regulation of axonal development and growth 
which is carried out in a complex series of interactions (Lee and Cleveland, 1994).  
NFs have a similar structure to the other IF proteins; each subunit of NF contains a head, a 
central rod and a tail domain (Yuan et al., 2012). During NF polymerization, the central rod 
domain (310 amino acids) plays an important role, whereas in NFM and NFH the tail 
domains have an important role in fine lateral projection formation (Yuan et al., 2012). NFs 
can form filaments 10 nm in diameter via the central rod domain of each NF being co-
assembled with the other NFs (Rao et al., 2003). NFM and NFH subunits are found on the 
Rod domain 
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surface of the filament and form radial projections to interconnect NFs with other 
cytoskeletal elements, and NFL forms the central core (Rao et al., 2003). This filament 
structure allows cross bridges to form between extensions of the NF tail domains and other 
cytoplasmic organelles, and this stabilizes the axonal outgrowth (Hirokawa et al., 1984). 
Studies on the effect of OPs on IFs have found an alteration in expression or activity of 
different types of IFs, all of which can affect neural development. Studies in differentiating 
N2a cells that used exposure of CPF at levels that were sub-cytotoxic, but still inhibitory to 
neurite outgrowth (3 µM), showed there was a significant reduction in the concentration of 
total NFH (Sachana et al., 2001). This change in NFH is further supported by the work of 
by Flaskos et al. (2011), who used neurite inhibitory concentrations of CPO in 
differentiating N2a cells and then detected changes in protein levels using densitometric 
analysis of Western blots; they found there was a reduction in total NFH levels, which 
occurred in a concentration-dependant manner (Flaskos et al., 2011). These results are also 
similar to those found by Hargreaves et al. (2006), who showed that using PSP at neurite 
inhibitory sub-cytotoxic concentrations resulted in reduced total NFH concentrations, after 
exposure of differentiating N2a cells for 4 and 24 hours, and Sindi et al., (2016) that found 
CPO and CPF induced transient changes in NFH phosphorylation after differentiation 
(Hargreaves et al., 2006; Sindi et al., 2016). Overall, these alterations in NFH levels 
suggest that OP compounds, such as CPF and CPO, can interfere with the expression of 
important axonal cytoskeletal proteins, and this can affect the arrangement within the cell 
of the cytoskeletal networks (Flaskos et al., 2007; Harris et al., 2009a).  
1.11.4 Glial fibrillary acidic proteins 
Within mature astrocytes in the nervous system the major IF protein is GFAP (Yang and 
Wang, 2015). It is also found in other types of cells, including the non-myelinating 
Schwann cells in the PNS (similar to astrocytes), and the glial cells of the digestive system 
(Yang and Wang, 2015). GFAP plays important roles in providing structural support to 
astrocytes, and it helps to modulate their motility and shape during their different processes 
(Eng et al., 2000). Astrocytes can be activated via reactive astrocytosis or astrogliosis in 
response to neuronal toxicity, brain injury, neural damage, or in genetic disorders 
(O’Callaghan, 1988). OP intoxication of astrocytes can be detected by the characteristics of 
increased GFAP expression levels and astroglial cells number; early studies into the effect 
of OP toxicity on astrocytes suggested GFAP expression and astro-glial cell levels were 
both increased in response to exposure (O’Callaghan, 1988). This was supported by studies 
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into the production of GFAP-deficient-mice, which showed there was an association with 
behavioural and neurological abnormalities, reduced spinal cord myelin thickness, and 
abnormal myelination (Gomi et al., 1995; Liedtke et al., 1996).  
 During brain development, glial development and differentiation can be detected by an 
increase in GFAP expression; they start as neural precursor cells and form astrocytes, and 
this process usually reaches a peak in the second or third postnatal week (Bramanti et al., 
2010). Due to this change GFAP is recognised as a biomarker for astrocyte differentiation, 
and as glial development continues into adolescence, the effects of CPF and CPO exposure 
on developing glia may contribute to developmental neurotoxicity (Bramanti et al., 2010).  
In vivo studies in developing rats by Garcia et al. (2002) showed that after 4 days of 
subcutaneous CPF administration, which corresponded to the peak of glial differentiation 
and gliogenesis, there was a decrease in GFAP levels (Garcia et al., 2002). Studies in 
differentiating rat C6 glioma cells have found similar results of a decrease in GFAP 
expression after treatment with sub-cytotoxic concentrations (1-10 µM) of diazinon oxon 
(DZO) for 24 hours, which suggests that the OPs can interfere with the development of 
astro-glial cells (Sidiropoulou et al., 2009b). 
Further evidence of the importance of GFAP in neurodevelopment and neurotoxicity comes 
from studies that have detected increased levels of this protein in the brains of humans 
suffering from neurodegenerative conditions including Parkinson’s and Alzheimer’s  
disease (Zhang et al., 2014). Overall, the results of these studies suggest that GFAP could 
be a useful protein marker for detecting alterations in neurological pathophysiology and 
developmental neurotoxicity (Liu et al., 2012). 
1.11.5 Microfilaments and GAP-43  
Another class of cytoskeletal network proteins are the MFs; the core filament is formed by 
polymerisation of actin, which has an approximate molecular weight of 43 kDa (Theriot, 
1994; Hargreaves, 1997). The polymerisation of two globular strands of actin (G-actin) 
monomers forms MFs; the actin strands twisted around each other to produce F-actin, and 
this occurs through adenosine triphosphate (ATP) binding (Theriot, 1994; Hargreaves, 
1997).  
The dynamics of MF production occur through the exchange (incorporation and release) of 
G-actin monomers at the polymer ends (Zhang et al., 2005). The process of exchange is 
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regulated by the binding/hydrolysis of ATP and interactions with specific actin binding 
proteins including growth associated protein-43 (GAP-43) and actin depolymerizing factor 
(ADF, also known as cofilin) (McGough and Chiu, 1999).  
GAP-43 has been suggested to also play an important role in neurite outgrowth regulation 
(Skene, 1989; Pekiner et al., 1996). It is found mainly in the elongating axons and growth 
cones in neurons (Das et al., 2004). GAP-43 regulates a number of processes during 
neuronal development, including the plasticity of synapses, the development of axons, and 
the formation of growth cones (Benowitz and Routtenberg, 1997). During axonal 
outgrowth, studies have shown an increase in GAP-43 synthesis, which means disruption of 
neurite outgrowth could be indicated by an altered expression of GAP-43 (Skene, 1989; 
Pekiner et al., 1996; Das et al., 2004). 
Studies on the effects of OPs on MFs have suggested that OP toxicity may be linked to        
a disruption in MF regulation. For example, a study by Harris et al. (2009b) in N2a cells 
found there was increased levels of cofilin after the cells were induced to differentiate in the 
presence of 10 µM diazinon (DZ) for 24 hours. These changes in the observed cofilin levels 
could indicate a disruption in MF polymerisation and dynamics, which would affect the 
organisation of the MF network (Harris et al., 2009b). 
Numerous studies have evaluated the effect of exposing differentiating N2a cells to neurite 
inhibitory concentrations of CPF, CPO and other OPs, and the results show an association 
with reduced levels of GAP-43 (Fowler et al., 2001; Sachana et al., 2001; 2003; 2005; 
Sidiropoulou et al., 2009a; Flaskos et al., 2011). These findings indicate that a reduction in 
GAP-43 synthesis may lead to a loss of transport of GAP-43 from the cell body to dendrites 
and axons, which would inhibit neurodevelopment. Overall, this suggests GAP-43 could be 
used as a molecular marker to detect OPs-induced inhibition neurite outgrowth (Sachana et 
al., 2005).  
1.12 Genotoxic effects of organophosphorus compounds  
Studies on the long-term effects of OP pesticide use suggest there is an association with 
increased incidence of certain cancers, such as non-Hodgkin’s lymphoma, in individuals 
who are occupationally exposed to OPs (Dreiher et al., 2005). This suggestion of OPs 
causing DNA damage is supported by the work of Atherton et al. (2006), who used the in 
vitro comet assay to demonstrate the ability of the concentration 2.7 nM of dichlorvos to 
cause DNA damage in freshly isolated human lymphocytes from six healthy individuals. 
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Additional studies of OP exposed workers, such as that by Atherton et al. (2009), who 
studied lymphocytes from horticultural farm workers in Spain immediately after application 
of OP to crops, provide a better picture of the extent of DNA damage. The results of this 
study showed there was an increase in oxidative stress linked to DNA damage, and 
increased levels of 8-oxodeoxyguanosine which correlated with increased concentrations of 
urinary OP metabolites, even though the sample number was low (Atherton et al., 2009). 
Further studies of OP exposed workers and studies on OP exposed cultured cells is needed 
to fully understand the mechanisms of OP associated DNA damage or altered gene 
expression (Paz-y-Mino et al., 2002). Of particular interest to the present study were the 
effects of CPF, CPO and PSP on gene expression and its regulation. 
1.12.1 CPF, CPO and PSP associated genotoxicity 
Early studies in the developing rodent brain, suggested that CPF exposure is associated 
with inhibition of protein and DNA synthesis, thereby affecting the normal brain 
development after the treatment by subcutaneous administration of 2 mg CPF/kg body 
weight (Whitney et al., 1995). Moreover, CPF exposure has also been associated with the 
inhibition of DNA synthesis, neuronal cell replication as well as neurite outgrowth in 
studies with neural cell lines (Song et al., 1998; Das and Barone, 1999; Qiao et al., 2001; 
Sachana et al., 2001).   
Exposure to in vivo (neonatal rats and female Sprague-Dawley rats) and in vitro (N2a, 
PC12 and HeLa cells) CPF can also stimulate increased ROS production, in a reversible 
manner, which may affect DNA and proteins within cells (Bagchi et al., 1995; Bagchi et 
al., 1996; Crumpton et al., 2000a).  
In vitro studies in PC12 and C6 mammalian cell lines have suggested that CPF may also 
interfere with the cell replication and differentiation of glial cells in the brain (Qiao et al., 
2001). Other studies have indicated that CPF and CPO at sub lethal concentrations 1-10 µM 
can inhibit the induction of glial cell differentiation in the presence of sodium butyrate 
(Sachana et al., 2008). Exposure of glial cells to CPF is linked with increased ROS 
production; however, the ROS production is not a result of a direct chemical action, rather 
it is associated with the ability of CPF to interfere with cell metabolism (Crumpton et al., 
2000b).  
In vitro studies have suggested that CPF does not cause DNA damage; for example, the 
work by Gollapudi et al. (1995) in rat lymphocytes and Chinese hamster cells (CHO) using 
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the chromosome aberration test showed 0.35 to 35.0 µg/ml CPF for 24 h did not cause 
DNA damage. Muscarella et al. (1984) also worked with CHO cells exposing them to 1, 10 
and 100 µg/ml of CPF, and a no increase in the rate of chromosome aberration or sister 
chromatid exchange. This is further supported by the work of Cui et al. (2006) who used 
mouse hepatocytes to evaluate the potential of cypermethrin and CPF to form DNA 
adducts, and their results suggested CPF caused an increase in micronuclei incidence but 
that CPF could not form DNA adducts. In contrast, Rahman et al. (2002) used the alkaline 
comet assay to measure DNA damage in mice leucocytes, and concluded that CPF could 
cause damage in a dose-dependent manner. They also found that any damage to the DNA 
was repaired 48 hours after exposure, which could explain was it was not detected in the 
other studies. 
However, it is important to consider both CPF and CPO for in vivo studies, as CPF is 
readily metabolised to the active oxon form in animals, due to the abundance of cytochrome 
P450s (Costa, 2006). There is some evidence from in vivo studies that CPF does have an 
effect, for example Amer et al. (1982) demonstrated significant increase micronuclei in the 
bone marrow of mice after repeated or dietary administration of CPF. They found that after 
two injections in one week of 45 mg/kg body weight (interval between dosing not stated), 
mice had a mean of 23 micronuclei (MN) per 1000 polychromatic erythrocyte (PCE), 
compared to 10.8 MN-PCE for the control. This MN-PCE background has been questioned 
as being quite high, with suggestions of a normal background being approximately 4 MN-
PCE, suggesting the results may not be valid. The same group in 1996 found that dosing 
mice with and intra peritoneal injection of CPF at 4 mg/kg resulted in 57 chromosomal 
aberrations (aberrant metaphase 22.8 ± 0.79 % including gaps (P < 0.01), 14.8 ± 1.35 % 
excluding gaps (P < 0.05)) 24 hours after exposure (Amer et al., 1996). In contrast 
Gollapudi et al. (1995) found there was no significant increase in MN in bone marrow after 
using a dose of 111 mg/kg that was 80 % of the estimated lethal dose (LD50) for CPF. 
Further in vivo studies in mice have been carried out by Rahman et al. (2002), who used 
Swiss albino mice to investigate the DNA damaging capacity of CPF, using 
cyclophosphamide as a positive control. The mice were administered 24, 48, 72, and 96 
hours using whole blood samples. They found a dose related statistically significant 
increase in DNA damage after 24 hours, when compared to the positive control, and the 
DNA damage decreased over time due to DNA repair pathways.  
Other groups have used Drosophila melanogaster to study DNA damage and apoptosis 
caused by CPF, for example Gupta et al. (2010) treated third instar Drosophila larvae with 
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different concentrations of CPF (0.015-15.0 µg/L) for 24-48 hours. To determine the 
damage caused, oxidative stress markers, ROS generation, apoptotic cell death and DNA 
damage end points were measured, and they found that in 15.0 µg/L CPF-treated 
organisms, there was a significant increase in DNA damage, which was associated with the 
apoptotic mode of cell death for both 24 and 48 hour treatments. The study also found that 
CPF exposure induced depolarisation of the mitochondrial membrane potential, and an 
increase in the activity of caspase-9 and caspase-3, suggesting that ROS may be involved in 
inducing DNA damage and apoptosis in Drosophila larvae (Gupta et al., 2010). 
Another type of study to evaluate the DNA damaging potential of CPF was carried out by 
Salazar-Arredondo et al. (2008), who evaluated the effect of different OPs on sperm DNA 
using the sperm chromatin structure assay. The damage was assessed in human 
spermatozoa from healthy volunteers after incubation with the non-cytotoxic (evaluated by 
eosin-Y exclusion) doses of 50-750 µM CPF and CPO. The results showed that CPO was 
15 % more toxic than CPF to sperm DNA. 
Other studies have investigated the toxicity of TOTP and PSP in SH-SY5Y human 
neuroblastoma cell cultures, using the fluorescent stain Hoechst 33342 to investigate 
whether OP-induced cell death was via apoptosis or necrosis (Carlson et al., 2000). The 
results showed that exposure to PSP (10 and 100 µM) resulted in significant (p < 0.05) 
increases in apoptosis in a time-dependent manner, with increases in budding and nuclear 
condensation at1 mM (Carlson et al., 2000). This study also investigated caspase-3 activity 
and found that exposure to all 3 concentrations of PSP resulted in significant (p < 0.05) 
increases in caspase-3 activation, again in a time-dependent manner (Carlson et al., 2000). 
To further elucidate the mechanisms involved, the cells were pre-treated with cyclosporin A 
(to inhibit apoptosis) or the serine esterase inhibitor PMSF (to help detect the method of 
inhibition) resulting in significantly (p < 0.05) decreased caspase-3 activation after 
treatment with 1 mM PSP and TOTP, which suggested that the OP-induced cytotoxicity 
could be modulated through different mechanisms, such as receptor-mediated caspase. In 
addition, they found that the exposure to 1 mM PSP induced random DNA fragmentation, 
and necrotic morphological changes (Carlson et al., 2000).  
Overall, these results suggest OPs like CPF, CPO and PSP do have the ability to induce 
DNA damage, but the questions remain as to the exact mechanisms involved in different 
cell types. The previous studies into OP, and specifically CPF, toxicity have highlighted 
changes in key neuronal proteins, which are good starting point for determining the actual 
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mechanism behind the toxicity. Moreover, as the effects of OPs on gene expression are still 
not fully understood, further study is needed to elucidate the actual mechanisms of toxicity, 
which will help to prevent and detect toxicity of OP. 
1.13 The use of in vitro mammalian cell line models for assessment of 
organophosphate induced neurotoxicity 
Animal experimentation is now associated with a high economic and ethical impact, 
combined with the time consuming, laborious, and complex processes required for 
neurological experiments due to the complexity and relative inaccessibility of the nervous 
system, which has meant that investigators are keen to identify alternative methods for use 
to assess both pathological and physiological processes. One such method is the use of in 
vitro cellular models; the main advantages of mammalian cell lines comes from their ability 
to grow and reproduce quickly. They form homogenous cells in large numbers using 
relatively simple preparation methods, which means they can be grown and maintained for 
extended periods, cryopreserved, and reanimated easily to re-test at different intervals with 
the same cells (Radio and Mundy, 2008; Flaskos, 2012). In addition, in vitro models can 
provide invaluable information as they are a simplified tool that can be used for studying 
OP induced neurotoxicity at both molecular and cellular levels in a specific cell type (Silva 
et al., 2006). There are some limitations for neurotoxicity assessment with cell culture 
models including partial involvement of pharmacokinetic factors, lack of cell to cell 
interaction, such as between glial and compromise their ability to reliably predict or model 
in vivo toxicity (Rice and Barone, 2000; Flaskos, 2012). However, there are important 
advantages of these culture systems which make them an appropriate approach in this 
project.  
The advantages of cell lines over in vivo studies include the ability to screen or study the 
effects of multiple doses of toxins or mixtures of toxins on specific cell models at relatively 
low cost compared to animal models, which has led to an increasing number of publications 
using different cell lines to study the effects of OPs. Another key advantage for the current 
study is the ability to allow different concentrations of CPF and CPO to be tested on glial 
cells and neuronal separately, which means the different contributions of the toxicity on 
these cells types can be determined (Flaskos, 2012). Using cell lines can result in not only 
qualitative assessment of cytotoxic effects, but also the quantitative detection of any 
cellular alterations, such as molecular changes within specific neuronal cells expressing 
specific neurite morphological features, such as dendrites and axons. This level of control 
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means the research methodology can be adjusted by controlling the onset and timing of 
development to fit the requirements of the study (Banker and Goslin, 1998). These 
advantages of cell lines mean that are suitable models for using in high throughput 
screening methods, which allows studies into the primary screening of compounds 
(Giacomotto and Ségalat, 2010).  One of the key disadvantages of the using a cell culture 
system is the lack of replication of systemic effects, such as cell-cell interactions in tissues, 
the input of other organs including the liver where toxic agents are degraded or 
bioactivated, bio-eliminated, and excreted form the body, or appropriate supply and balance 
of growth factors (Sprague and Castles, 1985; Sachana and Hargreaves, 2012). The 
availability of growth factors can be partially addressed by inclusion of suitable growth 
factors in the media, and cell-cell interactions can be tackled to some extent by using organ 
culture or co-culture systems (Sachana and Hargreaves, 2012). Some of the effects of the 
liver can be mimicked by using processes to bioactivate or inactivate the toxin being 
investigated using microsomal activation (Sprague and Castles, 1985). The systemic effects 
can also be addressed by using other metabolic activation systems, such as hepatic cells or 
microsomes that are nicotinamide adenine dinucleotide phosphate hydrogen (NADPH) 
activated contained in a cell culture well with a filtered-insert (Sachana and Hargreaves, 
2012). The insert allows the toxin to be introduced to the cells or microsomes and then the 
non-metabolized and metabolized toxin diffuses into the growth medium below where it 
can be accessed by the cell line of interest (Sachana and Hargreaves, 2012).  
A large proportion of OP neurotoxicity studies have used neuroblastoma cell lines from 
different species, including mouse N2a neuroblastoma, rat PC12 pheochromocytoma, and 
human neuroblastoma clones SH-SY5Y, IMR32, C-1300, and N-18, and there have also 
been many studies using the rat C6 glioma cell line. Some of these studies have used the 
cell lines to evaluate NTE inhibition after OP exposure, as a potential replacement for the 
use of homogenates from hen brains after OP exposure in vivo (Fedalei and Nardone, 1983; 
Ehrich, 1995; Ehrich et al., 1994).  
Other studies have focused on the effects of OPs on the cellular mechanisms in both glioma 
and neuroblastoma cell lines; for example, studies by Henschler et al. (1992) and Schmuck 
and Ahr (1997) both investigated a large number of OPs in rat C6 glioma and human N-18 
neuroblastoma cell lines. These cell lines were cultured, differentiated and then treated with 
a panel of OPs for up to three weeks. One of the major drawbacks of this experimental 
design was the lengthy incubation period, which would have resulted in high levels of 
cytotoxicity, which could affect the usefulness of the results observed. These culture 
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conditions were also very different from the conditions seen for OPIDN induction in vivo, 
studies have shown NTE and cytoskeletal protein inhibition occurs within 24 hours of OP 
exposure, which suggests these studies may have missed key early cellular changes based 
on their design (Abou-Donia 1993; 1995). 
A more mechanistic approach was developed by Flaskos et al. (1994; 1998), which used 
sub-lethal concentrations of OPs given to cultured cell lines, which were then studied for 
short time periods. As PC12 cells can be effectively cultured for several weeks before cell 
loss, they used them to study axon maintenance and found sub-cytotoxic levels of TCP (1 
µg/ml) inhibited neurite maintenance (Flaskos et al., 1994). The studies also used glioma 
and neuroblastoma cell lines to investigate the early OP effects, and they found there was 
no effect on cell viability even after 48 hours with the doses used (Flaskos et al., 1994; 
1998). These sub-cytotoxic conditions were also used in cell lines to investigate the effects 
of OPs on the nervous system, mainly the glial and neurons, neurite outgrowth, and the 
effects on expression of cytoskeletal proteins. The studies found CPF, CPO and PSP caused 
alterations neurite outgrowth, cytoskeletal protein expression, axon growth associated 
proteins and those involved in cell signalling pathways (Sachana et al., 2001; Sachana et 
al., 2008; Flaskos et al., 2011; Flaskos, 2014; Sindi et al., 2016). 
The use of human derived neural stem cells may enhance the ability to predict CPF and 
CPO neurotoxicity with more human relevant results, but currently there is not enough 
evidence to clearly show an advantage of these stems cells over rodent derived cell lines in 
terms of predicting human neurotoxicity (Radio and Mundy, 2008). Three mammalian cell 
lines that are commonly used to investigate CPF and CPO developmental neurotoxicity are 
further described below. 
1.13.1 N2a neuroblastoma cell line 
One of the most widely used cell lines for studying OP toxicity is the N2a cell line, 
especially for studies to investigate neurite outgrowth and neuronal differentiation 
(Henschler et al., 1992; Flaskos et al., 1998; 2011; Sachana et al., 2001; 2003; 2005; 2014; 
Hargreaves et al., 2006; Sidiropoulou et al., 2009a). The N2a cell line was originally 
derived from a C1300 mouse tumour (neuroblastoma); these cells are able to be 
differentiated into cells with a neuron-like morphology, and they can then express many 
neuronal markers, including cholinergic and adrenergic markers, and AChE, which is 
important for studying OP toxicity (Klebe and Ruddle, 1969). N2a cells grow under normal 
mitotic conditions as round neuroblasts. The differentiation process for N2a cells starts by 
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serum removal from the medium; this helps to form the non-dividing differentiating cells 
which have the morphological characteristics of neurons. This serum free medium is 
supplemented by the addition of dibutyl cyclic 3’,5’-monophosphate (dbcAMP), which 
mimics cAMP action to promote N2a cell differentiation (Schubert et al., 1969; Haffke and 
Seeds, 1975). During differentiation, N2a cells undergo morphological changes including 
the formation of dendrite- and axon-like processes contain have high concentrations of 
cytoskeletal proteins, including MTs and NFs, which makes them an ideal cell line for 
studying the effect of OPs on these types of proteins (Schubert et al., 1969). 
One of the main disadvantages of using the N2a cell line for OP toxicity studies is the fact 
that the dendrites and axons produced by these cells may not be able to reproduce some of 
the more complex characteristics that are observed in neurites from primary neurons, 
meaning that some effects of the toxicity may be missed or reduced due to the lack of 
connections (Radio and Mundy, 2008). Overall, these cells are a suitable model for 
investigating CPF neurotoxicity as they express some of the key targets for toxicity, 
including AChE, MTs and NFs, they grow quickly and reproducibly, and they are 
commercially available, which outweighs the disadvantages. 
1.13.2 C6 rat glioma cell lines 
The C6 rat glioma cell line has also been widely used to study the effect of OPs, with 
differing results between the studies (Sachana et al., 2008). The C6 cell line was originally 
derived from glioma cell line was originally derived from an N-nitrosomethyl-urea-induced 
rat brain tumour, and have been used as an in vitro model for the investigation of glial 
properties for many years, including expression of GFAP, 2':3'-cyclic nucleotide 3'-
phosphohydrolase, glycerol phosphate dehydrogenase by glucocorticoid hormones, and S-
100 protein (Wolfe et al., 1980). 
Schmuck and Ahr (1997) and Henschler et al. (1992) used C6 glioma and human N-18 
neuroblastoma cell lines to investigate the effects of many OPs by treating the cells for 
three weeks, and the results showed high levels of cytotoxicity due to the long exposure 
period. The C6 cell line has been used to study the effect of OPs neurite outgrowth, and the 
results of the studies have shown that sub-cytotoxic concentrations, OPs including CPF and 
CPO, inhibit neurite outgrowth (Henschler et al., 1992; Schmuck and Ahr, 1997; Flaskos et 
al., 1998). These cell lines are suitable for use in conjunction with the N2a cell line as they 
provide more information about how OPs cause neurotoxicity in different key cell types 
within the brain. 
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1.13.3 Human neural progenitor stem cells (ReNcell CX) 
Although N2a and C6 cell lines have many advantages for investigation the process of OP 
toxicity, they are both monocultures that lack neuronal-glial interactions and both of them 
are rodent cell lines. There is, however, a neural progenitor stem cell line that could offer 
different advantages for these types of studies, namely the ReNcell CX cell line. This cell 
line, is can be induced to differentiate to form a co-culture of different neuronal and glial 
cell types, such as cholinergic and dopaminergic neurons, astrocytes and oligodendrocytes, 
and is commercially available (Merck Millipore) (Seaberg and van der Kooy, 2003). The 
origin of the ReNcell X cells was a 14-week gestation human foetus with a normal male 
karyotype, specifically the cortical region of brain, which was then immortalized using c-
myc oncogene retroviral transduction and this produced unlimited growth of clonal human 
neural stem cells (Donato et al., 2007; Kornblum, 2007). The morphology of these cells on 
uncoated tissue culture flasks starts as round neurospheres when they are undifferentiated, 
but when they are grown on laminin coated surfaces as a monolayer, with the appropriate 
growth factors, they produce a normal diploid karyotype, which is maintained even after 
prolonged passage (Jakel et al., 2004). When grown on a laminin coated surface in the 
absence of miotogens these cells differentiate into a mixed population of three main 
nervous system cell types, astrocytes, oligodendrocytes, and neurons (Figure 1.9), which 
are identical to those found in the human nervous system (Kornblum, 2007). One key 
advantage of these cells over N2a and C6 cells is the fact the dendrites and axons produced 
in this cell line form the same level of complex interactions as neurons in humans, making 
them an ideal choice for studying OP toxicity in a more relevant human model (Bal-Price et 
al., 2008; Radio and Mundy, 2008). 
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Figure 1.9. Schematic representation of neural stem cell differentiation. 
1.14 Summary 
Historically, OPs have been used in a number of industrial, agricultural and domestic 
settings, with a wide range of applications, but as more investigations were carried out it 
became clear that these types of compounds are toxic, causing different levels of 
neurotoxicity depending on the dose, age of patient and route of exposure. Due to this 
toxicity, many countries have put restrictions on their use in residential settings and 
limitations in place for their agricultural use, but these pesticides are still very widely used 
in developing countries. Despite the potential dangers to health and the imposed 
restrictions, CPF remains a popular pesticide to use especially in many developing 
countries (Salyha, 2010). The main OPs selected for this study were CPF, CPO and PSP; 
these were chosen because they are widely used, have been studied for toxicity, and can 
induce the different stages of OP toxicity (acute cholinergic syndrome, intermediate 
syndrome, OPIDN, and COPIND) depending on dose, age of the patient, and the duration 
of exposure. CPF has been shown to affect different parts of nervous system, including glial 
cells, neurons, key cellular and cytoskeletal proteins, neurite outgrowth, and it can also 
affect DNA, therefore studying the effects on gene expression could provide key insights 
into its method of action.  
Studies of OP toxicity have shown that in vitro methods are suitable for studying the 
processes involved, and they have some advantages over in vivo methods, such as being 
able to produce large numbers of identical cells which will allow many OPs, or different 
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doses, to be screened at the same time. The main disadvantage of in vitro methods is that 
they lack the processing that occurs in the rest of the body, such as the bioprocessing that 
occurs in the liver, but some of these processed can be added into the methodology which 
will mimic the action of the liver, making the process more accurate.  
There have been many studies showing that CPF, CPO and PSP can all disrupt cytoskeletal 
protein formation and inhibit outgrowth in differentiating neural cell lines. Studies have 
also shown that the toxicity produced by OPs depends on when exposure occurs; exposure 
in different developmental stages can result in different effects. Previous in vitro studies 
have mainly involved OP administration at the induction of cell differentiation, meaning 
the results do not explore the full range of potential toxicities that could be produced. 
Currently, not many investigations have involved studying the genotoxic effects of OPs on 
cells, therefore this thesis has investigated this aspect of toxicity to increase the knowledge 
in this area, by examining the toxic effects of the selected OPs at different time points in 3 
different models of neural cell differentiation. 
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1.15 Project Aims  
Studies conducted by research colleagues have shown that treatments of sub-lethal 
concentration of CPF and CPO in differentiating mouse N2a neuroblastoma cells inhibited 
axon outgrowth and disrupted the cytoskeleton (Sachana et al., 2001; Sindi et al., 2016). 
Therefore, by replicating these culture conditions, the aims of this thesis were to: 
1. Determine the effects of CPF, CPO and PSP (1, 3 and 10 µM) on cell viability in 
differentiating N2a, C6 and human ReNcell CX stem cells, after treatment for 24 h.   
2. Determine the effects of sub-lethal exposure to all 3 OPs on different parameters of 
neurite outgrowth and the underlying effects on cytoskeletal proteins by high 
content analysis, cell ELISA and quantitative Western blotting. 
3. Generate oligonucleotide probes for neural marker genes for quantitative PCR in 
order to quantify the effects of sub-lethal concentrations of OPs on the expression of 
genes encoding key cytoskeletal proteins affected by OP exposure in these cell 
models.  
4. Investigate the effects of sub-lethal concentrations of CPF, CPO and PSP on the 
epigenetic regulation of gene expression focussing on histone deacetylatse activity 
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2.1 Materials 
2.1.1 General laboratory reagents 
All laboratory reagents were of the highest grade and purchased from Sigma-Aldrich 
Chemical Company (UK) unless otherwise specified in the text. They are listed in tables 
2.1 and 2.2. 
Table 2.1. List of cell culture reagents  
Reagents Code number Supplier 
Dulbecco’s Modified Eagle’s 
Medium (DMEM) with 4.5 
g/L glucose and 2 mM L-
glutamine 
BE12-614F 
Lonza (Slough, UK) 
Penicillin/streptomycin 
(penicillin 10,000 units/ml, 
streptomycin 10,000 
units/ml) 
DE17-602F 
Trypsin 10x 17-160E 
Foetal bovine serum (FBS) 
South American origin 
FB-1001 Biosera 
N6,2'-ODibutyryladenosine 
3',5'-cyclic monophosphate 
sodium salt (dbcAMP) 
D0627 
Sigma-Aldrich Sodium butyrate (NaB) B5887 
Dimethylsulphoxide 
(DMSO) sterile-filtered, 
BioReagent, suitable for  cell 
culture - hybridoma tested 
D2650 
Trypan Blue Solution 0.4% 
(w/v) 
1450021 Bio-Rad 
Laminin from Engelbreth-
Holm-Swarm murine 
sarcoma basement 
membrane 
L2020 Sigma-Aldrich 
StemPro® Accutase® cell 
dissociation reagent 
A11105-01 
Thermo Fisher Scientific StemPro
® Neural 
supplement 
A10508-01 
KnockOut™ DMEM/F-12 
(1X) 
12660-012 
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Neurobasal® -A medium, no 
L-glutamine, L-glutamic 
acid or aspartic acid 
10888-022 
Recombinant human 
epidermal growth factor 
(EGF) (10 µg) 
1380077C 
Recombinant human 
fibroblast growth factor b 
(FGFb) (10 µg) 
1424760B 
Table 2.2.List of other reagents and materials. 
Reagents Code number Supplier 
3,3',5,5'-
Tetramethylbenzidine 
(TMB) 
T0440 
Sigma-Aldrich 
3-(4,5-Dimethylthiazol-2-
yl)-2,5 diphenyltetrazolium 
bromide (MTT) 
M2128 
AccuGel 29:1 acrylamide 
(40% (w/v) 
acrylamide/bisacrylamide 
29:1) 
EC852 Geneflow 
StemPro Accutase Cell 
Dissociation Reagent 
A1110501 Thermo Fisher Scientific 
Acetone 121403/0031 Thermo Fisher Scientific 
Amersham Protran 0.2 μm 
pore size nitrocellulose 
membrane 
10600001 General Electric 
Ammonium persulphate 
(APS) 
A3678 
Sigma-Aldrich 
Bicinchoninic acid (BCA) 23223 
Bovine serum albumin 
(BSA) 
A1302 Melford 
Copper (II) phthalocyanine C2284 Sigma-Aldrich 
Dimethylsulphoxide 
(DMSO) 
CHE1854 Thermo Fisher Scientific 
Enhanced 
chemiluminescence reagent 
(ECL) 
ME157124 Thermo Fisher Scientific 
Ethanol 652261 Sigma-Aldrich 
Glacial acetic acid 200.580-7 Thermo Fisher Scientific 
Glycerol   10% (v/v) 15892001C ACROS organics 
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Hydrochloric acid H1000PB17 Thermo Fisher Scientific 
Hydrogen peroxide (H2O2) H1009 Sigma-Aldrich 
Methanol M400/17 Thermo Fisher Scientific 
β-Mercaptoethanol M3148 Sigma-Aldrich 
N,N,N,N-
Tetramethylethylene 
diamine (TEMED) 
T9281 Sigma-Aldrich 
Paraformaldehyde 4% (w/v) HT501128 Sigma-Aldrich 
Protogel® resolving buffer 
(4x) (1.5 M Tris-HCl buffer 
pH 8.8, 0.4% (w/v) SDS) 
EC892 
Geneflow 
Protogel® stacking buffer 
(4x) (0.5 M Tris-HCl buffer 
pH 6.8, 0.4% (w/v) SDS) 
EC893 
Sodium acetate S2889 Sigma-Aldrich 
Sodium azide S2002 Thermo Fisher Scientific 
Sodium chloride B22297 Sigma-Aldrich 
Sodium dodecyl sulphate 
(SDS) 
18299 Melford 
Sodium hydroxide (NaOH) 1823 
Sigma-Aldrich 
Sulphuric acid (H2SO4) 339741 
Tris (hydroxymethyl) 
aminomethane 
C22561 
Tween 20 P1379 
VectaShield® mounting 
medium for fluorescence 
containing 4',6-diamidino-2-
phenylindole (DAPI) 
H1400 Vector Laboratories Ltd 
2.1.2 Plastic ware 
All sterile cell culture flask sizes (T25 and T75) were supplied by Scientific Laboratory 
Supplies Nottingham, UK. Nunc brand Cryotube vials were purchased from Merck Ltd., 
Leicester, UK. NUNC-immuno 96-well and 24-well cell culture plates were purchased 
from Thermo Scientific, UK. IbidiTreat 8-well 15μ-slides were purchased from Thistle 
Scientific, UK. Counting slides with dual chambers (Cat#1450015) were from Bio-Rad 
Laboratories Inc., UK. Serological pipettes (5 ml, 10 ml and 20 ml), Gilson pipettes (P10, 
P1000, P200, P100, P20, P10, P2 and Integra pipettes were obtained from Scientific 
Laboratory Supplies, Nottingham, UK. 
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2.1.3 Test compounds 
Chlorpyrifos (CPF) and its metabolite, chlorpyrifos oxon (CPO) (purity 97.6 %) from 
Chem Service Inc. (West Chester, PA, USA), were supplied by Greyhound 
Chromatography (Birkenhead, UK). Phenyl saligenin phosphate (PSP) was synthesized by 
Dr Chris Garner (Department of Chemistry) at Nottingham Trent University and obtained 
at 98 % purity. Sterile filtered DMSO was used as control (purity 97.7 %). The final 
concentrations of the compounds 1, 3 and 10 µM were prepared freshly from the stocks 
0.2, 0.6 and 2 mM.   
2.1.4 Cell lines 
Three different cell lines were used in the current study and these were mouse 
neuroblastoma 2A (N2a), Rat C6 glioma and human neural progenitor stem cells (ReNcell 
CX). 
2.1.4.1 Mouse neuroblastoma 2A  
N2a is a well-established fast growing mouse neuroblastoma cell line derived from mouse 
neural crest (Klebe and Ruddle, 1969). N2a cells have been cultured and extensively used 
in research to study neural differentiation, neurofilament characteristics including neurite 
outgrowth and morphology, as well as signalling pathways involved in neurotoxicity, 
Alzheimer’s disease and asymmetric division of mammalian cells (Ogrodnik et al., 2014; 
Salto et al., 2015). It was purchased from the American Type Culture Collection (product 
no. CCL-131TM, Middlesex, UK). 
2.1.4.2 Rat C6 glioma  
The C6 glioma cell line was established after culturing a clone of a rat glial tumour 
induced by N-nitrosomethylurea (Benda et al., 1968). The C6 astrocyte cell line is 
fibroblast-like in morphology. It was purchased from the European Collection of Animal 
Cell Cultures (ECACC). The C6 astrocyte cell line, stains strongly positive for glial 
fibrillary acidic protein (GFAP). After 100 passages they can be used to study astrocytic 
functions including parameters of oxidative stress (Quincozes-Santos et al., 2009).  
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2.1.4.3 Human ReNcell CX 
The human neural progenitor stem cell line (ReNcell CX) was established by retroviral 
transduction of stem cells obtained from the cortical region of the brain from a 14-week 
gestating human foetus following normal termination and in accordance with nationally 
approved UK ethical and legal guidelines as described (Donato et al., 2007). It was 
purchased from Merck Millipore (catalogue no. SCC007, UK). ReNcell CX is an 
immortalized multipotent human neural progenitor cell line with the ability to differentiate 
into neurons, astrocytes and oligodendrocytes (Breier et al., 2010). ReNcell CX can be 
used for a variety of research applications including studies of neurotoxicity, neurogenesis, 
electrophysiology, neurotransmitter and receptor functions (Choi et al., 2014). 
2.2 Methods 
2.2.1 Cell culture and maintenance of N2a neuroblastoma cells and rat C6 glioma 
cells   
Mouse N2a and C6 glioma cell lines were grown and maintained as monolayer cultures in 
growth medium consisting of Dulbecco's modified Eagle’s medium (DMEM) containing 
4.5 g/L glucose and 2 mM L-glutamine, and supplemented with 10% (v/v) foetal bovine 
serum (FBS), penicillin (100 units/ml) and streptomycin (100 units/ml) at 37 °C, in            
a humidified atmosphere of 95% air /5% CO2. All experiments were performed using 
plastic tissue culture treated flasks, dishes, microplates or chamber slides. Culture medium 
was changed every 2-3 days. 
2.2.1.1 Sub culture and maintenance of N2a neuroblastoma cells and rat C6 glioma 
cells   
Mouse N2a neuroblastoma and rat C6 glioma cells were passaged when growth was 80 % 
confluent (i.e. every 3-5 days) as follows. In N2a cell monolayers, half of the growth 
medium was carefully removed from the culture flask without disturbing the attached cell 
monolayer. Cells were mechanically detached from the flask surface using a sterile extra-
long plastic Pasteur pipette to aspirate the rest of the growth medium and squirting it out on 
over the monolayer surface of the cell culture flask. C6 cells were mechanically detached 
from the flask by using the scraper in 5 ml of growth medium, and this method was shown 
to be effective and fast. In addition, there was an alternative method to maintain C6 cells, 
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after cell growth reached 80 % confluence in T75 culture flask before passage (i.e. every 3-
4 days). The spent medium was discarded from the culture flask, then the cell monolayer 
was washed with phosphate buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM 
Na2HPO4, 2 mM KH2PO4 pH 7.4) to remove all traces of serum. Cells were chemically 
detached from the flask surface by adding 2 ml of 1 % (v/v) trypsin solution to cover the 
cell monolayer and the flask was then placed in the 37 °C incubator for approximately 2 
min. The enzymatic reaction was stopped by adding 5 ml of pre-warmed fresh growth 
medium.  
N2a or C6 cells were then harvested by centrifugation at 300 × g at room temperature for 5 
min. The supernatant was carefully discarded and the resultant pellet was re-suspended in 1 
ml of growth medium by passing it 21 times through a P1000 micropipette tip to break up 
the pellet. About 1/5 of the cell suspension was then placed in a new T75 flask containing 
40 ml fresh growth medium and incubated in a humidified atmosphere containing 5 % 
CO2/95 % air at 37 °C until the growth reached 80 % confluent. All experiments were 
replicated at least 4 times, and controlled for passage number (less than 21), in order to 
avoid genetic drift, which may occur at higher passage.  
2.2.2 Human neural ReNcell CX stem cell culture and maintenance 
2.2.2.1 ReNcell CX maintenance medium 
ReNcell CX cells were maintained in KnockOutTM DMEM: nutrient mixture F-12 
(DMEM/F-12) low osmolality medium without HEPES buffer. The growth medium (500 
ml) was supplemented with recombinant human epidermal growth factor (EGF) (20 ng/ml; 
Gibco), basic fibroblast growth factor (FGFb) (20 ng/ml; Gibco), StemPro neuro 
supplement (2 % v/v; Gibco), L-glutamine (0.5 mM), penicillin (100 units/ml) and 
streptomycin (100 units/ml). 
2.2.2.2 ReNcell CX culture 
All plastic tissue culture ware used for ReNcell CX cells culture was pre-coated with 
laminin from Engelbreth-Holm-Swarm murine sarcoma basement membrane (Sigma-
Aldrich) prior to use. Laminin is an extracellular matrix (ECM) protein, which enhances 
neural progenitor stem cell adhesion, proliferation differentiation and neurite outgrowth 
(Flanagan et al., 2006). In brief, 1 mg/ml laminin was thawed at room temperature and 
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diluted to 20 µg/ml final concentration in Neurabasal medium (Gibco) that contained no L-
glutamine, L-glutamic acid, or aspartic acid.  Laminin solution was added to cover the 
surface of the required tissue culture vessels and left on a shaker for 4 h at room 
temperature if required to use on the same day, or afterwards stored at 4 °C until needed. 
The laminin solution was removed and the flask was rinsed with sterile PBS just before 
using a coated flask for culturing ReNcell CX cells. Cells were chemically detached from 
the flask surface by adding 1 ml of AccutaseTM cell detachment solution which contains 1x 
Accutase enzyme in Dulbecco’s PBS (0.2 g/l KCl, 0.2 g/l KH2PO4, 8 g/l NaCl, and 1.15 
g/l Na2HPO4) containing 0.5 mM EDTA-4Na and 3 mg/l Phenol Red). The flask was 
allowed to stand for 5min at room temperature. The enzymatic reaction was stopped by 
adding 4 ml of pre-warmed fresh growth medium and the cell suspension was centrifuged 
at 300 g for 5 min at 22⁰C.The pellet was resuspended by 10 passes up and down through   
a 1000 µl pipette tip in 1 ml of fresh growth medium. About 200 µl (i.e. ~ 1/5 of the total 
cells) of cell suspension were then placed in a new laminin coated T75 flask containing 40 
ml fresh growth medium and incubated in a humidified atmosphere containing 5 % CO2/95 
% air at 37 °C until the growth reached 80 % confluence.  
2.2.3 Cryopreservation of cell lines 
For cell storage and preservation, cells were stored under liquid nitrogen in cryovessels 
until needed. Briefly, the confluent cells from a T75 flask were detached, harvested and 
resuspended in 1 ml of freezing medium (DMEM for C6 and N2a or knockout DMEM/F-
12 medium for ReNcell CX, supplemented with 5 % (v/v) DMSO). Addition of DMSO to 
media prevents intracellular and extracellular crystals from forming in cells during the 
freezing process (Chen et al., 2017). This cell suspension was placed into 1 ml cryo vials, 
which were transferred to cell freezing container and incubated overnight at -80°C for        
a minimum of 8 h. The cryo vials were then transferred to a liquid nitrogen container        
(-196°C) and stored until needed. 
2.2.4 Cell recovery from liquid nitrogen storage  
For continuous growing, cells were thawed from liquid nitrogen and added to pre-warmed 
growth medium in culture flaks. In brief, a vial of cells was removed from the liquid 
nitrogen storage and held in a 37 °C water bath for 1-2 min. The outside of the vial was 
quickly wiped with 70 % v/v ethanol in distilled water to sterilise and the cells were 
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transferred into centrifuge tube using a 1 ml sterile pipette. A volume of 9 ml maintenance 
medium (pre-warmed to 37 °C) was gently added to avoid osmotic shock which may result 
in decreased viability. The cell suspension was centrifuged at 300 g for 5 min. The 
supernatant was completely discarded following centrifugation in order to remove any 
residual cryopreservation medium. The resultant pellet was resuspended in 1 ml of pre-
warmed growth medium. The cell suspension was then plated onto T75 tissue culture flask 
containing 40 ml of pre-warmed fresh maintenance medium for N2a and C6 glioma cell 
lines or onto a laminin coated T75 flask containing 20 ml of pre-warmed fresh growth 
medium for ReNcell CX. 
2.2.5 Cell plating for experimentation 
All experiments were preceded by cell seeding and counting in order to determine              
a specific cell density. In brief, cell monolayers were grown to reach 80 - 90 % confluence, 
then detached and harvested at 300 g by centrifugation for 5 min as described (sections 
2.2.1.1 and 2.2.2.2). Cell pellets were resuspended in 1 ml of growth medium. Cell 
dilutions were prepared depending on the pellet size and cell counting method. The initial 
cell count was performed either manually using a haemocytometer chamber slide, or 
automatically using an automated cell counter. 
2.2.5.1 Manual cell counting 
A volume of 10 µl was transferred to the chamber from a dilution of 10 µl cell suspension 
with (1:20 dilution) 190 µl of growth medium, and the cell number determined by using     
a haemocytometer. Chamber cell counts were performed in five fields of a Neubauer 
haemocytometer (each field has a volume of 10-4 cm3) by using an inverted light 
microscope (Inverso 3650 Fisher Scientific Ltd., UK). Cell density was calculated as 
follows: 
Cells / ml = cell number (average from five fields) x 104 (volume correction factor) x 
dilution factor 
The formula was used to calculate the volume necessary to achieve a specific cell density. 
The cells were allowed to recover for 24 h in a humidified atmosphere of 95 % air / 5 % 
CO2 at 37°C. 
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2.2.5.2 Automated cell counting 
Automated cell counting has recently become the robust alternative method to manual 
haemocytometer cell counting because it can provide total cell count and assess cell 
viability in one simple step. Moreover, automated cell counting produces an accurate, 
reproducible result with rapid performance. The results of the current study were achieved 
by using the Trypan blue exclusion procedure coupled with a TC20TM automated cell 
counter (BioRad, USA). The TC20™ automated cell counter can count cells with a 6-50 
µm diameter and within a broad concentration range of 5 x 104 to 1 x 107 cells/ml, which 
often eliminates the need to dilute cells, thus reducing the error associated with sample 
dilutions prior to counting. The device utilises already made Trypan blue dye (BioRad, 
USA) composed of 0.4 % (w/v) Trypan blue in 0.8 % (w/v) sodium chloride and 0.06 % 
(w/v) potassium phosphate dibasic solution. Trypan blue is a vital stain that differentiates 
between live and dead cells (Tran et al., 2011). The principle of this staining is based on 
the blue acid dye chromophores which are taken up by dead cells and excluded from viable 
cells.   
Briefly, depending on the size of the cells pellets which were resuspended in 2 ml pre-
warmed fresh growth medium and a volume of 10 µl from the suspended cells was added 
onto the same equal volume of Trypan blue solution in an Eppendorf tube and mixed 
gently by 10 passes through a P10 pipette tip. This was then left to stand for 4 min for cells 
to be exposed to the stain. A volume of 10 µl of the mixture was then loaded onto a dual-
chambered cell counting slide (BioRad, Watford, UK) using a pipette tip. The slide was 
inserted into the TC20 cell counter and counting was automatically initiated as soon as the 
presence of slide and Trypan blue dye were detected by the cell counter. When Trypan 
blue is detected in a sample, TC20 takes the dilution into account and multiplies results by 
2. The result was adjusted to account for 1 to 1 cell dilution and was reported on the 
monitor as estimated concentration of the undiluted sample. For example, a 1 x 106 
cells/ml mixed 1 to 1 with Trypan blue was at a concentration of 5 x 105 cells/ml. The total 
cell counts, live cell counts and the percentage of live cells appear on the count screen. The 
live cell counts per ml were used to determine the volume of cell suspension necessary to 
seed the cells at a required cell density in growth medium. A cell density of 50,000 cells/ml 
was used to plate out mouse N2a cells, rat C6 glioma cells and 100,000 cells/ml was used 
to plate out ReNcell CX cell according to the required size of flask or plate (Table 2.3). 
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Flasks were incubated in a humidified atmosphere containing 5 % CO2/95 % air at 37°C 
for 24 h to allow for cell recovery. 
Table 2.3. The cell density of N2a, C6 and ReNcell CX cell lines for the experiments of 
current study.  
Type of 
cell 
culture 
ware 
N2a C6 ReNcell CX 
Medium 
volume 
Total cell 
number 
Medium 
volume 
Total 
cells 
number 
Medium 
volume 
Total cell 
number 
T75 flask 
40 
ml/flask 
2,000,000 
40 
ml/flask 
2,000,000 40 ml/flask 4,000,000 
T25 flask 
10 
ml/flask 
500,000 
10 
ml/flask 
500,000 10 ml/flask 1,000,000 
8 well 
slide 
300µl/well 15,000 300µl/well 15,000 300µl/well 30,000 
24 well 
plate 
500µl/well 25,000 500µl/well 25,000 500µl/well 50,000 
96 well 
plate 
200µl/well 10,000 200µl/well 10,000 200µl/well 20,000 
2.2.6 Induction of cell differentiation 
For differentiation, cells were cultured in maintenance medium devoid of mitogens or 
serum. Prior to differentiation, all cells were passaged as described previously. Cells were 
plated out according to the required plating density (Table 2.3) in culture flasks or plates 
and incubated for 24 h to allow for recovery, after which growth medium was carefully 
removed without disturbing the monolayer and replaced with an equal volume of serum 
free medium. In N2a and C6 cells, differentiation was induced by replacing growth 
medium with serum free medium (i.e. DMEM containing 4.5 g/l glucose, 2 mM L-
glutamine, supplemented with penicillin (100 units/ml) and streptomycin (100 units/ml) 
and 0.3mM dibutyryl dbcAMP (for N2a) or 2mM sodium butyrate (for C6), which was 
diluted in serum free medium (Flaskos et al., 1998). For this study, a volume of 100 µl of 
dbcAMP stock solution (30 mM) or sodium butyrate (200 mM stock solution) were 
dissolved in 10 ml serum free medium and sterile-filtered to give final concentrations of 
0.3 mM and 2 mM respectively. 
ReNcell CX differentiation was initiated by replacing the growth medium with mitogen 
free medium, consisting of knockout DMEM/F-12 medium plus all supplements except the 
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growth factors EGF and FGFb (section 2.2.2). The removal of growth factor EGF and 
FGFb from the maintenance culture medium induces ReNcell CX cells differentiation by 
stopping cell proliferation (Donato et al., 2007). All cell lines were being treated with or 
without the OP compounds at the same time when they were induced to differentiate at 
37°C in a humidified atmosphere of 95 % air / 5 % CO2 for 24 h.  
2.2.7 Measurement of cell viability in cells exposed to OPs  
The measurement of cell viability plays a fundamental role in most in vitro studies of 
cellular response to toxic substance and sometimes forms the main purpose of the 
experiment, such as in toxicity assays. The effects of CPF, CPO and PSP on the viability of 
N2a cells, C6 cells and ReNcell CX in the present study were determined by the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay which was 
previously described by Mosmann (1983). The MTT assay is a test for enzymatic activity 
characteristic of a viable cell based on the ability of cellular dehydrogenase enzymes 
(mainly succinate dehydrogenase) from viable cells to cleave the tetrazolium rings of      
the pale yellow MTT and form purple formazan crystals that can be seen in a bright field 
microscope (Nikkhah et al., 1992; Liu et al., 1997). As these crystals are largely 
impermeable to the cell membrane, they accumulate within healthy cells. Addition of 
DMSO to the cells causes solubilisation of crystals resulting in their liberation which can 
be detected and quantified using a microliter plate reader. The ability of the cells to reduce 
MTT provides an indication of metabolic activity and the quantified level of the formazan 
product is directly proportional to the number of surviving cells; when compared to         
the amount produced by a control cell population, it can be used as a measure of cell 
viability. However, although often associated with the activity of mitochondrial 
dehydrogenases, it has also been shown that MTT can be reduced by other cellular 
dehydrogenases such as those found in cytoplasmic vesicles (Liu et al., 1997). Reduction 
of MTT can also be mediated by NADH or NADPH within other cellular compartments 
(Berridge and Tan, 1992; Fotakis and Timbrell, 2006). 
2.2.7.1 Assay buffers and reagents 
PBS was prepared in a total volume of 1L containing 137 mM NaCl, 2.7 mM KCl, 8.1 mM 
Na2HPO4, 2 mM NaH2PO4 at pH 7.4. 
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MTT was prepared by dissolving 5 mg of MTT per ml of PBS. Aliquots (1 ml) were stored 
frozen at -20°C until required. 
2.2.7.2 Assay procedure 
Cells were plated out at the required density in Corning 24 well plates (Table 2.3) in 0.5 ml 
growth medium, and then incubated for 24 h to allow recovery before the induction of 
differentiation. Differentiating cells were treated without or with CPF, CPO or PSP. 
Briefly, growth medium was carefully aspirated from the wells and replaced with fresh 
differentiation medium (sections 2.2.1 and 2.2.2) containing different concentrations (0, 1, 
3, 10 µM) of CPF, CPO or PSP for 24 h. A volume of 50 µl of MTT was added to each 
well 30 min prior to the end of the experimental incubation time and cells were incubated 
for a further 30 min at 37°C. Differentiation medium was then carefully aspirated from the 
well, 500 µl of DMSO were added to each well and the plates were gently agitated on        
a flat-bed shaker to dissolve the reduced formazan product. A total of 200 µl of each of the 
resulting solutions was transferred into a 96-well plate and the absorbance of the 
solubilised reduced MTT was then read at a wavelength of 570 nm using an ASYS Expert 
96 microliter plate reader (Biochrom, UK). The absorbance was expressed as a percentage 
of MTT reduction relative to the corresponding control ± SEM. 
2.2.8 Morphological measurements of fixed differentiated N2a and C6 cells 
The cells were induced to differentiate in 8-well chamber slides and then fixed in pre-
warmed 4 % (w/v) paraformaldehyde (Sigma-Aldrich, UK) for 15 min at room 
temperature. They were then stained for one min with Coomassie Brilliant Blue stain (1.25 
g Coomassie blue-R250, 10 % (v/v) glacial acetic acid, 40 % (v/v) methanol, 50 % (v/v) 
distilled water). Stained cells were washed with distilled water and left to dry overnight. 
Next day, the stained cells were checked by inverted light microscopy.  
After staining, the total number of the cells and the amount of round versus flat cells were 
determined in five fields of each well. Neurites (cellular processes produced on 
differentiated cells) were also measured as mentioned below. The microscope used was an 
Olympus CKx41 inverted light microscope (Olympus Optical Company Ltd, London, 
UK).  
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In the case of N2a cell lines, neurites were divided into two categories which were (a) 
extensions of 0.5-2 cell body diameters in length, and (b) axon-like processes, defined as 
processes more than 2 cell body diameters in length with an extension foot (Keilbaugh et 
al., 1991).  
2.2.9 Indirect immunofluorescence staining  
Morphological changes and the distribution of the structural proteins of cell lines were 
monitored by indirect immunofluorescence staining. This technique is based on the 
principle of the antibody-antigen binding when fluorescently labelled antibodies are used 
to detect particular target antigens by two steps. First, cells are stained with unconjugated 
primary antibody which binds to the antigen. Then a fluorescently labelled secondary 
antibody is used to detect the primary antibody (Odell and Cook, 2013). The fluorescent 
probe allows visualisation and study of the intracellular distribution of structures and 
proteins including neurofilament and microtubule proteins. Further analysis of such 
structures and proteins can be done by using fluorescence or confocal microscopy. 
2.2.9.1 Immunofluorescence materials 
2.2.9.1.1 Primary antibody 
Table 2.4. List of primary antibodies used for indirect immunofluorescence staining  
Target antigen Clone Dilution Species 
Approximate 
molecular 
weight of 
interest (kDa) 
Code Supplier 
Primary Antibodies for N2a cell lines 
β III tubulin 2G10 1:500 Mouse 55 T8578 
Sigma-
Aldrich 
 
Neurofilament 
heavy polypeptide 
(NFH)  
SMI 33 1:500 Mouse 200 N0142 
Merck-
Millipore 
Primary Antibodies for C6 cell lines 
Glial fibrillary 
acidic protein 
(GFAP) 
GA5 1:500 Mouse 50 
 
G3893 
 
Sigma-
Aldrich 
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2.2.9.1.2 Secondary antibody  
Table 2.5. Secondary antibodies for indirect immunofluorescence staining  
Secondary Antibody Species Dilution Code Supplier 
Alexa Fluor® 568 IgG Rabbit 1:500 A21069 Invitrogen 
Alexa Fluor® 488 
IgG(H+L) 
Mouse 1:500 A21204 Invitrogen 
2.2.9.2 Immunofluorescence methods 
Both N2a and C6 cells were plated out at 50,000 cells/ml in 8-well chamber Ibidi µ-slides 
(Ibidi(R). Thistle Scientific Ltd. UK) in 0.3 ml growth medium and left for 24 h to recover. 
Cells were induced to differentiate in the presence (1, 3 and 10 µM) and absence of CPF, 
CPO and PSP for 24 h as described in section 2.1.3 After 24 h exposure time, the medium 
was carefully removed from each well and cells were fixed to keep the shape and locations 
of all cellular proteins by using 500 µl/well of pre-warmed 4 % (w/v) paraformaldehyde 
(Sigma-Aldrich, UK) for 15 min at room temperature. Then, cells were washed three times 
with PBS for 5 min each rinse. Cell permeabilization was performed by incubating the 
cells for 15 min at room temperature with 0.05 % (v/v) Tween-20 in PBS, after which cells 
were washed 3 times with PBS allowing 10 min each rinse. The Tween-20 detergent 
solution permeabilized fixed cell membrane, which allowed the antibody to access the 
cytoplasm. After rinsing, blocking with 3 % (w/v) BSA in PBS was used to prevent non-
specific binding for 1 h at room temperature. After blocking, cells were then incubated 
overnight at 4 ºC in humidified chamber with 200 µl of primary antibodies (diluted 1: 500 
in BSA/TBS) against βIII tubulin and NFH in N2a, GFAP in C6 cells. Negative control 
cells were also included to confirm the specificity of the primary antibody and this 
involved incubating non organophosphate-treated cell with the secondary antibody only. 
Unbound primary antibodies were removed by three subsequent washes (10 min each 
wash) with TBS/Tween 20. Cells were then incubated for 2 h at room temperature with 
either Alexa fluor 488 goat anti-mouse IgG, or fluorescein isothiocyanate (FITC)-
conjugated secondary antibody (both diluted 1:500 in blocking buffer) (Invitrogen), after 
which a second series of washes was performed. For nuclei visualisation, cells were 
labelled with 4’, 6-diamidino-2-phenylindole (DAPI) counterstain for 1 min after careful 
aspiration of excess TBS, followed by a further TBS wash. Slides were filled with TBS 
containing 0.01 % (w/v) sodium azide as a preservative and stored at 4 ºC prior to image 
acquisition and analysis.  
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2.2.10 Image acquisition and analysis 
The effects of CPF, CPO and PSP on neurite outgrowth of N2a and C6 were further 
determined by using the ImageXpress Micro Widefield High Content Analysis System 
(Molecular Devices, USA). This is a high throughput system that allows rapid evaluation 
of the effects of a wide range of toxins at different concentrations on multiple parameters 
of neurite outgrowth. The screening system uses an inverted fluorescence microscope 
which combined with automated image acquisition and analysis software to quantify 
different measurements of neurite outgrowth such as cell count, cell body area, neurite 
count, neurite length (Smith and Eisenstein, 2005; Dragunow, 2008). 
For image analysis, the slides were loaded into the high content screening system plate 
holder for image acquisition and analysis. The system in the host laboratory is equipped 
with an automated microscope capable of fluorescence imaging of fixed-cells. Images were 
automatically focused and recorded from four different sites in each individual well. The 
size of each well was 9.4 x 9.4 mm, and the acquired image field was 741.6 x 587.6 µm. 
Fluorescence images were produced using matched laser excitation filters and multiple 
emission filter for two different channels, DAPI for nuclei (ex=377/50 nm, em=447/60 
nm) and FITC for cell body and neurites (ex=482/35 nm, em=536/40 nm). Images were 
acquired using a Nikon 10x objective lens and 1.4 megapixel cooled CCD camera, with     
a stand-alone illuminator (Lambda LS) connected to the system, which involves a 175W 
Xenon-arc lamp (Sutter Instrument, USA). The 10x objective lens was used in order to 
acquire all cell bodies and neurites in one field of view, hence enabling more reliable 
morphological analysis. The acquired images were segmented by multi-coloured tracing 
masks on neurites and cell bodies, where each neurite segment was given the same 
coloured mask as that of their parent neuronal cell bodies. Segmentation masks were 
produced using the MetaXpress imaging and analysis software (version 5.1.0.46; 
Molecular devices, USA). The segmentation images were analysed by the MetaXpress 
imaging and analysis software, using integrated neurite outgrowth settings to measure        
a number of morphological parameters including average number of cells/field, average 
cell body area/field, neurite length/cell, percentage of cells with significant outgrowth and 
average intensity of staining within the stained cells. Particles from each image were 
identified as cells if the cell body width ranged from 15 to 20 µm and valid nuclei width 
between 5 to 10 µm were detected. Neurite outgrowth was recorded as significant when 
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minimum cell outgrowth was more than 10 µm (approximately half a cell body diameter in 
length). The measurement ranges for cell bodies and outgrowth were determined in 
preliminary studies using untreated cells from multiple cultures to develop the settings to 
exclude non-cellular particles from the analysis. Using a 10x objective, 4 fields/well from 
four independent experiments were acquired for the analysis of at least 200 cells/well. The 
obtained results by the image analysis software were then analysed by using a Graphpad 
Prism spread sheet and results were presented as mean + standard error of mean (SEM) for 
each OP treatment and compared statistically to its corresponding control. 
2.2.11 Preparation of N2a and C6 cell lysates for one dimensional polyacrylamide gel 
electrophoresis (SDS-PAGE)    
Molecular changes to both cell lines were studied in total protein extracts. Initially, cells 
were plated out in T75 flasks at a density of 50,000 cells/ml in 40 ml growth medium and 
allowed 24 h recovery. Growth medium was carefully removed from the flask and replaced 
with 40 ml fresh differentiation medium, containing 0, 1, 3 or 10 µM CPF, CPO or PSP. 
Cells were re-incubated for 24 h. At the end of the exposure time, differentiation medium 
was carefully discarded from the flasks and cell monolayers washed twice gently with pre-
warmed PBS. A volume of 2 ml of boiling PBS containing 0.5 % (w/v) sodium dodecyl 
sulphate (SDS) was added to the flask to solubilise the cell monolayers. The resultant 
suspension was transferred to micro centrifuge tubes, heated at 100°C for 5 min and then 
allowed to cool at room temperature for 5-15 min. The insoluble materials such as nucleic 
acids that could affect the performance of the gel electrophoresis assay were then extracted 
from each lysate by placing 500 µl of cell lysate into a spin column (Dutscher Scientific, 
catalogue no. 789068) and centrifuged for few seconds at 10,000 g at room temperature. 
The filter with the captured DNA was carefully removed and discarded. The supernatants 
were collected from the lower chamber, placed into a clean micro centrifuge tube and 
stored at -20°C for future electrophoretic and western blotting analysis. The amount of 
protein available in the samples was then estimated by bicinchoninic acid (BCA) assay, as 
described in the following section. 
2.2.11.1 Sample protein determination  
The protein concentration of the samples was measured by the BCA assay, using BSA as 
the standard (Walker, 2002). The principle of the BCA assay is based on the formation of   
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a Cu2+ -protein complex under alkaline conditions, followed by reduction of the Cu2+ ions 
from cupric sulphate to Cu+ by the peptide bonds in a protein. The molecules of BCA then 
bind with Cu+ forming a purple-blue product, which can be detected and its absorbance 
measured at 570 nm. The absorbance is equivalent to the amount of protein present in the 
sample.  
2.2.11.1.1 Assay materials 
Microtitre 96-well plates were obtained from Sarstedt, (Leicester, UK). BCA Kits which 
comprised of reagents A (1 % (w/v) bicinchoninic acid sodium salt, 2 % (w/v) sodium 
carbonate, 0.16 % (w/v) sodium tartrate and 0.95 % (w/v) sodium bicarbonate in 0.1 M 
sodium hydroxide at pH 11.5) and reagent B (4 % (w/v) copper (II) sulphate pentahydrate 
solution) were obtained from Sigma-Aldrich. 
2.2.11.1.2 Assay procedure 
Using a BCA assay kit, a linear range of BSA standard concentrations from 0 to 1 mg/ml 
(Table 2.6) was prepared in the same buffer as with cell lysates, to produce a calibration 
curve to ensure that the relationship between protein content and absorbance was linear.    
A volume of 25 µl from each concentration of standard or from each cell lysate was 
pipetted into a clean, dry 96-well plate in four replicates and mixed with 200 µl of BCA 
working reagent. BCA working reagent was obtained by mixing BCA assay kit reagent A 
with reagent B in a volume ratio of 50:1. The samples were then incubated for 30 min at 
37°C in an LEEC incubator (LSC 2933) and absorbance was read at a wavelength of 570 
nm. The concentration of protein in the samples was then estimated from the linear 
correlation obtained from the BSA standard curve. 
 
 
 
 
 
 
Materials and Methods  Chapter 2 
62 
 
Table 2.6. BSA protein standards for protein estimation. 
Volume of 1 mg/ml BSA 
(µl) 
Volume of assay buffer 
(µl) 
Final concentration of BSA 
(mg/ml) 
0 1000 0 
200 800 0.2 
400 600 0.4 
600 400 0.6 
800 200 0.8 
1000 0 1 
When cell lysates showed very low protein concentration, the samples were precipitated by 
ice-cold acetone. This was achieved by mixing 9 volumes of acetone with 1 volume of 
protein sample in a micro centrifuge tube, which was vortex-mixed and incubated at -20°C 
overnight. Precipitated proteins were pelleted by centrifugation at 12,000 × g for 30 min at 
4 °C. The supernatant was then carefully decanted and the resultant pellet air dried at room 
temperature for 30 min. Following complete acetone evaporation, the pellets were 
dissolved and resuspended with 100 µl of 0.5 % (w/v) SDS in TBS. BCA assays was also 
performed on the samples obtained after acetone precipitation in order to estimate the 
amount of protein present.  
Once the protein concentration was determined, samples were prepared for polyacrylamide 
gel electrophoresis in the presence of sodium dodecyl sulphate (SDS-PAGE) and Western 
blotting.  
2.2.12 One dimensional polyacrylamide gel electrophoresis (SDS-PAGE) 
Protein samples from whole cell lysates were separated according to their molecular 
weight by Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE).   
2.2.12.1 SDS-PAGE materials 
Sample loading buffer (4x Laemmli buffer) was prepared in a total volume of 10.2 ml 
containing 40 % (v/v) glycerol, 8 % (w/v) SDS, 20 % (w/v) β-mercaptoethanol, 0.01 % 
(w/v) Bromophenol blue and 0.1 M Tris HCl, at pH 6.8. 
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Ammonium persulphate (APS) was purchased from Sigma-Aldrich and prepared by 
dissolving 0.1 mg of APS in 1 ml of dH2O. 
Electrophoresis running buffer (RB) was obtained from Geneflow Ltd. (UK) and was 
prepared in a total volume of 1 L containing 25 mM Tris base; 192 mM glycine; 0.1 % 
(w/v) SDS, pH 8.3.  
Tris-buffered saline (TBS) was prepared in a total volume of 1 L containing 10 mM Tris 
and 140 mM NaCl at pH 7.4. 
Blocking buffer was prepared in TBS containing 3 % (w/v) BSA and 0.01 % (w/v) sodium 
azide. 
AccuGel™ 29:1 was purchased from Geneflow Ltd. (UK) and contains 40 % (w/v) 
acrylamide:bisacrylamide (29:1). 
4x Protogel® Resolving buffer was purchased from Geneflow Ltd. (UK) and contains 1.5 
M Tris-HCl buffer pH 8.8 and 0.4 % (w/v) SDS.  
Protogel® Stacking buffer was purchased from Geneflow Ltd. (UK) and contains 0.5 M 
Tris-HCl buffer pH 6.8 and 0.4 % (w/v) SDS. 
N,N,N’,N’- tetramethylethylenediamine (TEMED) was obtained from Geneflow Ltd. 
(UK). 
Precision Plus Protein™ Blue Colour Standards was acquired from Bio-Rad. 
2.2.12.2 SDS-PAGE methods 
2.2.12.2.1 Preparation of polyacrylamide gels  
Typically, protein samples were separated by 10 % (w/v) polyacrylamide resolving gel 
(Table 2.7) overlaid with a 4 % (w/v) polyacrylamide stacking gel (Table 2.8) before being 
blotted onto nitrocellulose membranes (Towbin et al., 1979). Resolving gels of 10 % 
polyacrylamide were selected for use as they provided optimal separation over a broad 
range of molecular weights from 10 to 250 kDa. The protein separation was performed on 
1.5 mm thick polyacrylamide gels, in a Bio-Rad mini PROTEAN IIITM Cell 
electrophoresis chamber. Two glass plates of 1.5 mm thickness and spacer combs were 
Materials and Methods  Chapter 2 
64 
 
wiped first with dH2O and then with 70 % (v/v) ethanol prior to assembly. Glass plates 
were assembled evenly into the plate holders and then mounted on the casting stands. 
While on the casting stands, the plates were first filled with dH2O to check for any leakage 
and the water was then removed and replaced with the gel mixture. The 10 % (w/v) 
acrylamide resolving gel mixture was prepared according to the number of gels that were 
going to be used as indicated in table 2.7. This was made by mixing AccuGel™ 29:1 
acrylamide, 4x Protogel® Resolving buffer and distilled water as indicated in table 2.7. 
Acrylamide polymerisation was initiated by adding the indicated volume of APS and 
TEMED to the gel casting solution, mixed gently. Then 8 ml of the resolving gel casting 
solution were transferred into the gel casting cassette. Distilled water was carefully 
overlaid on top of the freshly poured resolving gel solution to create a smooth interface and 
prevent gel shrinkage. Resolving gels were allowed to polymerise at room temperature for 
approximately 30 to 40 min.  
In the meantime, the required amount of 4 % (w/v) polyacrylamide stacking gel mixture 
was prepared by mixing, AccuGel™ 29:1 acrylamide, Protogel® Stacking buffer and 
distilled water in the indicated volumes (Table 2.8). Once the resolving gel was 
polymerised, the distilled water above it was poured away. The indicated volume of APS 
and TEMED (Table 2.8) were added to the stacking gel solution to initiate polymerisation. 
The stacking gel solution was mixed gently and applied on top of the polymerised 
resolving gel. The stacking gel allows protein accumulation at the interface of the resolving 
gel (Laemmli, 1970). Once the chamber had been filled with stacking gel solution, a comb 
of the correct thickness was quickly inserted into the non-polymerised gel mixture to 
generate the wells into which the samples would be loaded. The gel mixture was allowed 
to polymerise for 45 min, after which the comb was carefully removed and the wells were 
rinsed by flushing with running buffer to remove any trapped air bubbles prior to sample 
loading. 
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Table 2.7. Reagent volumes required for preparation of SDS-PAGE resolving gel for 
two mini gels  
10 % (w/v) acrylamide resolving gel 
reagents 
Volumes 
40% (w/v) 29:1 AccuGel™ 
(Acrylamide stock) 
5.0 ml 
4x Protogel® Resolving buffer or 
(1.5 M Tris buffer, pH8.8 (5 ml), 10 % 
(w/v) SDS (100 µl) ) 
5 ml 
Distilled water 9.8 ml 
10 % (w/v) APS 200 µl 
TEMED 20 µl 
Total volume 20 ml 
Table 2.8. Reagent volumes required for preparation of SDS-PAGE stacking gel for 
two mini gels  
4 % (w/v) acrylamide stacking gel 
reagents 
Volumes 
40% (W/V) 29:1 AccuGel™ 
(Acrylamide stock) 
1 ml 
Protogel® Stacking buffer 2.5 ml 
Distilled water 6.4 ml 
10 % (w/v) APS 100 µl 
TEMED 20 µl 
Total volume 10 ml 
2.2.12.2.2 Preparation of protein samples for loading 
Once the protein concentration had been determined (section 2.2.11.1), each cell lysate was 
mixed with sample loading buffer (4x Laemmli) in the ratio 1:3 and boiled at 100ºC for 5 
min prior to loading on the polyacrylamide gel. Precision Plus Protein™ Blue Colour 
Standards (2.5 µl) were applied to the first well to estimate the molecular weights of the 
separated proteins. This protein ladder comprised a three colour protein marker with 12 
pre-stained proteins, in which the molecular weights ranged from 10 to 250 kDa. Equal 
amounts (µg) of protein from each sample were then loaded in order to obtain comparable 
results. 
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2.2.12.2.3 Separation of proteins in cell lysates by gel electrophoresis 
Once the sample loading was complete, gels were placed vertically in the electrophoresis 
chamber which was then filled with running buffer to the required levels. The system was 
run first at 50 volts using a Bio-Rad PowerPac 300 for 10 min in order to organise the 
samples in the stacking gel. The voltage was then changed to 150 volts, allowing 
electrophoresis to continue until the dye front (bromophenol blue) reached the base of the 
resolving gel. After that, the power was switched off and the gel was carefully removed to 
avoid damage.   
2.2.13 Western blotting  
2.2.13.1 Western blotting materials  
2.2.13.1.1 Primary antibodies 
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Table 2.9. List of primary antibodies used for Western Blot and ELISA assay 
Target antigen Clone Dilution Species 
Approximate 
molecular 
weight of 
interest (kDa) 
Code Supplier 
Primary Antibodies for N2a cell lines 
MAP-2 H-300 1:1000 Mouse 140-200 
sc-
20172 
Santa 
Cruz 
Biotechno
logy 
β III tubulin 2G10 1:1000 Mouse 55 T8578 
 
Sigma-
Aldrich 
 
Tau (a.a. 210-241) TAU-5 1:1000 Mouse 45-68 
MAB36
1 
merckmill
ipore 
Neurofilament 
heavy polypeptide, 
NF-H,  
SMI 33 1:1000 Mouse 200 N0142 
 
merckmill
ipore 
Growth associated 
protein-43 
(GAP43) 
GAP-
7B10 
1:1000 Mouse 
 
43 
G-9264 
 
Sigma-
Aldrich 
 
Primary Antibodies for C6 cell lines 
Glial fibrillary 
acidic protein 
(GFAP) 
GA5 1:1000 Mouse 50 
 
G3893 
 
Sigma-
Aldrich 
Primary Housekeeping Antibodies for N2a and C6cell lines 
GAPDH 6C5 1:1000 Mouse 37 
sc-
32233 
Santa 
Cruz 
Biotechno
logy 
2.2.13.1.2 Secondary antibodies  
Table 2.10. Secondary antibodies for probing Western blot 
Secondary Antibody Type Dilution Code Supplier 
Anti- mouse IgG HRP 1:1000 A9044 Sigma-Aldrich 
Anti- rat IgG HRP 1:1000 P0450 DAKO-Cytomation 
Anti- rabbit IgG HRP 1:1000 A6154 Sigma-Aldrich 
2.2.13.1.3 Other consumables 
Hybond C nitrocellulose membrane of 0.45 µm pore size and purchased from Amersham 
(Buckinghamshire, UK).  
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Continuous transfer buffer (CTB) was obtained from Geneflow Ltd. (UK), and consists      
a mixture of 0.25 M Tris and 1.92 M glycine at 10 times the making concentration, which 
is diluted with 7 volumes of water and 2 volumes of methanol prior to its use for 
electrophoretic transfer.   
Enhanced chemiluminescence (ECL) reagent was purchased from Insight Biotechnology, 
Wembley, U.K. and was used to detect the binding of horseradish peroxidase (HRP) 
secondary antibody conjugate to primary antibodies on probed Western blots. 
Whatman® filter paper of grade 3 MM filter paper was obtained from Sigma Aldrich. 
2.2.13.2 Western blotting methods 
2.2.13.2.1 Electroblotting 
Once the protein separation by SDS-PAGE was complete, the separated proteins contained 
on the resolving gel were electrophoretically transferred onto the nitrocellulose membrane 
to facilitate binding of antibody to the investigated proteins (Towbin et al., 1979). Briefly, 
the resolving gel was removed from the glass plate whilst the stacking gel was cut off.  
Three pieces of filter paper (9 cm x 6 cm), nitrocellulose membranes and 6 mm thick 
sponges were soaked in CTB working solution (192 mM glycine, 25 mM Tris and 20 % 
(v/v) methanol) for 5 min to equilibrate. Methanol is a necessary component of CTB which 
removes any non-protein-bound SDS and also enhances the adsorption of protein to the 
nitrocellulose membrane. A transfer sandwich was built on the side of the transfer cassette 
with the membrane oriented between the gel and the anode plate (+), starting with a wet 
sponge, followed by three wetted filter papers, nitrocellulose membrane, the resolving gel, 
three additional pieces of pre-soaked filter papers and finally a second sponge. Any air 
bubbles between the different layers of the sandwich were removed by rolling a glass rod 
lightly across the sandwich assembly. When air bubbles are trapped between sandwich 
components, they can create blank spots on the membrane and impede protein transfer. 
The assembled sandwich was securely fixed in the transfer cassette, which was closed and 
immersed in the blotting chamber (Mini Trans-Blot(R) Electrophoretic Transfer cell; Bio-
Rad), containing CTB. The cell was connected to the power supply and the electrophoretic 
transfer performed at 30 volts overnight at room temperature.  
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2.2.13.2.2 Immunoprobing of Western blots 
Nitrocellulose membranes containing the electrophoretically transferred proteins were 
incubated in 3 % (w/v) BSA in TBS for 1 h at room temperature to block all remaining 
protein binding sites on the membrane.   
After that, membranes were incubated with appropriate dilutions of primary antibodies 
prepared in 3 % (w/v) BSA/TBS at 4ºC overnight (Table 2.9). After incubation, probed 
membranes were washed to remove excess primary antibody which can otherwise cause 
high background. This washing was performed 6 times with constant agitation at room 
temperature using TBS containing 0.05 % (w/v) Tween-20 pH 7.4 over a period of 1 h, 
allowing 10 min each wash. Blots were then probed with appropriate dilution of the 
horseradish peroxidase (HRP) conjugated secondary antibodies diluted in 3 % (w/v) 
BSA/TBS (Table 2.10) for at least two hours at room temperature. This was followed by    
a further series of 6 washes to remove unbound secondary antibodies from the membrane 
as described above, with a final wash of TBS to remove possible traces of Tween 20.  
2.2.13.2.3 Antibody reactivity visualisation 
Antibody reactivity on the membrane was visualised with the enhanced chemiluminiscense 
(ECL) Western blotting detection reagent (Thermo Scientific, USA). The ECL reagents A 
and B were allowed to equilibrate at room temperature before they were mixed freshly in 
equal volumes and applied onto the blotted membranes to detect the band of interest. 
Digital images were captured using a G:BOX Chemi XT4 imager dark system (Syngene, 
Cambridge, UK), and band density was quantified by densitometric analysis using 
Advanced Image Data Analyser (AIDA) software (version 4.03) (Raytek GmbH, 
Straubenhardt, Germany). This software analyses band volumes, based on constant lane 
width and automatic band selection, from the raw data of pixel area and intensity that are 
independent of operator-altered contrast or brightness. All band densities were measured 
and corrected for background, then normalised to band densities for glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) reactivity, which was used as internal control for 
normalisation. Data are expressed as a percentage of the average value of the peak area 
compared to its corresponding control + SEM. 
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2.2.14 Enzyme linked immunosorbent assay (ELISA) 
The effects of OPs on the levels of cytoskeletal proteins in N2a and C6 cell lines was 
further examined by using a cell-based enzyme linked immunosorbent assay (ELISA). This 
was based on the previous approach (Schmuck and Ahr, 1997) with modifications. The 
assay is based on the principle that antibodies will bind to very specific antigens to form 
antigen-antibody complexes, and an enzyme linked to an antibody can be used as a marker 
for the detection of a specific antigen or protein in sample. The conjugated enzyme 
reaction is stopped by the addition of H2SO4 producing a yellow colour product, which can 
be detected and measured at 405 nm by spectrophotometer. The intensity of the colour 
change is related to the amount of protein or antigen present in the sample. 
2.2.14.1 Preparation of buffer and reagents 
100 mM Sodium acetate buffer was prepared by dissolving 8.2 g sodium acetate in 900 ml 
of dH2O at pH 6. The final volume made up to 1 litre with dH2O 
5 M Sulphuric acid (H2SO4) was prepared by adding a volume of 50 ml pure H2SO4 was 
added to 200 ml of dH2O 
3,3,5,5’-Tetramethylbenzidine (TMB) 
A total of 10 mg of TMB was dissolved in 1 litre of DMSO (stock).  
3 % (v/v) Hydrogen peroxide (H2O2)   
Volume of 10 µl of 30 % (v/v) H2O2 (stock) was added to 90 µl of dH2O 
Developing substrate 
The developing substrate was prepared by the addition of 150 µl of TMB stock solution 
and 30 µl of 3 % (v/v) H2O2 into 20 ml of 100 mM sodium acetate pH 6. 
2.2.14.2 Assay procedure 
The assay was performed in a sterile flat bottom 96-well plate. Cells were plated out at the 
density of 50, 000 cells/ml for N2a and C6 cell lines in a total volume of 200 µl growth 
medium per well in four replicates and incubated overnight at 37ºC in 5 % CO2. After 24 h 
recovery, cells were induced to differentiate in the presence (1, 3, and 10 µM) and absence 
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of CPF, CPO and PSP for 24 h as described in section 2.2.6. After 24 h exposure time, the 
medium was carefully removed from each well and cells were fixed using 200 µl/well of 
prewarmed 4 % (w/v) paraformaldehyde (Sigma-Aldrich, UK) for 10 min at room 
temperature. Fixative was removed and cells were washed 3 times with TBS allowing 5 
min each wash. Cells were permeabilized by incubating with 0.05 % (v/v) Tween-20 in 
PBS for 15 min at room temperature, after which they were rinsed 3 times with TBS 
allowing 5 min each rinse. After rinsing, a volume of 300 µl/well of 3 % (w/v) BSA/TBS 
(blocking buffer) was added for 1 h at room temperature to prevent non-specific binding. 
The blocking buffer was then removed and 100 µl/well of primary antibodies diluted 1 to 
1000 in blocking solution (Table 2.9) were added and incubated overnight at 4ºC.  
After that, the primary antibodies were removed and wells were washed three times with 
TBS/Tween20, followed by at least 2 h incubation at room temperature in 200 µl/well of 
HRP conjugated secondary antibodies (diluted at 1:2000) in blocking buffer (Table 2.10). 
Following that, the antibodies were removed and the cells were washed with 
TBS/Tween20 three times allowing 5 min in each wash. Any remaining wash solution was 
removed completely from wells, as complete removal of liquid at each step is essential to 
good performance. The reaction was initiated by the addition of 100 µl of developing 
substrate buffer into each well. After 5 min incubation at room temperature, a blue colour 
product was developed as a result of the reaction, which was then stopped by adding 100 
µl of 5 M H2SO4. The resultant yellow colour was detected and absorbance was measured 
spectrophometrically using a micro plate reader (ASYS Expert 96, Biochrom, UK) set at 
405 nm. Results were expressed as antibody binding in treated cells and presented as         
a percentage compared to untreated cells (set as 100 %) + SEM. The background level was 
estimated for correction by blank non populated wells. The specificity of antibody bindings 
was confirmed by non OP-treated cells incubated with the secondary antibody only. 
2.2.15 Reverse transcription polymerase chain reaction (RT-PCR)  
To investigate possible transcriptional responses to OP exposure, the expression of a few 
genes of interest was analysed in N2a, C6 and ReNcell CX cell lines after single treatment 
with the three OPs used throughout this study. Molecular biology grade laboratory reagents 
were used and they are listed in table 2.11.   
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Table 2.11. List of reverse transcription polymerase chain reaction reagents  
Reagents Code number Supplier 
Absolutely RNA Miniprep 
Kit.  
400800 Agilent Technologies 
 SYBR™ Safe™ DNA Gel 
Stain. 
VXS33102 Fisher Scientific UK Ltd  
Quick-Load® 100 bp DNA 
Ladder (125 lanes).  
N0467S 
New England Biolabs 
Ltd. 
Wizard®SV Gel and PCR 
Clean-Up System and x-
tracta™ Gel Extraction 
Bundle. 
A9283 Promega, UK. 
PrimePCR™ SYBR® Green 
Assay: Rps18, Mouse, Rat.  
100-25636 
 
Bio-Rad, UK 
PrimePCR™ SYBR® Green 
Assay: Gapdh, 
Mouse,Rat,Human.  
100-25636 
 
Bio-Rad, UK 
dNTP Mix is a premixed 
solution containing sodium 
salts of dATP, dCTP, dGTP 
and dTTP at 100 mM each. 
U1330 Promega, UK. 
M-MLV Reverse 
Transcriptase kit.  
M1701 Promega, UK. 
iTaq TM Universal sybr green 
supermix. 
172-5120 Bio-Rad, UK 
2.2.15.1 Primer design for the genes of interest  
To design specific primers, the cDNA sequences for each gene of interest were obtained 
from the Genome Browser (University of California, Santa Cruz (UCSC)). When a gene 
had more than one isoform, their sequences were aligned using the Multalin software and 
primers were designed in the common nucleotide regions between all the variants. The 
primers were designed using Primer-3 software (Untergasser et al., 2012) and their 
qualities, including annealing temperature, size, presence of hairpins and GC content were 
checked before ordering. The BLAST software was used to select those primers which had 
the highest specificity with the desired gene. 
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2.2.15.1.1 Primer design criteria 
a) A ‘GC’ content between 40-60 %. 
b) Melting temperature (Tm) between 55-80ºC. 
c) Primer size between 100-150bps. 
d) A and T mismatches were to be avoided at 3' ends. 
e) Self-complementarity of the sequences between forward and reverse primers was to 
be avoided. 
f) Self-hairpins of the sequences between forward and reverse primers were to be 
avoided.  
2.2.15.2 Disruption and homogenization of brain tissues 
 Mouse and rat brains were used as positive controls to optimise the polymerase chain 
reaction (PCR) and to check the specificity of the designed primers to amplify the genes of 
interest.  Total RNA was extracted from frozen rat and mouse brain tissue. After cleaning 
all equipment with 70% (v/v) ethanol, the brain tissues were removed from dry ice and 
approximately 40 mg were weighed and placed in a tube containing prepared Lysis 
Solution. A volume of 4.2 µl β-mercaptoethanol (β-ME) had been freshly added to 600 µl 
of lysis buffer, which was included in the Absolutely RNA Miniprep Kit. Then, the tissue 
was homogenised in the homogenizer Ultra Turrax (TR50) (Janke and Kunkel, IKA 
labortechnik). The homogenised samples were kept at -80oC for RNA isolation. 
2.2.15.3 RNA extraction from cells and homogenised tissues 
A T75 flasks were contained 40 ml of growth medium at cell density of 50,000 cells/ml of 
N2a cells and rat C6 glioma cells, or 100,000 cells/ml of ReNcell CX cell. When the cell 
monolayers were 80 - 90 % confluence, RNA extraction was performed according to the 
manufacturer’s protocol (Absolutely RNA Miniprep Kit. Code number, 400800, Agilent 
Technologies) by  the RNA binding column through a series of centrifugations then eluted 
in RNAse free water as shown in figure 2.1. A volume of 4.2 µ β-mercaptoethanol (β-ME) 
had been freshly added to 600 µl of lysis buffer, which was included in the Absolutely 
RNA Miniprep Kit. 
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Figure 2.1. Graphical protocol of the steps involved in RNA extraction. 
2.2.15.4 Quantification of RNA  
The concentration of RNA in the samples was determined using a NanoDrop 8000 
spectrophotometer (Thermo Fisher Scientific Inc). First, the samples pedestal of the 
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spectrophotometer were cleaned with wet lens tissue before setting the blank using either 
distilled water or elution buffer. For each RNA extract, 1 µl was loaded into the pedestals 
and the absorbance readings taken at 260 and 280 nm. The NanoDrop then provides           
a value for the concentration and a ratio measurement that reflects the purity of the 
samples. According to the Beer-Lambert (or Beer’s) Law, absorbance is proportional to 
concentration and nucleic acids concentrations can be determined with values of 
absorbance at 260 nm (Mayerhöfer et al., 2016). RNA concentrations were adjusted to 1 
µg/µl to use in the reverse transcription reactions.  
2.2.15.5 cDNA synthesis  
First-strand cDNA synthesis from RNA samples was performed following the 
manufacturer’s instructions (Promega,UK).  A total of 2μg RNA, 0.5 µg random primer 
and ddH2O were added to a final volume of 15μl. Samples were then heated using             
a thermal cycler (Bio-Rad, T100) to 70°C for 5 min to melt secondary structures that could 
be present in the RNA. Then, samples were put on ice before the following components 
were added to each sample (Table 2.12).  
Table 2.12. Final volumes and amounts of cDNA synthesis components 
Components Final volume (µl) Final amount 
5x M-MLV buffer 5 200 units 
dNTPs 2 10mM 
M_MLV RT 1 200 units 
RNasin ribonuclease 
inhibitor 
0.5 25 units 
Nuclease Free water 6.5 - 
Samples were mixed gently and incubated for 70 min at 37°C in a thermal cycler. After 
incubation, samples were heated at 95°C for 5 minutes and immediately stored at -20°C to 
be ready for qPCR. 
2.2.15.6 Optimisation of annealing temperature for the polymerase chain reaction 
(RT-PCR) 
A volume of 1 µl cDNA was added into PCR tubes containing 12.5 µl Go taq green master 
mix (Promega, Catalogue no. M7122), upstream and downstream primers for the gene of 
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interest and nuclease free water (Table 2.13). PCR tubes were placed in a T100 thermal 
cycler (Bio-Rad, UK) to perform gene amplification under a gradient of temperature 
ranging from 55 to 62 oC.  Thermal cycler settings are shown in the table 2.14. 
Table 2.13. Volumes and final concentrations of the components for RT-PCR 
Components volume (µl) Final concentration 
GoTaq® Green Master 
Mix, 2X 
12.5 µl Provided 
Upstream primer, 10 µM 0.25–2.5 µl 0.1–1.0 µM 
Downstream primer, 10 
µM 
0.25–2.5 µl 0.1–1.0 µM 
DNA template 1–5 µl <250 ng 
Nuclease-free water to 25 µl - 
Table 2.14. Settings of thermal cycler for PCR. 
Steps 
Denaturation Annealing Extension 
1 2 3 4 5 6 7 
95 oC 95 oC Variant 72 oC  72 oC 12 oC 
3:00 
min. 
0:30 sec. 0:30 sec. 0:45 sec. Step 2 5:00min - 
  
2.2.15.7 Agarose gel electrophoresis 
Agarose (1.5g) from Melford Biolaboratories Ltd, was added to 100 ml of 1x TAE buffer. 
The solution was boiled twice in order to improve the resolution of the gel. Syber safe (10 
µl of a 10,000x stock) was then added to be able to visualise the DNA later. The solution 
was poured into a casting tray and a well comb was placed in it and left to cool down. 
After the gel had formed, it was covered by 1xTAE buffer which was prepared from 50x 
TAE buffer (242g Tris base, 57.1 ml glacial acetic acid, 0.5 M EDTA at pH8 and adjust 
pH of the buffer at 8.5). After 45 min, 20 µl of the PCR samples were loaded into the 
34 X cycle 
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wells, placing 10μl of the DNA ladder standard (Quick-Load® 100 bp DNA Ladder, NEB) 
in the first well, and the gel was run for 60 min at 85 V. 
2.2.15.8 Visualization of bands on agarose gels 
The agarose gel was removed from the tank when the electrophoresis was finished and 
placed in the G:BOX iChemi dark system (Bio-Rad,UK). The gel was exposed to 
ultraviolet light to reveal Sybr Safe-stained DNA bands and the images were captured by 
the camera. The sizes of the amplified band were determined by comparison to the DNA 
ladder used. The PCR conditions for those lanes showing single bands of the expected size 
product were considered positive and optimised. 
2.2.15.9 PCR product confirmation by DNA sequencing 
PCR products of the expected size were cut from the agarose gel and cleaned using 
Wizard® SV Gel and PCR clean-up system, A9281, Promega, following the 
manufacturer’s guidelines. The extracted DNA was sent for sequencing to Source 
Bioscience, Nottingham, UK. The string of nucleotides received from the company was 
introduced in the Blast software to look for alignments with just the sequencing of our 
gene of interest. Those primers that amplified specific fragments of the expected size were 
then used in the quantitative PCR (qPCR) experiments.  
2.2.16 Quantitative PCR (qPCR) 
cDNA was obtained as described before and the reactions for qPCR were prepared in 0.1 
ml of capped qPCR microtubes using the volumes and reagents described in table 2.15. 
The concentration of primers used was determined after the optimisation through the use of 
a primer matrix. 
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Table 2.15. Volumes and amounts of the components used in qPCR. 
Component Volume (µl) Final concentration 
iTaq™ universal SYBR® 
Green supermix is 2x 
concentrated 
6.5 Master mix 
cDNA 1  
Forward primer 0.5 10 mM 
Reverse primer 0.5 10 mM 
Nuclease free water 4.5  
Then the qPCR mirotubes (strips of four) were placed in the blue 72 rotor disc of Rotor 
Gene Q (Qiagen, 115H). Gene expression was obtained under the conditions in table 2.16.   
Table 2.16. Quantitative RT-PCR protocol 
Polymerase 
activation and 
DNA 
denaturation 
Amplification 
Melt 
curve 
analysis 
Denaturation Annealing/Extension Cycles 
95 oC 
2 min 
95 oC 
5 sec 
60 oC ( or depending on 
annealing temperature of 
gene of interest ) for 30 
sec 
40 
95 oC 
5 sec 
When amplification was complete, Ct values were obtained and analysed following the 
delta-delta Ct method of Rao et al. (2013) as indicated below. 
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2.2.17 Histone deacetylases assay (HDAC)  
2.2.17.1 Nuclei extraction buffers 
Molecular biology grade reagents were used to prepare the buffers for the extraction (Table 
2.17).  
Table 2.17. List of nuclei extraction buffers for HDAC assay 
Reagents Supplier 
Buffer A 
10 mM HEPES (pH7.9 at 4°C) Sigma-Aldrich 
1.5 mM Magnesium chloride (MgCl2) Sigma-Aldrich 
10 mM Potassium chloride (KCl) Sigma-Aldrich 
0.5mM 1,4-Dithiothreitol (DTT) [Add 
fresh] 
Sigma-Aldrich 
Buffer B 
0.3 M HEPES pH 7.9 Sigma-Aldrich 
1.4 M KCl Sigma-Aldrich 
0.03 M MgCl2 Sigma-Aldrich 
Buffer C 
20 mM HEPES pH 7.9 Sigma-Aldrich 
25% v/v Glycerol Sigma-Aldrich 
0.42 M NaCl Sigma-Aldrich 
1.5 mM MgCl2 Sigma-Aldrich 
0.2 mM EDTA Sigma-Aldrich 
0.5mM  PMSF [Add fresh] Sigma-Aldrich 
0.5 mM DTT [Add fresh] Sigma-Aldrich 
Buffer D 
20 mM HEPES pH 7.9 Sigma-Aldrich 
20% v/v Glycerol Sigma-Aldrich 
0.1 M KCl Sigma-Aldrich 
0.2 mM EDTA Sigma-Aldrich 
0.5 mM DTT [Add fresh] Sigma-Aldrich 
0.5 mM PMSF [Add fresh] Sigma-Aldrich 
2.2.17.2 Preparation of nuclear extraction for HDAC 
According to Dignam et al. (1983), after washing the cells with ice cold PBS, they were 
scraped off the culture flask in 5 ml PBS ice-cold per flask. Then, cells were centrifuged at 
448 × g for 10 min. The pellet was resuspended in 5 x volumes of Buffer A and kept on ice 
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for 10 min. and then centrifuged at 448 × g for 10 min at 4°C. The pellet was resuspended 
in 2 volumes of buffer A. The mixture was homogenized with a glass Teflon homogeniser 
using around 20 strokes to break any intact plasma membranes. The destruction of the 
membranes was confirmed using a light microscope (Figure 2.2). Then, the extract was 
centrifuged at 448 × g for 10 min at 4°C. The resultant pellet contained nuclei and was 
resuspended in 1 ml buffer B, then transferred to ultracentrifuge tubes and centrifuged at 
25,000g at 4°C for 30 min. After resuspending the pellet in 0.6 ml buffer C, the mixture 
was homogenized, then, stirred with a magnet for 30 min at 4°C. It was then centrifuged at 
25,000g for 30 min. The supernatant (~1ml) was dialysed against buffer D for 5 hours and 
then centrifuged at 25,000g, 4 °C for 20 min. Then, the supernatant containing the nuclear 
proteins was kept at -20 ⁰C. 
 
 
Figure 2.2. Phase contrast microscopy images of homogenaised cells for nuclear 
extraction. 
2.2.17.3 Histone deacetylation (HDAC) protocol 
Total HDAC activity was performed in a microliter plate, and it was determined by using 
HDAC activity colorimetric assay kits (Catalogue No. 17-374, EMD Millipore, UK). 
HDAC assay was based on a two-step of colorimetric reaction. The first step was 
deacetylation of the incubated substrate with the samples. Then the substrate was 
sensitized as consequence of the activator solution that releases p-nitroanilide from the 
deacetylated substrate. Briefly, the protein was extracted after the fractionation of the 
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nucleus using the procedure mentioned above. Following BCA assay, as mentioned in 
2.2.11.1, 20 µg of cell lysate of test sample, 20µg of HeLa nuclear extract (positive 
control), and 20µl of water (negative control) were each incubated with HDAC 
colorimetric substrate for 1 h at 37 ⁰C, following the manufacturer’s instructions (Table 
2.18). The absorbance was set at 405 nm by using a micro plate reader (ASYS Expert 96, 
Biochrom, UK), and it expressed as the relative O.D value per µg of protein.  
Table 2.18. Assay incubation setup  
 
Negative 
Control 
Positive 
Control 
Test Sample 
2X HDAC Assay 
Buffer 
10 µl 10 µl 10 µl 
Test sample/ µg the(s) 0 µl 20 µl 20 µl 
4mM Substrate, 
colorimetric detection 
10 µl 10 µl 10 µl 
Water 20 µl 0 0 
Activator Solution 20 µl 20 µl 20 µl 
Total Assay Volume 60 µl 60 µl 60 µl 
2.2.18 Statistical analysis  
All data sets were generated from a minimum of 4 independent experiments and expressed 
as mean + SEM. GraphPad Prism (version 7) (GraphPad software, California, USA), was 
used for all statistical analysis. The significance of the differences between the average 
values for each treatment were compared to the corresponding controls or other treatment 
group by one-way analysis of variance (ANOVA) and comparison between means was 
analysed by a Sidak post hoc test, which takes into account multiple comparisons, with 95 
% confidence interval. Results were considered to be significantly different when P < 0.05.     
 
 
  
 
Chapter 3 
Cytotoxic Effects of Organophosphate 
Compounds on Differentiating Mouse N2a 
Neuroblastoma and C6 Glioma Cells 
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3.1 Introduction  
Organophosphate compounds are widely used as pesticides, but because they are non-
selective for the target organism, their use has caused severe health damage and even death 
in humans and domestic animals (Murray et al., 2005). 
CPF remains one of the most commonly used OP insecticides around the world (Coronado 
et al., 2006). In spite of its potential dangers to health and the imposed restrictions, CPF 
remains a major pesticide to use in both residential and in the industrial settings especially 
in many developing countries (Salyha, 2010). Moreover, tricresyl phosphate (from which 
the analogue of PSP is derived) has long been used in jet engine oils and jet hydraulic 
fluid, due to its anti-wear properties under extreme conditions (Liyasova et al., 2011). It 
was linked to toxicity in both passengers and aircrew, with symptoms including muscle 
weakness, dizziness, nausea, disorientation and memory loss (Schopfer et al., 2010; 
Liyasova et al., 2011). A considerable effort has been made by the government, advocating 
control measures for prevention of potentially toxic organophosphate exposure, 
particularly amongst employees in manufacturing industries or those using or exposed to 
the compounds and in the most susceptible groups of the population, such as the young and 
the elderly. However, in a recent study, despite the suggestion by EPA that the use of all 
OPs should be banned not only in households but also in agriculture, it has not been well 
accepted, and OPs are still being used extensively (EPA, 2016; 2017).  
As discussed previously in section 1.1.2, glial cells are specialized cells that do not 
transmit electrical signals but they are of major importance, in that they provide structural 
and metabolic support in the nervous system. They also play a key role in antioxidant 
activity, which is important for protection against potential effects of OPs on neural cells 
(Bagchi et al., 1995). However, the cytotoxic effects of OPs may vary between neural and 
glial cells, the precise reasons remaining elusive as evidence keeps accumulating. One 
study has, however, suggested that, as glial cell development takes longer than that of 
neurons, the former may be more susceptible to prolonged exposure to CPF (Garcia et al., 
2002). 
Substantial evidence has emerged from a number of epidemiological studies demonstrating 
that both CPF and CPO have the ability to induce neurotoxicity in developing organisms 
through their effects on developmental processes in the nervous system, such as neurite 
outgrowth (Campbell et al., 1997; Crumpton et al., 2000a; Flaskos, 2012). 
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Many studies have shown that OPs adversely affect most cell types in the nervous system, 
especially the neurons and glial cells (Sachana et al., 2008; Flaskos et al., 2011). The 
molecular basis of OP-induced neurotoxicity has been extensively studied and reported in 
both in vivo and in vitro models, as discussed in chapter 1 (Timofseeva and Gordon, 2002; 
Coronado et al., 2006). The understanding of OP associated acute toxic effects, resulting 
from the inhibition of cholinesterase activity thereby causing accumulation of 
acetylcholine at nerve endings, has played a major part in providing a rationale for 
therapeutic and diagnostic approaches. Many in vitro studies on neural cell lines such as 
N2a and C6 have facilitated a better understanding of the cellular mechanism(s) involved 
in OP-induced cytotoxicity. For example, in viability assays such as MTT reduction, the 
IC50 values for CPF and CPO were approximately 50 and 40 µM, respectively, and it was 
established that concentrations of 1-10 µM had no significant effect on the viability of 
differentiating C6 cells under the same experimental conditions as those used in the current 
study (Sachana et al., 2008). Likewise, PSP was shown to inhibit the reduction of MTT in 
cultured mitotic N2a and hepatic (HepG2) cell lines, as indicated by their IC50 values 
which were estimated to approximately 10-15 µM (Harris et al., 2009a). This showed that 
the two cell lines exhibited similar trends in their sensitivity to PSP. Subsequent studies 
assessed the effects of PSP on MTT reduction in mitotic H9c2 cells at shorter time points 
than in the previous study (1, 2, 4, and 8 h) (Felemban et al.,2015). The results showed that 
PSP-induced inhibition of MTT reduction was first evident at 4 h (IC50 = 8.5  5.5 µM), 
with comparable results obtained at 8 h exposure (IC50 = 7.1  4.7 µM). This suggests that 
PSP displays marked cytotoxicity towards mitotic H9c2 cells.  
According to Sindi et al. (2016), the concentration of 3 µM CPF and CPO was chosen for 
studies of neurite retraction based on its ability to induce approximately 50 % reduction in 
both neurite outgrowth and in the number of pre-formed neurites in differentiating N2a 
cells. CPF at the sub-lethal concentration of 3μM had the ability to induce retraction of 
approximately 50 % of axon-like processes formed by differentiating N2a cells, as 
determined by light microscopy of Coomassie Brilliant Blue stained cells (Sachana et al., 
2001). In previous work by the same research group, it was found that the sub-lethal 
concentrations of OP pesticides such as CPF and diazinon (DZ) inhibited the outgrowth of 
axon-like processes in differentiating N2a cells (Sachana et al., 2001; 2003; Flaskos et al., 
2007). Accordingly, a concentration range of (1-10 µM) was adopted for subsequent 
experiments in the current study.  
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Several in vitro and in vivo studies have shown that the adverse effects of CPF and CPO on 
the developing brain are not limited to inhibition of cholinesterase activity, but that it 
involves other potential targets (Slotkin, 2004). For example, CPF and CPO were found to 
interfere with the unique developmental process of the brain and the nervous system by 
causing several morphological changes in the formation of neurites, as discussed above. 
These neurites play key roles in axonal plasticity (Andrieux et al., 2002; Wall, 2005). 
Neurite outgrowth is a unique morphological feature of neural development and has been 
investigated in several in vitro studies. Extension of neurites (axons and dendrites) during 
brain development is a crucial factor that determines neuronal connectivity (Radio et al., 
2008). Any interference with this critical cellular process, for example by OP exposure, 
may cause severe damage or could lead to neurodegenerative effects in developing 
organisms (Rice and Barone, 2000; Costa, 2006; Grandjean and Landrigan, 2006). As 
shown by in vitro studies, neurite outgrowth reflects many of the morphological and 
molecular changes that occur in axon outgrowth during nerve regeneration in vivo 
(Burgoyne, 1991; Berger-Sweeney and Hohmann, 1997). Neurotoxin-induced changes in 
this phenomenon may also reflect the ability of xenobiotics to cause axon retraction and/or 
inhibit nerve regeneration in adult animals (Burgoyne, 1991; Berger-Sweeney and 
Hohmann, 1997). Sub-lethal concentrations of PSP inhibited the outgrowth of axon-like 
processes in differentiating N2a cells (Hargreaves et al., 2006). The mechanisms involved 
in OP-induced neurotoxicity may vary depending on the differentiation conditions used 
(Sachana et al., 2001). Several developmental studies of OPs have been carried out under 
similar cell differentiation conditions, in which cells were treated with OPs at the point of 
induction of cell differentiation (Sachana et al., 2008; Flaskos et al., 2006; 2011; Sindi et 
al., 2016). This method, also known as co-differentiation, forms a platform whereby the 
ability of OPs to inhibit the outgrowth of neurites can be studied.  Also, reports have 
shown that CPF not only has the ability to inhibit neurite outgrowth but it can also cause 
the retraction of pre-formed neurites (Sachana et al., 2001). This was demonstrated in        
a study that involved exposure of pre-differentiated N2a cells to a non-cytotoxic 
concentration of CPF at two different time points. The results showed that CPF caused       
a significant reduction in the number of axon-like processes in pre-differentiated N2a cells 
following 4 and 8 h exposure (Sachana et al., 2001; Sachana et al., 2005).  
In the present study, in order to study the neurotoxic effects of CPF, CPO or PSP on 
neurite outgrowth in differentiating N2a cells, they were stained with Coomassie blue, after 
which neurites were quantified using manual counting. Although this method demonstrated 
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the ability of the compounds to induce changes in the process of neurite outgrowth, the 
limitation of this method is that the manual counting of neurite outgrowth is time-
consuming. Therefore, high throughput screening (HTS) system was used to further 
measure the extent of neurite outgrowth in differentiating N2a cells exposed to CPF, CPO 
or PSP. This screening system was developed using fully automated integrated systems for 
cell imaging and data analysis (Abraham et al., 2004; Smith and Eisenstein, 2005), which 
provides rapid measurements, time efficient and reliable of neurite outgrowth overcoming 
the common limitations of manual methods used in the earlier part of the current study and 
in previous research carried out at Nottingham Trent University. Additionally, HTS can 
assess the effects of a wide range of various chemicals and neurotoxicants on multiple 
parameters of neurite outgrowth including neurite number, neurite length, cell body area 
and the extent of neurite branching. Furthermore, high throughput assays can be used with 
different cellular models in order to compare and characterise the effects of several OPs or 
other chemicals on neurite outgrowth in multiple cell types (Mundy et al., 2010). Earlier 
studies have validated the feasibility of this approach to evaluate the neurotoxicity 
potential of various chemicals on neurite outgrowth in neural cell lines under different 
exposure conditions (Radio et al., 2008; Radio et al., 2010; Harrill and Mundy, 2011; 
Wilson et al., 2014; Sindi et al., 2016).  
3.2 Aims  
The main aims of the present work were: 
(a) to investigate the cytotoxic effects of CPF, CPO and PSP on the viability of 
differentiating N2a and C6 cell lines. Cell viability was assessed by MTT reduction assay 
following exposure to the three OPs at 24 h. This was a preliminary study carried out to 
determine the time point of potential cytotoxicity.   
(b) to determine the effects of sub-lethal concentrations of the same 3 compounds on 
neurite outgrowth. 
It was of particular interest to develop high throughput assays in order to examine the 
effects of a range of sub-lethal concentrations of OPs on multiple parameters of neurite 
outgrowth in a rapid quantitative analysis. Therefore, cells were fixed and stained by 
indirect immunofluorescence with antibodies against β-tubulin III (clone 2G10) and NFH 
(clones SMI 33) and monoclonal antibody of GFAP (clone GA5) and subsequently 
analysed by HTS. 
Results  Chapter 3 
86 
3.3 Effects of CPF, CPO and PSP on the viability of differentiating N2a cells 
The toxic effects of organophosphates of the current study on the two cell lines were 
further compared in terms of their IC50 values, which is the concentration required to 
decrease the level of MTT reduction by 50 % compared to the non-organophosphate 
control. After 24h, an IC50 value was not reached in both at 1-25 µM (Appendix 8.1, 8.2). 
Mouse N2a neuroblastoma cells were induced to differentiate by the addition of 0.3 mM 
dbcAMP in the absence (0.5 % v/v DMSO control) or presence (1, 3, and 10 µM) of CPF, 
CPO or PSP for 24 h. To examine the viability of differentiated N2a cells after being 
exposed to the OPs, MTT reduction assays were performed, as described in section 2.2.7. 
As indicated in figures 3.1, the results showed no effect on the reduction of MTT by 
differentiating N2a cells when compared to its corresponding control after 24 h exposure to 
all three concentrations of CPF, CPO and PSP.  
3.4 Effects of CPF, CPO and PSP on the viability of differentiating C6 cells 
Similarly, mouse C6 glioma cells were induced to differentiate by the addition of 2 mM 
sodium butyrate in the absence (0.5 % v/v DMSO control) or presence (1, 3, and 10 µM) 
of CPF, CPO or PSP for 24 h. To determine the viability of differentiated C6 cells after 
being exposed to the OPs, MTT reduction assays were performed, as described in section 
2.2.7. As indicated in figures 3.2, there was no significant change in the reduction of MTT 
by differentiating C6 cells when compared to its corresponding control after 24 h exposure 
to all the three concentrations of CPF, CPO or PSP.  
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h24a after 2CPF in NA. 
h24a after 2CPO in NB. 
h24a after 2PSP in NC. 
 
 
Figure 3.1. Effects of CPF, CPO and PSP on MTT reduction in differentiating N2a 
cells after 24 h.  
N2a cells were induced to differentiate in the absence and presence of different concentrations of 
CPF (panel A), CPO (panel B) and PSP (panel C) of induction of cell differentiation, and the levels 
of MTT reduction were measured to evaluate cell viability. Results are expressed as a mean 
percentage of the corresponding untreated control ± SEM from five separate experiments. 
Statistical significance of data was analysed by using one way ANOVA.  
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h24after 6 CPF in CA. 
h24after 6 CPO in CB. 
h24after 6 PSP in CC. 
 
 
Figure 3.2. Effects of CPF, CPO and PSP on MTT reduction in differentiating C6 
cells after 24 h. 
C6 cells were induced to differentiate in the absence and presence of different concentrations of 
CPF (A), CPO (B) and PSP (C) of induction of cell differentiation, and the reduction of MTT 
levels were measured to evaluate cell viability. Data are expressed as a mean percentage of the 
corresponding untreated control ± SEM from five separate experiments. Statistical significance of 
data was analysed by using one way ANOVA. When SEM bar is not apparent means that error is 
smaller than the symbol size.  
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3.5 Effects of CPF, CPO and PSP on N2a and C6 cell growth  
In order to further explore OP cytotoxicity on the growth of N2a and C6 cells, cell number 
and viability number were monitored at 24 h using a Trypan blue exclusion assay, and 
measured with the aid of an automated cell counter (TC20TM, Bio-Rad Laboratories Inc., 
Hemel Hempstead, UK) as described in materials and methods.  
The results showed that neither the total cell number nor the percentage of viable cells was 
affected after 24 h exposure to all concentrations of CPF, CPO or PSP in N2a cells (Figure 
3.3). Similarly, both cell number and viable cells were unaffected by all concentrations of 
CPF, CPO and PSP in C6 cells. However, the overall viable cell percentage was slightly 
but not significantly reduced under the same condition in C6 cells compared to the 
corresponding non CPO-treated control (Figure 3.4). 
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Figure 3.3. Effects of CPF, CPO or PSP on the cell number and viability of differentiating N2a cells. 
N2a cells were induced to differentiate for 24h in the presence or absence of 1,3,10 µM CPF, CPO or PSP, before assessment of cell viability via the Trypan blue exclusion 
assay, as described in Materials and Methods. An average of four separate experiments is shown, and the results are presented as total cell count per ml, live cell count per 
ml and percentage (%) of live cell relative to the corresponding control. Statistical significance of data was analysed by using one way ANOVA. When SEM bars are not 
apparent means that error is smaller than the symbol size. 
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Figure 3.4.  Effects of CPF, CPO or PSP on the number and viability of differentiating C6 cells.  
C6 cells were induced to differentiate for 4h in the presence or absence of 1,3,10 µM CPF, CPO or PSP, before assessment of cell viability via the Trypan blue exclusion 
assay, as described in Materials and Methods. Four separate experiments are shown, and the results are presented as total cell count per ml, live cell count per ml and 
percentage (%) of live cell relative to the corresponding control. Statistical significance of data was analysed by using one way ANOVA.  
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3.6 Effects of CPF, CPO and PSP on N2a cell morphology  
Morphological changes in differentiating N2a cells were assessed after 24 h exposure to 
different concentrations of CPF, CPO and PSP. Cells were incubated in the absence (0) or 
presence (1, 3 or 10) µM of CPF, CPO and PSP. They were then fixed and stained with 
Coomassie Brilliant Blue dye (Figure 3.5). By using light microscopy, the structural 
features that were studied included the 1) Extensions between half and 2 cell body 
diameters in length 2) axon, the latter being defined as a neurite outgrowth that is double 
the cell body diameter or longer. There were differences in the morphological changes in 
N2a cells exposed to varying concentrations of CPF, CPO and PSP after 24 h. The 
proportion of cells exhibiting clearly discernible extension was decreased with all 
concentrations of CPF and PSP after 24 h in N2a cells. The number of cell extensions was 
however unaffected by CPO.  
Similarly, there was a decrease in axon-like neurite formation with all concentrations of 
CPF, CPO and PSP after 24 h exposure. The decrease was statistically significant except 
with 1 µM and 3 µM CPF and CPO, and the decrease was highly significant with 10 µM 
PSP (Table 3.1). 
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Table 3.1. Quantification of neurite outgrowth in differentiating N2a cells 
OPs 
Concentrations 
(µM) 
Extension 
(%) 
Axon 
(%) 
CPF 
0 45±1.2 15±0.4 
1 24±0.3* 14±1.00 
3 27±1.2* 14±1.2 
10 15±2.5** 7±0.8* 
CPO 
0 31±2.00 10±0.8 
1 26±0.3 7±0.3 
3 26±4.9 9±1.00 
10 23±1.4 6±0.5* 
PSP 
0 58±0.5 20±0.5 
1 26±3.2* 11±0.5** 
3 24±3.6* 11±0.7** 
10 21±4.2* 3±1.2*** 
N2a cells were induced to differentiate for 24 in the presence of a range of CPF, CPO or PSP 
concentrations. Cells were fixed and stained with Coomassie blue prior to morphological 
measurements. Data are indicated to the number recorded per hundred cells ± standard error from 
an average of four wells of cells cultured on four separate occasions for 24 h exposure.
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Figure 3.5. Effects of CPF, CPO or PSP on the morphology of differentiating N2a cells.  
N2a cells were induced to differentiate for 24 h in the presence or absence of 1,3,10 µM CPF, CPO or PSP, as described in Materials and Methods. Shown are images of 
typical fields of cells viewed by phase contrast microscopy after 24 h differentiation by using an inverted light microscope following methanol fixation and staining with 
Coomassie blue after 24 h differentiation. Projecting from each individual N2a cell are outgrowth processes defined as (a) axon-like processes (if greater than 2 cell body 
diameters in length) (black arrows) or (b) extensions (shorter processes that are between 0.5 -2 cell body diameters in length) (red arrows) . Bar represents 25 µm. 
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3.7 Development of high content screening assay of neurite outgrowth 
The neurotoxic effects of CPF, CPO and PSP on neurite outgrowth in differentiating N2a 
and C6 cells observed in the previous assay (sections 3.5, 3.6) were assessed using manual 
laboratory techniques, by which the number of axon-like processes was quantified per 100 
cells following Coomassie and Trypan blue staining. Consistently, these methods 
demonstrated the ability of these compounds to impair the process of neurite outgrowth. 
However, the acquisition of microscopic images as well as the quantitative analyses was 
time-consuming and gave information only about neurites that were longer or shorter than 
two cell body diameters in length. The key aims of the work presented in this chapter was 
to develop medium to high throughput assays in order to examine the effects of multiple 
concentrations of CPF, CPO and PSP at 24 h on neurite outgrowth in differentiating N2a 
and C6 cells in a rapid quantitative analysis. This would, in turn validate the previous 
findings obtained from analysis of Coomassie Brilliant Blue staining of N2a and C6 cells 
induced to differentiate in the presence and absence of sub-lethal concentration of CPF, 
CPO and PSP.  
For quantitative analysis of multiple parameters of neurite outgrowth in differentiating N2a 
and C6 cells following CPF, CPO and PSP exposure, cells were fixed and stained by 
indirect immunofluorescence with antibodies against their specific proteins. Anti-βIII-
tubulin (clone 2G10) and anti-neurofilament heavy chain NFH (clone SMI 33) antibodies 
were used for N2a cells while anti-GFAP (clone GA5) was used for C6 cells. The anti-
tubulin antibody was expected to stain microtubules in axons, dendrites, cell bodies, and 
anti-NFH antibody was expected to preferentially stain mainly neurofilaments in axons of 
neuronal cells. These specific antibodies were used mainly because they detect neurite-
enriched cytoskeletal proteins and thus facilitate the monitoring OP-induced effects on 
multiple parameters of neurite outgrowth to be investigated. Likewise, anti-GFAP was 
specifically selected for C6 cells because it detects a useful marker of astroglial 
neurotoxicity that is highly expressed by astrocytes (Harry et al., 1998). Images of stained 
cell monolayers were acquired using the ImageXpress Micro Widefield High Content 
Screening System and neurite outgrowth analysis was performed using MetaXpress 
imaging and analysis software, as described by Sindi et al. (2016) and in section 2.2.10.  
Shown in figure 3.6 is the segmentation of acquired images obtained by high throughput 
assays as previously described (section 2.2.10). As shown, all representative images are 
from non OP-treated controls stained with antibodies to βIII tubulin, NFH and GFAP. The 
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procedure for image acquisition included using two fluorophores; FITC to detect cell body 
and neurites (green) and DAPI for all nuclei visualisation in a field (blue). The composite 
merged images showed staining distribution of FITC and DAPI within each neuronal cell. 
Following the image acquisition, image segmentation was performed and displayed as 
multicoloured masks tracking the neurites and cell bodies in the acquired image. For 
accurate image segmentation, the analysis settings of the integrated neurite outgrowth 
application mode were configured and optimised to capture maximum relevant detail with 
reduced background noise. The measurement and analysis of neurite outgrowth parameters 
were achieved by the use of mathematical algorithms and included the following: 
▪ Average number of cells/field (total number of neural cell bodies averaged by the 
number of fields). 
▪ Average cell body area/field (total area of cell bodies in square micron averaged by 
the number of fields). 
▪ Percentage of cells with significant outgrowth (cells with at least one neurite ˃ 10 
µm in length). 
▪ Average number of neurites (total number of neurites produced from the cell bodies 
averaged by the number of fields).  
▪ Maximum neurite length/cell (the length in microns of the longest neurite from the 
neuronal cell body to an extreme segment per cell). 
▪ Average neurite length/cell (the total length in microns of all significant outgrowths 
averaged by the number of cells). 
▪ Significant outgrowth (neurites longer than 10 µm in length). 
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Figure 3.6. Segmentation of stained differentiating N2a and C6 cells using high 
throughput screening assay.  
Cells were induced to differentiate for 24 h in the absence of OPs for 24 h. Cells were fixed and 
stained with antibodies recognising the neuronal marker of N2a cells βIII-tubulin and NFH, and 
GFAP as glial neural marker for C6, followed by Alexa Fluor conjugated anti-IgG secondary 
antibodies, as described in Materials and Methods. The shown images were from a single field of 
view of untreated controls. Acquired images were obtained by using ImageXpress Micro system 
(10x objective) with two wavelengths; FITC to detect cell bodies and neurites and DAPI to detect 
nucleus counting. The multicoloured of segmented images with tracing masks on neurites and cell 
bodies were generated using the Neurite Outgrowth Module within the MetaXpress analysis 
software to monitor different parameters of neurite outgrowth including cell number, cell body area 
and outgrowth length for each identified cell. 
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3.8 Monitoring multi-parameters of neurite outgrowth in differentiating N2a cells  
The sub-lethal effects of CPF, CPO and PSP on neurite outgrowth in co-differentiated N2a 
cells were investigated following 24 h exposure using high throughput assay. The results of 
multi-parametric analysis of neurite outgrowth achieved by quantitation of βIII tubulin and 
NFH staining are shown in Figures 3.7, 3.8, 3.9, 3.10.  
Figure 3.7 shows the high content data for cell number and cell body area obtained by 
analysis of βIII tubulin and NFH staining at 24 h exposure. The presented data show that 
all concentrations of CPF, CPO and PSP had no significant effects on the average neuronal 
cell number/field after 24 h exposure compared to the untreated controls (Figure 3.7, panel 
A1-A4). Similarly, both βIII tubulin and NFH staining showed no significant effects on the 
measurements of cell body area/field of co-differentiated N2a cells following 24 h 
exposure to all the three OP treatments (Figure 3.7, panel B1-B4).  
The effects of multiple concentrations of CPF, CPO and PSP on the average intensity of 
staining within the positive cells and the percentage of cells with significant outgrowth 
(neurites ˃ 10 µm in length) are shown in figure 3.8. The presented data show that all 
concentrations of CPF had no effects on the average intensity of staining/field after 24 h 
exposure compared to the untreated controls (Figure 3.8, panel A1, A3). As indicated in 
figure 3.8, panel A1, A3, no effects were observed on the average intensity of staining in 
cells treated with 1 and 3 µM CPO. In addition, exposure to the highest concentration (10 
µM) of CPO and PSP resulted in significantly reduced intensity (p< 0.05), as with both 
βIII tubulin and NFH staining. Exposure of cells to 3 µM PSP significantly reduced the 
average intensity of staining to 25 % of control values using anti-NFH stain (Figure 3.8, 
panel A4). The quantitative analysis of both stains for the average intensity of staining 
number of neurites/field in co-differentiated N2a cells showed that the exposure to 10 µM 
CPO and PSP caused 20 % and 25 % decline respectively, compared to the corresponding 
non OP-treated control (Figure 3.8).  
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Figure 3.7. Effects of CPF, CPO and PSP on cell number and cell body area in differentiating N2a cells as assessed by high throughput assays. 
 Cell were fixed and stained with antibodies to βIII tubulin and NFH, then data were acquired by using the ImageXpress Micro system, the cell number and cell body area 
were measured using MetaXpress imaging and analysis software. Data show the effects of CPF, CPO or PSP on the average cell number/field (panel A) and the average 
cell body area (µm2)/field (panel B). High throughput data are represented as mean values ± SEM from four independent experiments. Data were analysed using one-way 
ANOVA. The CPF effects are presented as red dashed lines; the CPO effects are presented as blue solid lines, whereas PSP effects are showed as green solid lines. When 
SEM bars are not apparent means that error is smaller than the symbol size. 
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Figure 3.8. Effects of CPF CPO or PSP on average intensity of staining and percentage of cells with significant outgrowth in differentiating N2a 
cells as assessed by high throughput analysis.  
Cells were stained with antibodies to βIII tubulin and NFH, after which data were acquired using ImageXpress Micro system and measured using MetaXpress imaging and 
analysis software. Data show dose-related effects of CPF, CPO or PSP on the average intensity of staining/field (panel A) and the percentage of cells with significant 
outgrowth (panel B). Data are presented as mean values ± SEM from four independent experiments. Data were analysed using one-way ANOVA. The CPF effects are 
presented as red dashed lines; the CPO effects are presented as blue solid lines, whereas PSP effects are showed as green solid lines. Asterisks indicate changes that are 
statistically different from the non OP-treated controls (*p ˂ 0.05), (**p ˂ 0.01).  When SEM bars are not apparent, this means that error is smaller than the symbol size. 
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Figure 3.8 (panel B) quantitation of βIII tubulin staining showed lack of detectable changes 
on the number of cells with significant outgrowth in differentiating N2a cells treated with 
multiple concentrations of CPF and CPO for 24 h. In contrast, this staining showed dose 
dependent decreases in this parameter in PSP-treated cells which was statistically 
significant at the highest concentration (p˂0.05). However, exposure to the highest 
concentration (10 µM) of CPO and PSP significantly reduced the number of cells bearing 
neurites stained with anti-NFH (p ˂ 0.01) staining (Figure 3.8, panel B3, B4). The 
quantitative analysis of NFH stain for the significant outgrowth in differentiating N2a cells 
showed that the treatment of 10 µM CPF, CPO and PSP caused 20 %, 45 % and 65 % 
decline, respectively, compared to the corresponding non OP-treated control.  
Further parameters of neurite outgrowth such as the maximum and average neurite length 
per neuronal cell were also assessed using high throughput assays. Following 24 h 
exposure, CPO (p ˂ 0.05) and PSP (p ˂ 0.01) significantly reduced maximum and average 
neurite length per neuronal cell, respectively, as indicated by anti- βIII tubulin staining 
(Figure 3.9, panel B1). There was a dose-dependent decrease in both parameters of neurite 
outgrowth in PSP-treated cells compared to the non-treated controls. A significant 
concentration-related reduction (p ˂ 0.05, p˂0.01) was observed in both parameters of 
neurite outgrowth at two concentrations (3 and 10 µM) of PSP respectively, as indicated 
with anti- βIII tubulin staining. Anti-NFH staining exhibited significant decreases in the 
maximum and average neurite length/cell following 10 µM CPO and PSP treatments for 24 
h. With regard to the measurement of maximum neurite length per neuronal cell were 
similar for both antibodies at around 25-65 µm (Figure 3.9).  
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Figure 3.9. Effects of CPF, CPO or PSP on maximum and average neurite length/cell in differentiating N2a cells as assessed by high throughput 
analysis.  
Cells were stained with antibodies to βIII tubulin and NFH, after which data were acquired using ImageXpress Micro system and measured using MetaXpress imaging and 
analysis software. Data show dose-related effects of CPF, CPO or PSP on the maximum neurite length/cell (panel A) and the average neurite length/cell (panel B). Data are 
presented as mean values ± SEM from four independent experiments. Data were analysed using one-way ANOVA. The CPF effects are presented as red dashed lines; the 
CPO effects are presented as blue solid lines, whereas PSP effects are showed as green solid lines. Asterisks show changes that are statistically different from the controls 
(*p ˂ 0.05), (**p ˂ 0.01). When SEM bars are not apparent, this means that error is smaller than the symbol size. 
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3.9 Monitoring multi-parameters of neurite outgrowth in differentiating C6 cells  
Using high content throughput analysis, the effects of CPF, CPO and PSP were assessed 
over different concentrations (1, 3 and 10 µM) on the multi-parameters of neurite 
outgrowth in differentiating C6 cells after 24 h exposure. The parameters used to determine 
the impacts of these compounds on C6 cells were similar to those applied in N2a cell 
experiments, which included cell number, cell body area, and percentage of cells with 
significant outgrowth, maximum and average neurite length. Additionally, the average 
intensity of GFAP (clone GA5) staining within neurites and cell bodies of each antibody-
positive cell were evaluated by high throughput assay, as described in section 2.2.10.  
Figure 3.10 demonstrates the segmentation of acquired images obtained by high 
throughput assay employed for C6 cells in the current study. All procedures for image 
acquisition and image analysis were similar to those applied in N2a experiments. All 
representative images shown are from untreated control C6 cells from four single fields of 
view.  
The high throughput data presented in Figure 3.10 show that all concentrations of CPF and 
PSP had no significant effect on either the average number of glial cells/field or on the 
average area of cell bodies/field after 24 h exposure compared to untreated controls, as 
indicated by the analysis of anti-GFAP staining (Figure 3.10, upper panels A1-B2). The 
average number of glial cells/field and the average area of cell bodies/field were, however, 
significantly (p ˂ 0.05) reduced after 24 h exposure to the highest CPO concentration 
(Figure 3.10, panels A1 and B1). The average count of differentiated glial cells ranged 
between 110 to 150 cells/field in controls, as indicated by anti-GFAP staining (Figure 3.10, 
panels A1 and A2). 
Figure 3.10 (lower panels C1-D2) displays the high throughput measurement of the 
average intensity of staining and the percentage of cells with significant outgrowth. The 
data demonstrated that CPF and CPO at all concentrations had no effect on either 
parameter following 24 h exposure, compared to non OP-treated controls. The average 
intensity of staining was, however, significantly (p ˂ 0.05) reduced by all concentrations of 
PSP and the percentage of cells with significant outgrowth was significantly (p ˂ 0.05) 
reduced following exposure to 10 µM PSP.  
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Measurements of glial cell extension length were also obtained using high throughput 
screening with GA5 staining. As illustrated in figure 3.11, while the maximum neurite 
length per cell in co-differentiated C6 cells was significantly (P < 0.01) reduced by 10 µM 
CPF and CPO following exposure for 24 h, there was a significant dose-dependent 
reduction in the average neural length per cell following PSP exposure for 24 h. As 
demonstrated in figure 3.11 (panels A1 and A2), the maximum length of astrocyte 
extensions/cell ranged between 35 to 58 µm in untreated controls. The data in figure 3.11 
(panels B1 and B2) indicated that 24 h exposure to CPO at 1, 3 and 10 µM concentrations 
caused a significant reduction in the average neurite length/cell by 90 % at 10 µM (p<0.01) 
compared to the untreated controls. However, the data show that all concentrations of PSP 
had no statistically significant effect on either parameter following 24 h exposure 
compared to non OP-treated controls, except the average neurite length per cell which was 
significantly reduced (p<0.05)  by exposure to 10 µM PSP.  
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Figure 3.10. Effects of CPF CPO or PSP on multiple parameters in differentiating C6 cells as assessed by high throughput analysis.  
Cells were stained with antibody to GFAP, after which data were acquired using ImageXpress Micro system and measured using MetaXpress imaging and analysis 
software. Data show dose-related effects of CPF, CPO or PSP on cell number (panel A), cell body area (panel B), the average intensity of staining (panel C) and percentage 
of cells with significant outgrowth (panel D). Data are presented as mean values ± SEM from four independent experiments. Data were analysed using one-way ANOVA. 
The CPF effects are presented as red dashed lines; the CPO effects are presented as blue solid lines, whereas PSP effects are showed as green solid lines. Asterisks indicate 
changes that are statistically different from the non OP-treated controls (*p ˂ 0.05). When SEM bars are not apparent, this means that error is smaller than the symbol size. 
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Figure 3.11. Effects of CPF CPO or PSP on multiple parameters in differentiating C6 
cells as assessed by high throughput analysis.  
Cells were stained with antibody  to GFAP, after which data were acquired using ImageXpress 
Micro system and measured using MetaXpress imaging and analysis software. Data show dose-
related effects of CPF, CPO or PSP on the maximum neurite length/cell (panel A), the average 
neurite length/cell (panel B). Data are presented as mean values ± SEM from four independent 
experiments. Data were analysed using one-way ANOVA. The CPF effects are presented as red 
dashed lines; the CPO effects are presented as blue solid lines, whereas PSP effects are showed as 
green solid lines. Asterisks indicate changes that are statistically different from the non OP-treated 
controls (*p ˂ 0.05), (**p ˂ 0.01).  
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3.10 Effect of CPF, CPO and PSP on cytoskeletal organization in cultured 
differentiating N2a and C6 cells  
In order to show whether the morphological changes observed in sections 3.6, and 3.7 
reflected cytoskeletal disruption, cells from control and OP exposures were stained with 
antibodies to cytoskeletal proteins (βIII tubulin, NFH and GFAP) by indirect 
immunofluorescence as described in Materials and Methods (section 2.2.9). The images in 
figures 3.12 – 3.17 show the effects of treatment of differentiating N2a cells with 1, 3 and 
10 µM CPF, CPO and PSP for 24 h on cytoskeletal networks as indicated by anti-βIII 
tubulin (Clone 2G10) and anti-NFH (clone SMI33)staining.  
Exposure to all of the OP concentrations modified the cells’ cytoskeletal network after a 24 
h treatment. This was mainly evident by some disruption in the microtubule and 
neurofilament networks in N2a cells showing cytoplasmic staining, which was reduced in 
intensity with treatments. Anti-tubulin staining was reduced and disrupted with OP 
treatments. The cytoplasmic staining was reduced compared to the control with CPF 
(Figures 3.12), CPO (Figures 3.13) and PSP (Figures 3.14) treatments, and the neurite 
outgrowth was visibly truncated in some cells with OP treatments.  
Neurofilament staining intensity was also reduced in differentiating N2a cells with OP 
treatments, in particular with 3 and 10 µM CPF (Figures 3.15), CPO (Figures 3.16) and 
PSP (Figures 3.17). The proportion of N2a cells exhibiting a clearly discernible neural 
outgrowth was visibly reduced with both concentrations of all the OP concentrations in 
N2a cell lines.  
The images in Figures 3.18, 3.19 and 3.20 show that changes were observed in the staining 
intensity of GFAP in differentiating C6 cells with CPF and CPO treatments. However, in 
PSP treated C6 cells there was disruption in the GFAP staining, showing cytoplasmic 
staining, which was reduced in intensity compared to the non OP-treated control.  
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Figure 3.12. Indirect immunofluorescence staining of CPF effects on βIII tubulin 
staining of differentiating N2a cells as detected by EVOS cell imaging system.  
Shown are representative images of immunofluorescently stained cell monolayers with anti-βIII 
tubulin. Cells were induced to differentiate for 24 h in the presence of 1 µM (panel B), 3 µM (panel 
C) and 10 µM (panel D) or absence (panel A) of CPF for 24 h, then they were fixed and 
immunoflourescently stained for the neural marker of interest as described in Materials and 
Methods. The white arrow indicates to the axon. All Images shown were from a single 
representative field of view by using an EVOS FL cell imaging system (10x objective) with two 
channels; FITC for detecting cell bodies and neurites and DAPI for nucleus counting. Scale bar 400 
µm.  
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Figure 3.13. Indirect immunofluorescence staining of CPO effects on βIII tubulin 
staining of differentiating N2a cells as detected by EVOS cell imaging system.  
Shown are representative images of immunofluorescently stained cell monolayers with anti-βIII 
tubulin. Cells were induced to differentiate for 24 h in the presence of 1 µM (panel B), 3 µM (panel 
C) and 10 µM (panel D) or absence (panel A) of CPF for 24 h, then they were fixed and 
immunoflourescently stained for the neural marker of interest as described in Materials and 
Methods. The white arrow indicates to the axon. All Images shown were from a single 
representative field of view by using an EVOS FL cell imaging system (10x objective) with two 
channels; FITC for detecting cell bodies and neurites and DAPI for nucleus counting. Scale bar  
400 µm.  
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Figure 3.14. Indirect immunofluorescence staining of PSP effects on βIII tubulin 
staining of differentiating N2a cells as detected by EVOS cell imaging system.  
Shown are representative images of immunofluorescently stained cell monolayers with anti-βIII 
tubulin. Cells were induced to differentiate for 24 h in the presence of 1 µM (panel B), 3 µM (panel 
C) and 10 µM (panel D) or absence (panel A) of CPF for 24 h, then they were fixed and 
immunoflourescently stained for the neural marker of interest as described in Materials and 
Methods. The white arrow indicates to the axon. All Images shown were from a single 
representative field of view by using an EVOS FL cell imaging system (10x objective) with two 
channels; FITC for detecting cell bodies and neurites and DAPI for nucleus counting. Scale bar  
400 µm.  
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Figure 3.15. Indirect immunofluorescence staining of CPF effects on NFH staining of 
differentiating N2a cells as detected by EVOS cell imaging system.  
Shown are representative images of immunofluorescently stained cell monolayers with anti-NFH    
(Clone SMI 33). Cells were induced to differentiate for 24 h in the presence of 1 µM (panel B), 3 
µM (panel C) and 10 µM (panel D) or absence (panel A) of CPF for 24 h, then they were fixed and 
immunoflourescently stained for the neural marker of interest as described in Materials and 
Methods. The white arrow indicates to the axon. All Images shown were from a single 
representative field of view by using an EVOS FL cell imaging system (10x objective) with two 
channels; FITC for detecting cell bodies and neurites and DAPI for nucleus counting. Scale bar  
400 µm.  
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Figure 3.16. Indirect immunofluorescence staining of CPO effects on NFH staining of 
differentiating N2a cells as detected by EVOS cell imaging system.  
Shown are representative images of immunofluorescently stained cell monolayers with anti-NFH    
(Clone SMI 33). Cells were induced to differentiate for 24 h in the presence of 1 µM (panel B), 3 
µM (panel C) and 10 µM (panel D) or absence (panel A) of CPF for 24 h, then they were fixed and 
immunoflourescently stained for the neural marker of interest as described in Materials and 
Methods. All Images shown were from a single representative field of view by using an EVOS FL 
cell imaging system (10x objective) with two channels; FITC for detecting cell bodies and neurites 
and DAPI for nucleus counting. Scale bar 400 µm.  
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Figure 3.17. Indirect immunofluorescence staining of PSP effects on NFH staining of 
differentiating N2a cells as detected by EVOS cell imaging system.  
Shown are representative images of immunofluorescently stained cell monolayers with anti-NFH    
(Clone SMI 33). Cells were induced to differentiate for 24 h in the presence of 1 µM (panel B), 3 
µM (panel C) and 10 µM (panel D) or absence (panel A) of CPF for 24 h, then they were fixed and 
immunoflourescently stained for the neural marker of interest as described in Materials and 
Methods. The white arrow indicates to the axon. All Images shown were from a single 
representative field of view by using an EVOS FL cell imaging system (10x objective) with two 
channels; FITC for detecting cell bodies and neurites and DAPI for nucleus counting. Scale bar  
400 µm.  
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Figure 3.18. Indirect immunofluorescence of CPF effects on anti-GFAP staining 
differentiating C6 cells as detected by EVOS cell imaging system.  
Shown are representative images of immunofluorescently stained with anti-GFAP (GA5) . Cells 
were induced to differentiate for 24 h in the presence of 1 µM (panel B) ,3 µM (panel C) and 10 
µM (panel D) or absence (panel A) of CPF for 24 h, then they were fixed and immunoflourescently 
stained for GFAP as described in Materials and Methods. All Images shown were from a single 
representative field of view by using an EVOS FL cell imaging system (10x objective) with two 
channels; FITC for detecting cell bodies and neurites and DAPI for nucleus counting. Scale bar  
400 µm.  
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Figure 3.19. Indirect immunofluorescence of CPO effects on anti-GFAP staining 
differentiating C6 cells as detected by EVOS cell imaging system.  
Shown are representative images of immunofluorescently stained with anti-GFAP (GA5) . Cells 
were induced to differentiate for 24 h in the presence of 1 µM (panel B) ,3 µM (panel C) and 10 
µM (panel D) or absence (panel A) of CPF for 24 h, then they were fixed and immunoflourescently 
stained for GFAP as described in Materials and Methods. All Images shown were from a single 
representative field of view by using an EVOS FL cell imaging system (10x objective) with two 
channels; FITC for detecting cell bodies and neurites and DAPI for nucleus counting. Scale bar  
400 µm.  
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Figure 3. 20. Indirect immunofluorescence of PSP effects on anti-GFAP staining 
differentiating C6 cells as detected by EVOS cell imaging system.  
Shown are representative images of immunofluorescently stained with anti-GFAP (GA5) . Cells 
were induced to differentiate for 24 h in the presence of 1 µM (panel B) ,3 µM (panel C) and 10 
µM (panel D) or absence (panel A) of CPF for 24 h, then they were fixed and immunoflourescently 
stained for GFAP as described in Materials and Methods. All Images shown were from a single 
representative field of view by using an EVOS FL cell imaging system (10x objective) with two 
channels; FITC for detecting cell bodies and neurites and DAPI for nucleus counting. Scale bar  
400 µm.  
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3.11 Discussion 
There is a large amount of evidence highlighting the risks of OP exposure, which has led to 
restrictions being put in place over their use. However, CPF is still one of the most 
commonly used insecticides, especially in developing countries (Minton and Murray, 
1988; Murray et al., 2005; Coronado et al., 2006; Salyha, 2010).  
The current study investigated the effects of sub lethal concentrations (1, 3 and 10 µM), 
confirmed by MTT reduction and Trypan blue exclusion assays, of CPF, CPO or PSP on 
neurite outgrowth in differentiating N2a and C6 cells in order to extend findings from 
previous studies and allow the development of a high throughput screening system to study 
changes in neurite outgrowth much more comprehensively. The morphological effects of 
OPs on axon-like neurites were investigated initially by staining cells with Coomassie 
Brilliant Blue and manual quantification, then by developing a fully automated, HTS 
system to measure multiple parameters of neurite outgrowth in cells that were fixed and 
stained by indirect immunofluorescence with antibodies against NFH (clone SMI33) and β 
III tubulin (clone 2G10) in N2a cells, and in C6 cells stained with the monoclonal antibody 
to GFAP (clone GA5).  
The results of the MTT assays showed that in N2a and C6 cells there was no significant 
decrease in MTT reduction after 24 h treatment with all 3 compounds. This finding fits 
well with previous MTT reduction studies in N2a and C6 cells, which have shown that 
concentrations of 1-10 µM CPF and CPO had no effect over 24 h, (Sachana et al., 2008; 
Flaskos et al., 2011). The PSP results in this study match the findings of previous 
investigations, which found higher concentrations of PSP inhibited the reduction of MTT 
in cultured N2a cells, but concentrations up to 10 µM had no effect (Hargreaves et al., 
2006; Harris et al., 2009a). Further confirmation that the MTT reduction assay data 
indicated no effect of 24 h treatments on cell viability was obtained by Trypan blue 
exclusion assay using an automated cell counter to assess the effect of CPF, CPO and PSP 
on cell number and viability of differentiating N2a and C6 cells. Overall, the MTT and 
Trypan blue exclusion data suggest that the 1-10 µM OP concentration range s is suitable 
to investigate sub-lethal effects on neurite outgrowth in N2a and C6 cells if used in 
combination with a 24 h time point. 
The initial investigation into changes in morphology used Coomassie Brilliant Blue 
staining to allow the cell features of neurite outgrowth to be monitored. The results 
indicated that all 3 OPs could inhibit neurite outgrowth in both cell lines. These results 
Results  Chapter 3 
118 
 
correlate with previous studies in C6 glioma cells that were exposed to sub-cytotoxic (1-10 
µM) doses of CPF and CPO (Sachana et al., 2008), studies in differentiating N2a cells that 
were exposure to sub-cytotoxic levels of CPF (Sachana et al., 2001), and studies of 
differentiating neuroblastoma N2a cells exposed to PSP, which all produced inhibited 
neurite outgrowth (Hargreaves et al., 2006; Flaskos et al., 2007; Pomeroy-Black and 
Ehrich, 2012). These results suggest that this manual counting method is suitable for 
measuring changes in the parameters investigated, and confirmed that the OP treatments 
used do cause changes in neurite outgrowth. However, the application of this technique is 
limited in the detail it provides, and it is also time consuming and labour intensive.  
In order to overcome the limitations of the manual counting method, a HTS approach using 
advanced technology was investigated, which is considered to be a novel and more 
powerful approach to determine the effects of OPs on differentiating mammalian cell lines. 
Previous studies have shown that high throughput assays can be used to compare the 
effects of different chemicals on neurite outgrowth in different cellular models of neural 
differentiation under a range of exposure conditions (Radio et al., 2008; Mundy et al., 
2010; Radio et al., 2010; Harrill and Mundy, 2011; Wilson et al., 2014; Sindi, 2015).  
A HTS approach used in a previous study with pre-differentiated N2a cells that were 
treated with or without 1, 3 and 10 µM CPF and CPO. Cells were then fixed and stained by 
indirect immunofluorescence with antibodies against NFH, βIII tubulin, and GFAP. Anti-β 
III tubulin was chosen to stain microtubules in cell bodies, dendrites and axons anti-NFH 
was chosen to stain neurofilaments in axons of neuronal cells, and anti-GFAP was selected 
for use in C6 cells as it is an astro-glial marker (Sindi, 2015). The results for the indirect 
immunofluorescence staining showed good staining for all the antibodies and qualitative 
differences could be seen after some of the treatments, suggesting these were suitable 
markers for use in this study. By using the HTS system, multiple parameters of neurite 
outgrowth could be measured. The results for both cell types showed that the treatments 
had no significant effect on cell number, and only 10 µM CPO reduced cell body area in 
C6 cells stained for GFAP in agreement with metabolic and viability assays, and further 
confirming that the treatments did not cause cell death. The results agree with previous 
HTS studies which also showed no major changes to the number cells or cell body area at 
sub lethal concentrations. The reductions in staining intensity observed for anti-βIII tubulin 
and anti-NFH after treatment with 10 µM of all OPs, 3 µM PSP for anti-NFH, and all 
concentrations of PSP for anti-GFAP, suggest that the OPs, and especially PSP, are having 
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an effect on these protein levels and that this could be related to reduced neurite length, 
which is different to the results of previous studies where no changes in staining intensity 
were observed for these cell types, which is possibly due to the difference in exposure time 
between these studies, and the fact that they used different exposure starting points, as this 
study used a longer exposure time which would allow the differences on staining intensity 
to develop   (Sindi, 2015).  
For the N2a cells, the reductions observed by HTS in neurite length and neurite number per 
cell and the percentage of cells bearing neurites suggest that treatment with all 3 OPs 
inhibits neuronal cell differentiation as indicated by reductions the outgrowth of neurites 
that are positive for anti-βIII tubulin and anti-NFH in a concentration dependent manner. 
For the C6 cells stained for GFAP, HTS analysis of differentiating C6 cells showed that the 
3 OPs were also able to inhibit neurite outgrowth in glial  cell differentiation, as indicated 
by concentration dependent reductions in the percentage of cells bearing neurites, the 
average number of neurites per cell and neurite length. 
These results are in agreement with those found by Coomassie Brilliant Blue staining, and 
both approaches show impairment of neurite outgrowth due to treatment with the higher 
concentrations of all three OPs used. The HTS data also show that all of the OPs tested 
inhibited the formation of neurite extensions in neuronal and glial cells, which agree with 
previous studies that have shown outgrowth impairment in N2a cells after treatment at the 
point of induction with 3 µM CPF (Sachana et al., 2001; Sachana et al., 2005), a similar 
concentration dependent response after treatment with CPO for 24 h (Flaskos et al., 2011) 
and after treatment with PSP, with no significant effect on cell shape (Hargreaves et al., 
2006; Flaskos et al., 2006). The results also agree with previous studies in glial cells which 
found an inhibitory effect on extension outgrowth of 24 h exposure to 1-10 µM CPF and 
CPO in C6 cells (Sachana et al., 2008).  
Overall, the results correlate with the findings of previous studies that have shown that in 
differentiating neuronal cells, reduced neurite outgrowth is associated with neuronal 
degeneration and modification of axonal morphology, which are critical events in the 
development of OPIDN (Flaskos et al., 1994; Ehrich and Jortner, 2001; Hargreaves et al., 
2006). 
On the other hand, CPO caused the largest significant differences for some conditions, 
with the largest reduction in % cells with significant outgrowth for anti-NFH; the reduction 
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in maximum neurite length/cell was higher for CPO than PSP for NFH and CPO produced 
a similar response for NFH average neurite length/cell as PSP. The impairment of neurite 
outgrowth followed a similar pattern for anti-GFAP after treatment of C6 cells with CPO 
and CPF for maximum neurite length/cell; GFAP average neurite length/cell was affected 
more by CPO than PSP. These significant effects of CPO are mainly seen for anti-NFH 
and anti-GFAP staining, which suggests CPO exhibits potent effects on axon-like neurites 
and glial extensions more than cell bodies and dendrites, which is in agreement with 
previous studies which have shown CPO was more potent than CPF following 24 h 
exposure in pre-differentiated rat PC12 pheochromocytoma cells, and in differentiating 
N2a cells, causing inhibited neurite outgrowth, and a reduction in axonal length in 
embryonic derived primary cultures of sensory and sympathetic neurons (Das and Barone, 
1999; Howard et al., 2005; Yang et al., 2008).  
These results are also consistent with studies showing that CPO exposure can cause           
a reduction in NFH levels in vitro (Sidiropoulou et al., 2009b; Flaskos et al., 2011), that 
CPO can bind covalently to tubulin and disrupt polymerisation of bovine brain MT in vitro 
(Grigoryan and Lockridge, 2009), and disrupt the neurofilament network after 24 h 
treatment with non-cytotoxic neurite inhibitory concentrations of CPO (Flaskos et al., 
2011). The morphological changes observed after treatment with CPO occur at similar 
concentrations found in vivo in developing humans (Gupta, 1995; Ostrea et al., 2002; 
Pelkonen et al., 2006) and therefore can be linked to the developmental neurotoxicity 
observed (Bramanti et al., 2010; Liu et al., 2012). 
The reduction in the staining intensity for βIII tubulin and NFH after treatment with CPF, 
CPO and PSP could indicate a reduction in the protein levels of the neuron specific βIII 
tubulin isoform and the axon enriched protein NFH, and changes, or a breakdown, in the 
NF networks, which would result in reduced axon stability (Sindi, 2015). The effects on 
neurite length depend on the OP and concentration used, which can easily be measured the 
sensitive high throughput assay, and these axon extensions play a key role in connecting 
single and multiple neurons (Hjorth et al., 2014).  
In summary, the data from this chapter show that sub-lethal concentrations of CPF, CPO 
and PSP impaired the outgrowth of neurites in differentiating N2a and C6 cells. The data 
also demonstrate that HTS was able to detect and quantify multiple changes in neurite 
outgrowth caused by the different OPs, and allowed a rapid analysis overcoming some of 
the disadvantages of manual methods, and validated the previous results obtained by the 
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Coomassie method both in this chapter and in other previous studies (Sachana et al., 2001; 
Sachana et al., 2005; Hargreaves et al., 2006; Flaskos et al., 2011). The results of this 
assay show there are inhibitory effects of all OPs on neurite number and length for the 
different markers measured, with each OP producing a slightly different pattern of effects. 
Based on the results of the studies presented in this chapter, further investigations into how 
CPF, CPO and PSP affected neurite outgrowth were planned. This included quantitative 
analysis of protein levels for a selection of key cytoskeletal and associated regulatory 
proteins MAP-2, βIII tubulin, Tau, GAP-43, NFH and GFAP, which would be analysed for 
changes in the levels of expression in N2a and C6 cell lines differentiated with or without 
1, 3 and 10 µM of CPF, CPO or PSP by Western blotting analysis. The aims of this further 
study are to investigate how changes in expression of these key proteins are related to the 
morphological changes observed in this chapter, to help to elucidate the method of action 
of these OPs. 
 
 
 
 
 
 
  
Chapter 4 
Effects of Organophosphates on 
Cytoskeletal and Associated Regulatory 
Proteins in Differentiating N2a 
Neuroblastoma and C6 glial Cells 
Results  Chapter 4 
122 
 
4.1 Introduction 
Having observed from the previous chapter, that changes in morphology of the two cell 
lines occurred as a result of exposure to sub-cytotoxic concentrations (1, 3 and 10 µM) of 
CPF, CPO and PSP, it was hypothesised that this might involve changes in the levels of 
cytoskeletal and associated regulatory proteins in rodent neural cell lines.  
The neuronal cytoskeleton, particularly microtubules (MTs) and neurofilaments (NFs), is 
one of the most important endogenous factors that control normal neurodevelopment and 
stability including the process of axonal/neurite outgrowth (Cambray-Deakin, 1991). 
Disruption of the axonal cytoskeleton by OPs has often been associated with changes in 
neuronal cell morphology, particularly in cases of toxic neuropathies in which NFH which 
is one of the potential targets of OPs (Lee and Cleveland, 1994).  
Impairment of neurite outgrowth following exposure to OPs has been linked with 
disruption of the expression levels of cytoskeletal proteins (Flaskos et al., 1998; Sachana et 
al., 2001; Sachana et al., 2003; Sachana et al., 2005; Hargreaves et al., 2006; Flaskos et 
al., 2007; Flaskos et al., 2011; Sachana et al., 2014; Sindi et al., 2016).  
Earlier reports evaluated the effects of CPF on a number of cytoskeletal and associated 
regulatory proteins in N2a cells under different differentiation and exposure conditions 
(Sachana et al., 2001; Sachana et al., 2005). Furthermore, the mechanisms underlying the 
ability of certain OPs to cause axon retraction and to inhibit axon outgrowth have been 
associated with some axon growth-associated proteins such as GAP-43, which is important 
in the regulation of axonal outgrowth and/or stabilization (Meiri et al., 1986; 1998; Knoops 
and Octave, 1997).  
Sachana and colleagues (2005) showed reduced levels of GAP-43 in pre-differentiated N2a 
cells that were subsequently treated with CPF. However, exposure of N2a cells to CPF for 
4h at the point of induction of cell differentiation had no impact on GAP-43 expression 
(Sachana et al., 2005). The findings of these previous studies suggest that the effects of 
CPF on the protein depend on the differentiation stage of the cells when exposure occurs. 
In another study, exposure of N2a cells at the point of induction of differentiation to 1-10 
µM CPO caused reduced levels of GAP-43 and NF-H after 24 h (Flaskos et al., 2011).  
Exposure to 10 µM diazoxon and after differentiation for 24 h (DZO) decreased the 
expression of βIII-tubulin and microtubule associated protein 1B (MAP1B) in 
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differentiating N2a cells. However, DZO had no effect on the expression of the 
microtubule associated protein Tau, NFL or NFM at the protein level. Thus, DZO disrupts 
the microtubule (MT) network affecting the expression and distribution of two specific MT 
proteins known to be important in neurite outgrowth (Sachana et al., 2014). However, the 
effects of CPF, CPO and PSP on the levels of MAPs in N2a cells are not known. 
There is a lack of quantitative data in the case of PSP treatment of C6 cells, as in early 
work it was suggested that PSP had no effect on C6 cell differentiation, as measured by 
neurite (extension) number (Fowler et al., 2001). Given that the original data were 
preliminary and only involved a simple morphological assessment of Coomassie blue 
stained cells (i.e. a total count of extensions irrespective of length), further studies could be 
worthwhile. Moreover, the effects of PSP on cytoskeletal proteins in C6 cells have not 
been determined yet (Sachana et al., 2001; 2005; 2008; 2014; Harris et al., 2009a).  
It was observed in a recent study that the levels of phosphorylated NFH (detected by the 
monoclonal antibody Ta51) were reduced significantly after 8 h exposure of pre-
differentiated N2a cells to CPF and CPO, which corresponded to a collapse of the 
neurofilament network (Sindi et al., 2016).  Likewise, CPF and CPO can exert toxic effects 
directly on glial cell differentiation through disruption of the cytoskeleton and its 
associated proteins, and CPO in particular has a potent effect on the microtubule network 
(Sachana et al., 2008). CPO was found to cause significant decreases in the levels of 
tubulin and MAP-1B in differentiating C6 cells after 24 h exposure by western blot 
analysis (Sachana et al., 2008).   
Inhibition of outgrowth of axon-like processes in differentiating N2a cells has been 
associated with exposure to sub-lethal concentrations of PSP (Hargreaves et al., 2006). 
These morphological changes were associated with altered phosphorylation and levels of 
NFH protein detected on Western blots. Exposure of differentiating N2a cells to 2.5 µM 
PSP increased the phosphorylation of NFH after 4 h as indicated by a relative increase in 
reactivity of the lysates with monoclonal antibody Ta51 (which recognises the 
phosphorylated form of NFH) compared to N52 (total NFH). However, 24 h exposure of 
differentiating N2a cells to the same compound resulted in decreases in both total and 
phosphorylated forms of NFH (Hargreaves et al., 2006). Thus, there is clear evidence for 
cytoskeletal effects of the three OPs used in the current study on N2a cells but little data 
regarding molecular effects of PSP on cultured glial cells. As the current work is focussed 
on the cytoskeletal gene expression changes that might be associated with exposure to the 
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OPs it was important to show that known OP-induced protein changes could be reproduced 
in the N2a cells and to determine whether novel protein changes could be detected 
particularly in PSP-treated C6 cells.         
4.2 Aims 
Since a number of MT, NF and associated regulatory proteins are important in 
neurodevelopment and may be involved in neurite outgrowth and stability, a key aim of the 
work presented in this chapter was to examine the effects of CPF, CPO and PSP on the 
levels of expression of cytoskeletal and associated regulatory proteins involved in neural 
cell differentiation and survival in differentiating mouse N2a neuroblastoma cells and C6 
glioma cells.   
The molecular changes underlining the morphological effects of OPs on neurite outgrowth 
in N2a and C6 cell lines differentiated in the absence and presence of CPF, CPO and PSP 
(during differentiation) were studied by quantitative Western blotting. For immunoblotting, 
Western blots of lysates of N2a and C6 cells induced to differentiate in the absence and 
presence (1, 3 and 10 µM) of CPF, CPO or PSP for 24 h were probed with antibodies 
against a range of proteins, including MAP-2, βIII tubulin, Tau, GAP-43, NFH and GFAP, 
as described in section 2.2.13 and table 2.9.  
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4.3 Effects of CPF, CPO and PSP on the expression level of GAPDH in N2a and C6 
cell lines 
GAPDH levels were quantified by Western blot analysis. Western blots of lysates prepared 
from N2a and C6 cells differentiated in the presence (1, 3 and 10) µM of CPF, CPO or PSP 
for 24 h were probed with antibodies against GAPDH, after which reactivity was detected 
using ECL reagent and was quantified densitometrically as described in Materials and 
Methods, section 2.2.13.  
As indicated in figure 4.1 and table 4.1, the reactivity of anti-GAPDH with protein lysates 
from both cell lines showed no significant changes following exposure of cells to all the 
OPs and concentrations tested at 24 h. Therefore, the band intensities of all studied 
proteins were normalised to that for GAPDH in the same sample, which was used as 
internal control. 
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Table 4.1. Densitometric analysis of Western blots probed with antibody to GAPDH 
protein in N2a and C6 cell lines. 
Antigen Toxin (µM) 
Densitometric peak (% control ± SEM) 
CPF CPO PSP 
GAPDH of 
N2a cells 
1 90 ± 2 84 ± 4 93 ± 3 
3 103 ± 7 86 ± 13 92 ± 4 
10 103 ± 13 102 + 16 96 ± 4 
GAPDH of C6 
cells 
1 105 ± 2 101 ± 7 99 ± 2 
3 104 ± 3 98 ± 10 100± 6 
10 105  ± 8 99 ± 4 97 ± 8 
Western blots of cell lysates from N2a and C6 cells induced to differentiate in the absence and 
presence of CPF, CPO and PSP at the concentrations indicated, were probed with antibodies that 
recognise GAPDH. The antibody reactivity was then visualized with ECL reagents as described in 
Materials and Methods. Densitometric peak areas were quantified using AIDA software. Data 
represent means of four separate experiments and values are expressed as a percentage of 
corresponding non OP-treated control ± SEM. 
4.4 Effects of CPF, CPO and PSP on the expression levels of microtubule proteins in 
differentiating N2a cells 
In order to determine the effects of OPs on the expression levels of microtubule proteins, 
Western blots of lysates prepared from cells differentiated in the absence and presence of 
1, 3 and 10 µM of CPF, CPO or PSP for 24 h were probed with antibodies against a range 
of MT proteins which included MAP2, βIII-tubulin and Tau as described in chapter 2. 
Changes were observed in the levels of antibody reactivity on Western blots of cell lysates 
from cell lines treated with OPs compared to the controls (Figures 4.1and Table 4.2). 
The three OP treatments showed significant effects on reactivity of lysates with anti-
MAP2, which decreased significantly after exposure to 3 µM CPF (p<0.05) and 10 µM 
CPF, CPO and PSP (p<0.05). However, there was no statistically significant effect on the 
reactivity with same antibody in cell lysates for 1 µM CPF, 1 µM and 3 µM CPO and PSP.  
Similarly, all OP treatments also showed significant effects on reactivity of lysates with 
anti-βIII tubulin, which decreased significantly after exposure to 10 µM CPF (p<0.05), 
CPO (p<0.05) and PSP (p<0.01).  
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Antibody cross reactivity of anti-Tau with whole cell lysate was significantly reduced after 
24 h exposure to 3 and 10 µM concentrations of both CPF (p<0.01) and PSP (p<0.05) of  3 
µM and (p<0.01) of 10 µM. However, there was no statistically significant effect on 
reactivity with anti-tau in cells for any of the CPO concentrations tested.  
 
 
Figure 4.1. Detection of microtubule proteins by Western blots of differentiating N2a 
cell lysates.  
N2a cells were induced to differentiate for 24 h with the treatment of (0, 1, 3, 10 μM) of CPF, 
CPO, PSP or without OP (Control 0 μM). Equal amounts of N2a cell lysates were loaded in SDS-
PAGE and Western blotting as mentioned in the Material and Methods chapter. Shown are typical 
blots which probed with antibodies against MAP-2, βIII tubulin and Tau followed by HRP-
conjugated secondary antibodies and developed by ECL reagents. Blots probed with GAPDH were 
used as internal control.  
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Table 4.2. Densitometric analysis of Western blots probed with antibodies to 
microtubule proteins in N2a cell lines.  
Antigen Toxin (µM) 
Densitometric peak (% control ± SEM) 
CPF CPO PSP 
MAP-2 
1 101± 1 100 ± 2 91 ± 3 
3 75± 6* 87 ± 15 84 ± 7 
10 69±7* 64 ± 11* 72 ± 6* 
βIII-tubulin 
1 102±1 104 ± 1 96 ± 2 
3 90±5 76 ± 17 89 ± 3 
10 74±13* 64 ± 12* 50 ± 6** 
Tau 
1 85±3 101 ± 1 95 ± 1 
3 59±10** 100 ± 1 78 ± 9* 
10 35± 4** 94 ± 4 68 ± 9** 
Western blots of lysates from differentiating N2a cells were probed with antibodies that recognise 
MAP-2, βIII-tubulin and Tau. The antibody reactivity was then visualized with ECL reagents as 
described in Materials and methods and densitometric peak areas were quantified using AIDA 
software. Data represent means of four separate experiments and values are expressed as a 
percentage of the corresponding control (band densities for all proteins were normalised to blots 
probed with GAPDH) ± SEM; *P<0.05, **P<0.01, asterisks indicate significant differences 
compared to the corresponding untreated control. 
4.5 Effects of CPF, CPO and PSP on the expression levels of neurofilament and 
growth associated proteins in N2a cells  
To examine possible effects of the OP treatments on the levels of axonal intermediate 
filament and growth associated proteins in N2a cells, the immunoreactivity of antibodies 
with GAP43 and the core neurofilament forming protein NFH was quantified by Western 
blotting analysis.  
For immunoblotting, Western blots of lysates prepared from cells induced to differentiate 
for 24 h in the absence and presence (1, 3 and 10 µM) of CPF, CPO or PSP were probed 
with antibodies against NFH and GAP43.  
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As indicated on figure 4.2 and table 4.3, there were no significant effects on the cross 
reactivity with the antibody that recognised NFH of lysates from differentiating N2a cells 
exposed to 1 µM CPF, CPO or PSP for 24 h compared to control.  However, probed 
Western blots of N2a cell lysates showed a significant decrease after exposure to 3µM CPF 
(p<0.01) and to 3µM PSP (p<0.05), while the decrease was high significant after exposure 
to 10 µM CPF, CPO or PSP (p<0.01).  
Similarly, GAP43 reactivity was unaffected following exposure to 1 µM CPF, 1 µM and 3 
µM CPO and PSP. However, probed Western blots of N2a cell lysates showed a 
significant decrease in antibody reactivity with GAP43 on exposure to 3µM CPF (p<0.05) 
and after exposure to 10 µM CPF, CPO and PSP (p<0.01). 
 
Figure 4.2.  Detection of neurofilament and growth associated proteins by Western 
blots of differentiating N2a cell lysates.  
N2a cells were differentiated for 24 h in the absence (0) and presence of1, 3 and 10 μM CPF, CPO 
or PSP. N2a cell lysates were separated by SDS-PAGE and Western blotting as explained in 
Material and Methods. Shown are typical blots which were probed with antibodies against NFH 
and GAP-43 followed by HRP-conjugated secondary antibodies and developed by ECL reagents. 
Blots probed with anti-GAPDH were used as internal control.  
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Table 4.3. Densitometric analysis of Western blots probed with antibodies to 
neurofilament and growth associated proteins in N2a cell lysates.  
Antigen Toxin (µM) 
Densitometric peak (% control ±SEM) 
CPF CPO PSP 
 
NFH 
1 77 ± 15 90 ± 13 89 ± 3 
3 48 ± 2** 87 ± 7 73 ± 3* 
10 23 ± 5** 38 ± 4** 7 ± 1** 
 
GAP-43 
1 96± 12 99 ± 3 89 ± 9 
3 65±5* 86 ± 11 88 ± 7 
10 39 ± 15** 45 ± 16** 62 ± 9** 
Western blots probed with antibodies that recognise NFH and GAP43. The antibody reactivity was 
visualized with ECL reagents as described in Materials and Methods and densitometric peak areas 
were quantified using AIDA software. Data represent means of four independent experiments and 
values are expressed as a percentage of the corresponding non OP treated control (band densities 
for all proteins were normalised to blots probed with GAPDH) ± SEM.; *P<0.05, **P<0.01, 
asterisks indicate significant differences compared to the corresponding untreated control. 
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4.6 Effects of CPF, CPO and PSP on the expression levels of glial fibrillary acid 
protein in C6 cells  
To examine possible effects of the OP treatments on the levels of cytoskeletal in C6 cells, 
the immunoreactivity of antibodies with the core astrocyte intermediate filament forming 
protein GFAP was quantified by Western blot analysis.  Interestingly, the cross reactivity 
of C6 cell lysates with anti GFAP antibody was significantly reduced after exposure to 10 
µM CPF, CPO and PSP (p<0.01) and after exposure to 3 and 10 µM of both CPO (p<0.01) 
and PSP (p<0.05) (Table 4.4). In addition, cross reactivity of cell lysates with anti GFAP 
antibody was unaffected by 1 and 3 µM CPF and1 µM CPO and PSP (Figure 4.3 and 
Table 4.4).  
PSP CPO CPF 
kDa 
µM 10 3 1 0 10 3 1 0 10 3 1 0 
 
GFAP 55  
 
GAPDH 37  
  
Figure 4.3. Detection of Glial fibrillary acidic protein by Western blots of 
differentiating C6 cell lysates.  
C6 cells were differentiated for 24 h in the absence (0) and presence of 1, 3, 10 μM of CPF, CPO, 
PSP. C6 cell lysates were separated by SDS-PAGE and Western blotting as explained in Chapter 2. 
Shown are typical blots, which were probed with antibodies against GFAP followed by HRP-
conjugated secondary antibodies and developed by ECL reagents. Blots probed with anti-GAPDH 
were used as internal control.  
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Table 4.4. Densitometric analysis of Western blots probed with antibodies to glial 
fibrillary acid protein (GFAP) in C6 cells.  
Antigen Toxin (µM) 
Densitometric peak (% control ± SEM) 
CPF CPO PSP 
GFAP 
1 103±1 100 ± 3 87 ± 1 
3 91±4 61 ± 9** 72 ± 4* 
10 39±4** 23 ±8** 51 ± 7** 
Western blots were probed with antibodies that recognise GFAP. The antibody reactivity was then 
visualized with ECL reagents as described in Materials and Methods and densitometric peak areas 
were quantified using AIDA software. Data represent means of four separate experiments and 
values are expressed as a percentage of the corresponding non OP treated control (band densities 
for all proteins were normalised to blots probed with anti GAPDH) ± SEM.; *P<0.05, **P<0.01, 
asterisks indicate significant differences compared to the corresponding untreated control. 
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4.7 Determination of concentration-response effects of CPF, CPO and PSP on 
cytoskeletal and associated regulatory proteins using cell ELISA  
The effects of multiple concentrations of CPF, CPO and PSP on cytoskeletal and 
associated regulatory proteins associated with their regulation in neurite outgrowth were 
further assessed in differentiating N2a and C6 cells using a cell ELISA technique, which 
could potentially facilitate rapid quantification. Cells were induced to differentiate in the 
absence (0) or presence of 1, 3 and 10 µM CPF, CPO and PSP as described in Materials 
and Methods. The differentiating cell monolayers were then fixed and changes in the 
binding levels of monoclonal antibodies against MAP-2, βIII tubulin, Tau, NFH, GAP-43 
and GFAP were determined and quantified in controls and OP-treated cells following 24 h 
exposure, as described in section 2.2.14.  
Figure 4.4 (panels A1 and A2) shows data from cell ELISA using a monoclonal antibody 
that recognises MAP-2. In figure 4.4 (panel A1), a dose-dependent decrease was seen in 
the level of MAP-2 binding in differentiating N2a cells treated with both CPF and CPO for 
24 h. The decline in MAP-2 level was statistically significant at 3 µM of CPF and CPO 
(p<0.05) and (p<0.01) at 10 µM of CPF and CPO compared to that of non OP-treated 
controls. After 24 h treatment of differentiating N2a cells with all concentrations of PSP, 
there was a progressive reduction in the binding level of anti MAP-2 when compared to 
controls; however, the observed changes were not statistically significant  (Figure 4.4, 
panel A2).    
Quantification of anti-βIII tubulin cross reactivity by cell ELISA in differentiating N2a 
cells also showed a progressive reduction but this effect was not statistically significant for 
either CPF or CPO at the concentrations tested at 24 h (Figure 4.4, panel B1). However, in 
panel B2 of figure 4.4, a dose-dependent decrease was seen in the level of βIII tubulin 
binding in differentiating N2a cells treated with PSP for 24 h. The decline in βIII tubulin 
level was statistically significant at 10 µM concentration of PSP (p<0.05), p = 0.03 
compared to that the non OP-treated control (Figure 4.4, panel B2) 
However, treatment with all concentrations of CPF and 1 and 3 µM of CPO showed no 
significant decrease on the binding levels of Tau compared to the untreated controls 
(Figure 4.4, panel C1). By contrast, in figure 4.4 panel C2, a dose-dependent reduction was 
observed with statistically significant changes in the level of anti-tau binding at 10 µM 
concentration of PSP (p<0.01) compared to the non PSP-treated controls.  
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Figure 4.4. Effects of CPF, CPO and PSP on microtubule proteins in differentiating 
N2a cells as determined by cell ELISA.   
N2a cells were induced to differentiate for 24 h either without (0) or with 1, 3 and 10 µM 
concentrations of CPF, CPO or PSP for 24 h. Changes in the binding levels of antibodies that 
recognise MAP-2 (panel A), βIII-tubulin (panel B) and Tau (in panel C) were quantified in controls 
and OP-treated cells using cell ELISA. Data are presented as a percentage of the non OP-treated 
control ± SEM (from 4 independent experiments). Data were analysed using one-way ANOVA, 
and Sidak post hoc test. The CPF effects are presented as red dashed lines; the CPO effects are 
presented as blue solid lines and PSP effects are presented as green solid lines with square symbols. 
Asterisks indicate changes that are statistically different from the non OP-treated controls (*p ˂ 
0.05) or (**p ˂ 0.01). In cases where SEM bars are not apparent, the error is smaller than the 
symbol size. 
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Figure 4.5 (panels A1and A2) shows dose-dependent decreases in the binding levels of 
anti-NFH with cell monolayers following the exposure to the three OPs used in the current 
study. The reduction was statically significant (p<0.01), p=0.001 after exposure to 10 µM 
CPF (Figure 4.5, panel A1). After PSP exposure (Figure 4.5, panel A2), treatment of 
differentiating N2a cells with 1, 3 and 10 µM showed decreases in the binding levels of 
anti NFH but the changes were not statically significant.     
However, progressive decreases in the binding levels of anti GAP-43 with lysates of 
differentiating N2a cells following exposure to CPF, CPO and PSP can be observed in 
panels B1 and B2 of figure 4.5. Interestingly, in the case of CPF the reduction was 
statistically significant at 1 and 3 µM (p < 0.05), p= 0.02, and high significant (p < 0.01) at 
10 µM. However, the reductions in anti GAP-43 binding observed following CPO and PSP 
exposure were not statistically significant compared to non OP-treated controls at 24 h 
(Figure 4.5, panel B2).  
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Figure 4.5. Effects of CPF, CPO and PSP on neurofilament and growth associated 
proteins in differentiating N2a cells as determined by cell ELISA.  
N2a cells were induced to differentiate for 24 h either without (0) or with 1, 3 and 10 μM 
concentrations of CPF, CPO or PSP. Changes in the binding levels of antibodies that recognise 
NFH (SMI33) (panel A) and GAP-43 (panel B) were quantified in controls and OP-treated cells 
using cell ELISA. Data are presented as a percentage of the non OP-treated control ± SEM (from 
four separate experiments). Data were analysed using one-way ANOVA, and Sidak post hoc test. 
The CPF effects are presented as red dashed lines; the CPO effects are presented as green solid 
lines; and PSP effects are presented as green solid lines with squares. Asterisks indicate changes 
that are statistically different from the non OP-treated controls (*p ˂ 0.05) or (**p ˂ 0.01). In cases 
where SEM bars are not apparent the error is smaller than the symbol size.  
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Since some dose-dependent changes were detected in the levels of binding cytoskeleton 
proteins in N2a cells, it was of interest to investigate the potential effects of the exposure to 
CPF, CPO or PSP on GFAP in the C6 glioma cell line used in the current study.  Figure 
4.6 (panel A)  demonstrates the dose-response effects of both CPF and CPO on the levels 
of anti GFAP which caused similar concentration-dependent decreases, which was 
statistically significant at 1 µM (p ˂ 0.05), 3 µM (p<0.05) and 10 µM (p ˂ 0.01) compared 
to non OP-treated controls. By contrast, compared to the control, no significant effects 
were detected in anti-GFAP cross reactivity with monolayers of differentiating C6 cells 
exposed to all 3 concentrations of PSP at 24 h (Figure 4.6, panel B). 
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Figure 4.6. Effects of CPF, CPO and PSP on glial fibrillary acidic protein in 
differentiating N2a cells as determined by cell ELISA.  
C6 cells were induced to differentiate for 24 h with incubation without (0) or with 1, 3 and 10 µM 
concentrations of CPF, CPO  (panel A) or PSP (panel B) for 24 h. Changes in the binding levels of 
antibody that recognise GFAP quantified in controls and OP-treated cells using cell ELISA. Data 
are presented as a percentage of the non OP-treated control ± SEM (from four separate 
experiments). Data were analysed in one-way ANOVA, and Sidak post hoc test. The CPF effects 
are presented as red dashed lines; the CPO effects are presented as blue solid lines; and PSP effects 
are presented as green solid lines with squares. Asterisks indicate changes that are statistically 
different from the non OP-treated controls (*p ˂ 0.05) or (**p ˂ 0.01). In cases where SEM bars 
are not apparent, the error is smaller than the symbol size. 
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4.8 Discussion  
Based on the results of the previous chapter, which showed exposure to sub-cytotoxic 
concentrations of CPF, CPO and PSP caused morphological changes in N2a and C6 cells, 
the hypothesis that these changes may be due to alteration of cytoskeletal proteins was 
investigated in this chapter. Studies have shown that proteins, such as those of NFs and 
MTs, are key endogenous factors that control normal axonal and neurite outgrowth, neuro-
stability and neurodevelopment. This investigation was supported by the evidence that 
disruption of the axonal cytoskeleton by OPs is associated with changes in neuronal cell 
morphology (Sachana et al., 2001).  
The aim of the work presented in this chapter was to examine the molecular changes 
underlining the morphological effects of CPF, CPO and PSP by analysing the expression 
levels of neural cell differentiation associated cytoskeletal and associated regulatory 
proteins, in differentiating mouse N2a neuroblastoma cells and rat C6 glioma cells. To 
achieve these aims, N2a and C6 cell lines were differentiated for 24 h with and without 1, 
3 and 10 µM of CPF, CPO and PSP (co-differentiated), and changes in the key proteins 
MAP 2, Tau, βIII tubulin, GAP-43, NFH and GFAP, were analysed by quantitative 
Western blotting and ELISA approaches. 
MAP family members, such as MAP 2 and Tau, are important in central nervous system 
development; their roles include maintenance of the stability of growth cones, and the 
modulation of axonal and dendritic MT dynamics (Schoenfeld and Obar, 1994). They are 
involved in the stimulation of MT assembly, the cross-linking of MTs to other cytoskeletal 
elements, and interactions between IFs and actin filaments (Leterrier et al., 1982; Nixon et 
al., 1990; Cleveland, 1993). β-III tubulin plays an important role during nervous system 
development; it is one of earliest cytoskeletal proteins expressed in neurons and it has an 
essential role in neurite growth and cell differentiation (Easter et al., 1993). 
GAP-43, which is mainly found in elongating axons and growth cones in neurons, has 
been shown to play an important role in neurite outgrowth regulation (Skene, 1989; 
Perkiner et al., 1996; Das et al., 2004). It regulates many processes during 
neurodevelopment, including axon development, growth cone formation, and synapse 
plasticity (Benowitz and Routtenberg, 1997).  NFH is usually found in mature neurons and 
axons, where they provide support during axonal extension, and regulate axonal 
development and growth, by forming cross bridges between extensions of the NF tail 
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domains and other cytoplasmic organelles (Hirokawa et al., 1984; Lee and Cleveland, 
1994). GFAP is found in mature astrocytes, and non-myelinating Schwann cells in the 
PNS, and glial cells of the digestive system, in which it provides structural support (Eng et 
al., 2000; Yang and Wang, 2015). Increased levels of GFAP can be detected during glial 
development and differentiation (Bramanti et al., 2010). The Western blot results for 
GAPDH showed there were no significant changes in expression following exposure of 
both cell types to all the concentrations of the different OPs tested at 24 h, which suggests 
this was a suitable internal control to use for normalisation of the band intensities of the 
other proteins under investigation. 
The investigation of the effect of the OPs on the MT proteins MAP 2, βIII-tubulin and Tau 
in N2a cells showed the different OPs did influence protein expression, with a reduction in 
expression seen for all three proteins with at least one OP treatment, but there were no 
differences seen for 1 µM of any of the OPs. For MAP 2, there was a reduction in 
expression after treatment with 3 µM CPF (p < 0.05) and 10 µM CPF, CPO and PSP (p < 
0.05), and no significant differences for 3 µM CPO and PSP. For βIII tubulin, there was     
a significant decrease in expression after treatment with 10 µM CPF (p < 0.05), CPO (p < 
0.05) and PSP (p < 0.001), but no significant differences were produced with 3 µM of any 
of the OPs. The results for Tau show there was a significant reduction in expression after 
treatment with 3 and 10 µM concentrations of CPF (p < 0.01) and PSP (p < 0.05), whereas 
CPO produced no significant differences, suggesting that there were differences in the 
cytoskeletal effects of the parent compound and its metabolite.  
These results fit with the in vivo studies of Abou-Donia (1993), that showed OP exposure 
in hens disrupted the neural cytoskeleton and increased phosphorylation of cytoskeletal 
proteins including MAPs and tubulin (Abou-Donia, 1993). Further evidence to support 
these results come from structural and immunoreactivity studies in cultured rat brain slices; 
the results showed exposure to doses of CPO between 0.1 to 10 µM after 24 h induced 
alterations in MAPs and MT ultra-structure, with a significant reduction in MAP 2 levels 
in each brain region investigated at concentrations as low as 0.1 µM (Prendergast et al., 
2007). Similar results were also found in another study in that used single subcutaneous 
dose of chlorpyrifos (250 mg/kg) in Wistar rats for 15 days and detected a significant 
reduction of MAP 2 in the pre-frontal cortex (Ruiz-Muñoz et al., 2011). 
The results of the current investigation show some differences to those found by Sachana 
et al. (2008) who used Western Blot analysis to study the effects of sub lethal 
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concentrations (1–10 µM) of CPF and CPO on C6 cells. They found there was significant 
concentration-dependent reduction in antibody reactivity to α-tubulin by CPO after 
treatment for 24 h, which is similar to the response of βIII-tubulin this study. However, in 
the Sachana et al. (2008) study there were no significant differences in α-tubulin 
expression after CPF treatment, and no significant differences in MAP2 expression seen 
for either treatment, which is different to the results of this study and may be due to the 
different cell types used (Sachana et al., 2008). The effect of all 3 OPs on N2a cells in the 
current study is, however, similar to the results of Sachana et al. (2014) in a study that used 
differentiating N2a cells exposed to 10 µM DZO for 24 h, which decreased the expression 
of βIII-tubulin in a similar way to this investigation, but their study showed DZO had no 
effect on Tau, which is different to our results for CPF and CPO (Sachana et al., 2014). 
This suggests that some cytoskeletal effects of OPs may be cell type specific while others 
are compound specific. 
To examine possible effects of the OP treatments on the levels of cytoskeletal axonal 
intermediate filament and growth associated proteins in differentiating N2a cells, the 
effects of 24 h exposure of CPF, CPO and PSP on NFH and GAP-43 were determined by 
Western blot analysis. As with results for the MT proteins, there were no significant 
differences seen after treatment with 1 µM of any of the OPs, suggesting this dose was too 
low to create a significant response at this time point. The results for NFH showed             
a significant decrease in expression after treatment with 3 µM CPF, 10 µM CPO and 3, 10 
µM PSP. The results for GAP-43 were similar to NFH, in that there were significant 
decreases in expression after exposure to 3 µM CPF (p < 0.05) and 10 µM CPF, CPO and 
PSP (p < 0.01).  
The results from this study agree with the results of other studies of the effects of CPF and 
CPO in N2a cells. Sachana et al. (2001) showed significantly reduced levels of NFH 
following 8 h exposure to 3 µM CPF. Flaskos et al. (2011) investigated the effect of 1-10 
µM CPO for 24 h on N2a cells when added at the point of induction of differentiation and 
found reduced expression of both NFH and GAP-43, Sindi et al. (2016) found that 
exposure of pre-differentiated N2a cells to 3 µM CPF and CPO caused a transient 
reduction in GAP-43 expression after 4 h treatment, and a significant reduction in NFH 
expression after 8 h exposure, whereas Hargreaves et al. (2006) found treatment of 
differentiating N2a cells with 2.5 µM PSP for 24 h resulted in a significant reduction in 
NFH protein expression. Thus, taken together with previous data, the results in this chapter 
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suggest that reduced GAP-43 and NFH protein levels are effective markers of impaired 
neurite outgrowth following OP exposure. 
The effects of CPF, CPO and PSP on cytoskeletal proteins in differentiating C6 cells were 
assessed by measuring changes in expression of GFAP by Western blot analysis. As with 
the other proteins measured, 1 µM of all the OPs produced no significant differences 
compared to the non OP-treated control. There was a significant reduction in GFAP 
expression after exposure to 10 µM CPF (p < 0.05), 3 and 10 µM of both CPO and PSP (p 
< 0.05). These results are similar to the in vivo studies in developing rats Garcia et al. 
(2002) which found that 4 days of subcutaneous CPF administration resulted in decreased 
in GFAP levels. These results are also supported by a study of the effects of 1-10 µM DZO 
for 24 h in differentiating rat C6 glioma cells, which reported a decrease in GFAP 
expression after treatment (Sidiropoulou et al., 2009b). There are some similarities of these 
results to those found by Wang and Zhao (2017), who used purified astrocytes and 
Western blot analysis to investigate the effect of 25, 50, and 100 µM CPF combined with 1 
µg/mL LPS on GFAP expression.  
Further assessment of the effect of the selected OPs on the cytoskeletal and associated 
regulatory proteins MAP-2, βIII tubulin, Tau, NFH, GAP-43 and GFAP in differentiating 
N2a and C6 cells was carried out using a cell ELISA technique. Cells were induced to 
differentiate for 24 h in the absence (0) or presence of 1, 3 and 10 µM CPF, CPO and PSP 
and an ELISA was carried out on the fixed cell monolayer to detect changes in protein 
expression. 
By comparing the treated cells to the relevant controls for the MT proteins, the results 
show that, as with the Western blot results, there were no differences seen for 1 µM of any 
of the OPs, and for most of the treatments there were also no significant differences 
observed for 3 µM of the OPs. For MAP 2 there was a significant decrease in expression 
detected by the ELISA after treatment with 10 µM CPF (p < 0.05), and 3 and 10 µM CPO 
(p < 0.05), when compared to the non OP-treated controls. For anti-βIII tubulin and Tau, 
the result showed there was only a statistically significant decrease in protein levels after 
treatment with 10 µM PSP (p < 0.05, and p < 0.01, respectively) when compared to the 
non PSP-treated control. Thus, although these results show a similar pattern of decreased 
expression after OP treatment as observed by Western blot analysis, the ELISA only 
detects significant changes at the highest concentrations investigated, suggesting it is less 
sensitive that the Western blot. 
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By comparing the treated cells to the relevant controls for the NF and growth associated 
proteins, the results show a similar pattern to the ELISA results for the MT proteins. NFH 
protein levels were significantly reduced after treatment with 10 µM CPF (p < 0.01), when 
compared to the relevant control, and GAP-43 showed a statistically significant reduction 
in expression after treatment with 1, 3, and 10 µM CPF (p < 0.05, p < 0.05, and p < 0.01, 
respectively), when compared to the non OP-treated controls. This suggest the ELISA for 
GAP-43 is slightly more sensitive to changes in protein levels that the other proteins tested, 
but still not as sensitive as the Western blot analysis.  
The expression levels of GFAP in C6 cells were also investigated by ELISA, and the 
results show that PSP treatment caused no significant differences in protein levels, whereas 
all three concentrations of CPF and CPO produced a statistically significant reduction in 
protein expression (1 µM p ˂ 0.05, 3 µM p < 0.05. and 10 µM p ˂ 0.01, for both) when 
compared to the untreated controls. Again, these results follow a similar pattern to those of 
the Western blot analysis as they all show decreases in protein expression after OP 
treatment, but the actual magnitude of the effect, and the OPs that cause it, show some 
differences between the detection methods. It may also reflect the fact that not all 
antibodies are equally suitable for ELISA and Western blot analysis. 
Overall, the results of this investigation have shown that the OPs selected do influence the 
expression levels of the different cytoskeletal and regulatory proteins investigated, 
suggesting they may be important in the neurotoxic effects produced by OPs. Based on 
these results the aim of the next chapter is to investigate the genotoxic effects of these OPs 
on the expression level of selected cytoskeletal genes in differentiating N2a neuroblastoma 
and C6 cell lines.  
 
 
 
 
 
 
 
  
 
Chapter 5 
Genotoxicity of Organophosphate 
Compounds Chlorpyrifos, Chlorpyrifos 
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5.1 Introduction  
CPF, CPO and PSP are known to induce neurological effects, as discussed in Chapter 1. 
While the neurodegenerative effect of these OPs on cell morphology and the expression of 
related proteins is widely established, their effect at the gene level remains to be fully 
elucidated. There have been relatively few studies performed to evaluate the genotoxic 
effect of CPF in models of neural cell differentiation including neural differentiation of 
mouse adipose tissue-derived stem cells (ADSCs) (Zarei et al., 2016) and PC12 cells 
(Slotkin and Seidler, 2010). Despite the poor understanding of this action, genotoxic 
potential is considered a primary risk factor leading to long-term health effects. The 
concept of OP exposure causing malignant tumours as well as their effect on reproductive 
health has been accepted (Bolognesi, 2003).  
Changes in genetic material, particularly DNA damage, were proposed as a useful measure 
of genotoxic properties of OPs (Kornuta et al., 1996). As such, recent studies have aimed 
to understand the potential genotoxic effect of CPF (Sandhu et al., 2013; Ismail et al., 
2014; Muller et al., 2014; Wang et al., 2014). These in vivo studies involved exposure of 
rats or fish to different concentrations of CPF followed by analysis of DNA damage using 
the Comet assay. Ismail et al. (2014) determined the acute LC50 value for L. rohita fish 
exposed to various concentrations of CPF (73.8 – 221.4 µg/L for 96 h). Analysis of blood 
and gill samples showed that the amount of DNA damage was concentration and time 
dependent. Wang et al. (2014), who exposed zebrafish to CPF (0.01-1 mg/L) for 5 - 25 
days, reported that the DNA damage had a clear dose-response relationship. Muller et al. 
(2014) gave Sprague-Dawley adult rats daily subcutaneous injections of CPF to model 
typical exposures of agricultural workers; a daily CPF dose of 10 mg/kg body weight was 
shown to induce DNA damage in blood samples. Using Wistar rats, Sandhu et al. (2013) 
administered oral CPF doses of 3 and 12 mg/kg. After 7 and 14 days, blood lymphocytes 
were harvested. In this case, CPF-induced DNA damage was observed at a concentration 
of 12 mg/kg. Overall, the studies described above confirm that even at sub lethal 
concentrations of CPF, DNA damage was occurring. However, the mechanism by which 
CPF induced cytotoxicity remains poorly understood. The observation of CPF binding to 
DNA and the outcome of DNA adducts has led to an increase in social concern about the 
CPF genotoxic risk in humans (Li et al., 2015). 
A variety of biological responses can be triggered by genotoxic stress, including the 
transcriptional activation of genes regulating DNA repair (Dickinson et al., 2004). 
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Genotoxicity may also affect key structural genes, which is consistent with the 
morphological changes observed by the causative agent. Even though there are studies 
targeting DNA damage as a cytotoxicity marker, currently there are few studies examining 
this effect to further characterise the affected genes. As such, the use of real time PCR to 
analyse the effect of OPs on gene expression in mammalian neural cell lines provides         
a cutting edge approach to complement our understanding of the mechanism by which 
these compounds exhibit their toxicity. For example, as CPF, CPO and PSP cause 
morphological changes, understanding the gene expression patterns of related genes would 
open a new window towards exposing a new field in this area. 
Another factor that could be involved in the genotoxicity of OPs is epigenetic changes. 
While there are numerous processes that are involved in epigenetic control of gene 
expression, histone acetylation is the most understood modification. The modification 
occurs at the histone epsilon amino group in specific lysine residues where an acetyl group 
is added. This reaction is catalysed by a class of enzymes that are known as histone 
acetyltransferases (HATs). The removal of the acetyl group is the reverse reaction and it is 
carried out by histone deacetylases (HDACs) (Altman-Price and Mevarech, 2009). There is 
a recognised correlation between transcription and histone acetylation levels, and it has 
been shown that modulating histone acetylation plays a pivotal role in regulating gene 
expression (Witt et al., 2009). As such, histone deacetylation it is considered as a tag for 
epigenetic repression. HDACs regulate many processes including DNA damage response 
and apoptosis (Urnov et al., 2001). Aberrant HDACs are implicated in many diseases 
including cancer; consequently, it is important to analyse their activity in disease states, 
particularly where gene expression studies are targeted (Peng et al., 2015). 
The fact that HDACs were highlighted as important in a variety of diseases that are caused 
by mutagenesis, together with the recognised genotoxic effect of CPF, CPO and PSP, 
raises the question as to whether these OPs have epigenetic effects. And, if they do, does it 
influence the genes that encode proteins associated with the defects observed at the 
morphological and developmental levels in cellular models of OP toxicity? Studying the 
effect of HDAC activity in neuronal and glial cell lines in response to exposure to the OPs 
would be a novel approach in the field of OP neurotoxicity.     
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5.2 Aims 
The aim of the work presented in this chapter was to study the effect of CPF, CPO, and 
PSP exposure on: 
1) The expression level of selected cytoskeletal genes in differentiating N2a 
neuroblastoma and C6 cell lines. The targeted genes are involved in maintaining 
the cytoskeletal integrity of the cells. These include:-  
• GAP43; Growth associated protein 43 
• MAP2; Microtubule-associated protein 2 
• MAPT; Microtubule-associated protein Tau 
• NEFH; Neurofilament heavy chain 
• TUBB3; Tubulin β-III isoform 
• GFAP; Glial fibrillary acidic protein  
2) HDAC activity in nuclear extracts of control and OP-treated cells and relate it to 
the changes in the expression levels of the genes of interest. 
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5.3 Results  
5.3.1 Primer validation 
The primers were designed using the Primer3 program and their specificities were tested 
prior to running the experiments. By means of conventional PCR, primers were used to 
amplify the targeted amplicons in cDNA which was reverse transcribed from the total 
RNA extracted from mouse and rat brain tissues (positive controls), as well as from mitotic 
and differentiated N2a and C6 cell lysates. The PCR conditions were initially optimised 
using RNA extracted from brain tissues, where the target genes were known to be 
expressed. Figure 5.1 and figure 5.3 illustrate that the primers were specific, as their cDNA 
amplification resulted in a single defined band at the expected size and showed no 
amplification product in the negative template control. To achieve that result, the annealing 
temperature was selected according to the properties of the primers’ melting temperature 
and, where needed, a gradient PCR in the range of ±5 oC of the mean (forward and reverse) 
melting temperature was used. The list of primers along with their corresponding annealing 
temperature and product size is shown in Table 5.1.  The bands with N2a or C6 in Figure 
5.1 and Figure 5.3 were excised and the amplified products were eluted and sequenced. 
Neither NEFM nor NEFL showed amplification in N2a cell extracts (Figure 5.2) which fits 
with the results of Hornburg et al. (2014). However, both sets of primers showed a clear 
band with the positive control. The sequences were blasted against the genome of Mus 
musculus or Rattus norvegicus, respectively. All sequenced PCR products were in a 100% 
alignment with their corresponding gene of interest (Appendix 8.3-8.8) accession numbers 
are listed in table.5.1.  
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Table 5.1. Designed primers targeting N2a and C6 cell lines neuronal markers. 
Cells Genes Accession Number Primer Sequence (5’ to 3’) Annealing T (oC) 
Product size 
(bp) 
N2a 
MAP2 
1. Isoform1 NM_001039934.1  
2. Isoform2 NM_008632.2 
3. Isoform3 NM_001310634.1 
Forward AGATAGACTTAAGCCATGTGACATCCAAAT 63 100 
Reverse GTTTTACACTCTCAATTTTCACACGTCCAC 
TUBB3 NM_023279.2  
Forward CTATTCAGGCCCGACAACTTTATCTTTGGTCA 68 131 
Reverse CAATTCTCACACTCTTTCCGCACGACATCTAG 
MAPT 
1. Isoform 1 NM_001038609.2 
2. Isoform 2 NM_010838.4  
3. Isoform 3 NM_001285454.1 
4. Isoform 4 NM_001285455.1 
5. Isoform 5 NM_001285456.1 
Forward GAGGAGGGAATAAGAAGATTGAAACCCACA 60 138 
Reverse CATTGCTGAGGTGCCGTGGAGATGTGT 
 
NEFH NM_010904.3 
Forward CCATATCCACGCACATAAAAGTCAA 60 100 
Reverse ATCTCTTCTGTCTGTCCTTCTACAA 
NEFM NM_008691.2 Forward AGGAGAGGATAGCAGTGATGATAAA 60 109 
  Reverse GACGGTTACAGATTTGGTGATGTAT   
NEFL NM_010910.1 Forward GACACAATCAACAAACTGGAGAATGAG 60 130 
  Reverse GTTTTCTGTAAGCTGCAATCTCGATG   
GAP43 NM_008083.2 
Forward ACAGGTTGAAAAGAATGATGAGGAC 60.5 122 
Reverse TTTTCCTTGTTATGTGTCCACGGAA 
C6 GFAP NM_017009.2 
Forward TTCTCCAACCTCCAGATCCG 60 123 
Reverse CGACTCCTTAATGACCTCGC 
MAP2; Microtubule-associated protein 2, TUBB3; Tubulin beta-3 chain, MAPT; Microtubule-associated protein tau, NEFH; Neurofilament heavy chain, GAP43; Growth 
associated protein 43, GFAP; Glial fibrillary acidic protein. 
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Figure 5.1. Analysis of genes of interest in mitotic and differentiating N2a cells by 
PCR.  
A representation of PCR products amplified using A- Microtubule associated protein 2 (MAP2), B- 
β III tubulin (TUBB3), C- Microtubule associated protein tau (MAPT) D- Neurofilament Heavy 
chain (NEFH), and E- Growth associated protein-43(GAP43) primers. Bands were visualised after 
electrophoretic separation in a 1.5% agarose gel stained with SyberSafe. Mouse brain RNA extracts 
were used as a positive control (C+). RNA was obtained from mitotic (M) and differentiating (D) 
N2a cells and reverse transcribed into cDNA and analysed by PCR. Non-template controls were 
used as negative controls (C-). Amplified products are presented as a single defined band at size of 
approximately 100 base-pairs (bp). 
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Figure 5.2. Analysis of other neurofilament genes of interest in mitotic and 
differentiating N2a cells by PCR.  
A representation of PCR products amplified using A- Neurofilament medium chain (NEFM), B- 
Neurofilament light chain (NEFL) primers. Bands were visualised after electrophoretic separation 
in a 1.5% agarose gel stained with SyberSafe. Mouse brain RNA extracts were used as a positive 
control (C+). RNA was obtained from mitotic (M) and differentiating (D) N2a cells and reverse 
transcribed into cDNA and analysed by PCR. Non-template controls were used as negative controls 
(C-). Amplified products are presented as a single defined band at size of approximately 100 base-
pairs (bp). 
 
 
Figure 5.3.  GFAP expression in mitotic and differentiating C6 cells.  
Shown is a representation of PCR products amplified using primers for the gene encoding glial 
fibrillary acidic protein (GFAP) visualised on a 1.5% agarose gel stained with SyberSafe. Rat brain 
RNA extracts were used as a positive control (C+). RNA was obtained from mitotic (M) and 
differentiating (D) C6 cells and reverse transcribed into cDNA and analysed by PCR. Non-template 
reactions were used as negative controls (C-). Amplified products are presented as a single defined 
band at size of 100 base-pairs (bp). 
5.3.2 Housekeeping genes 
According to the literature, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and 
ribosomal protein S18 (Rps18) are frequently used as reference genes (Al-Bader and Al-
Sarraf, 2005; Stephens et al., 2011) since their expression levels are reported to be 
relatively stable when exposed to toxic compounds. As such, these two were selected as 
reference genes for the gene expression analysis in the current study. To assure their levels 
did not change across the studied groups, their expression was first analysed. Treatment 
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with CPF, CPO (Figure 5.4, panel A) and PSP (Figure 5.4, panel B) did not alter the 
expression of either GAPDH or Rps18 in the N2a cell line (Figure 5.4, panel C and D).  
 
Figure 5.4. Ct values obtained for GAPDH and Rps18 expression (qPCR) in 
differentiating N2a cells after different OP treatments.  
Shown is quantitative RT-qPCR analysis of the expression levels of GAPDH in N2a cells induced 
to differentiate for 24 h either in the absence (0) or presence of variable concentrations of CPF or 
CPO (panel A) and PSP (panel B), as well as the expression of Rps18 N2a cell lysate treated with 
CPF or CPO (panel C) and PSP (panel D). Statistical analysis was by one-way ANOVA with Sidak 
post-hoc test comparing treatments to the control (0). Data are presented as mean ± SEM for four 
independent experiments. 
 
Their expression levels were also unaffected in the differentiating C6 cells across all the 
used concentrations of CPF, CPO (Fig.5.5, panel A and C) and PSP (Fig.5.5, panel B and 
C). As both genes exhibited similar patterns with no difference in their expression across 
all studied groups in both cell lines, they were both used independently to normalise the 
expression of targeted genes. 
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Figure 5.5. Ct values obtained for GAPDH and Rps18 expression in C6 cell line. 
The expression level of GAPDH in differentiated C6 cell lysate for 24 h then exposed to 0, 1, 3 or 
10 µM of CPF or CPO (panel A) and PSP (panel B) as well as the expression of Rps18 in 
differentiated C6 cell lysate for 24hr then exposed to 0, 1, 3 or 10 µM of CPF or CPO (panel C) 
and PSP (panel D). Analysis was by one-way ANOVA with Sidak post-hoc test comparing 
treatments to the (0) control. Data is presented as mean ± SEM for four independent experiments. 
5.3.3 Effect of CPF, CPO and PSP on neural markers in mammalian cell lines. 
The mRNA expression level of neuronal marker genes including MAP2, TUBB3, MAPT, 
NEFH and GAP43 was measured in differentiating N2a cells that were exposed to 1, 3 and 
10 µM concentrations of CPF, CPO or PSP. Similarly, the mRNA expression of GFAP 
was measured in differentiating C6 cells after exposure to 1, 3 and 10 µM concentrations 
of CPF, CPO or PSP. All of these results are discussed in the next subsections. 
5.3.3.1 Microtubule-associated protein 2 (MAP2). 
The MAP2 gene encodes the MAP2 protein. It is involved in microtubule assembly, which 
is considered as an essential step in neurite outgrowth, by promoting intracellular 
microtubule bundling and elaboration (Harada et al., 2002). Due to its importance in 
neuritogenesis, the effect of the organophosphates on MAP2 at the gene level was studied.  
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After the expression level of MAP2 was normalised to the expression of GAPDH, it 
became apparent that MAP2 expression was significantly reduced in N2a cells when 
exposed to 3 (p= 0.017) and 10 µM (p= 0.014) concentrations of CPF (Figure 5.6, panel 
A1). CPO and PSP had similar effects but the reduction was only significant at                   
a concentration of 10 µM (Figure 5.6, panel A1 and A2). The expression of MAP2 was 
then normalised to the expression of Rps18 to further characterise it and, in this case, the 
statistical analysis corroborated that CPF induced a significant effect at both 3 (p= 0.02) 
and 10 µM (p= 0.018) (Figure 5.6, panel B1). MAP2 expression was also significantly 
lower than its corresponding control when cells were exposed to 3 µM as well as 10 µM 
CPO and PSP when using Rps18 (Figure 5.6, panel B1 and B2).  
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Figure 5.6. Relative expression of MAP-2 mRNA in differentiating N2a cells after 
CPF, CPO and PSP exposure as determined by quantitative PCR.  
N2a cells were induced to differentiate for 24 h incubation without (0) or with 1, 3 and 10 µM 
concentrations of CPF, CPO or PSP. Data were analysed using one-way ANOVA with Sidak post-
hoc test comparing treatments to the (0) control. The normalization of data to the first 
housekeeping gene GAPDH is shown in panel A, whereas the normalisation to the second 
housekeeping gene Rps18 is shown in panel B. Expression values are relative to the non-OP-treated 
control ± SEM. Data presented are an average of four independent experiments, and all samples 
were amplified in triplicates. Asterisks indicate changes that are statistically different from the non-
OP-treated controls (*p ˂ 0.05) or (**p ˂ 0.01).  
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5.3.3.2 Tubulin βIII chain (TUBB3). 
The TUBB3 gene encodes the βIII isotype of tubulin, which is abundant in neurons and 
involved in the development and maturation of neuronal cells the nervous system. While 
the mechanism by which it controls the neuronal development is not known, there is 
evidence showing that any alteration in its expression results in serious consequences to 
the cells’ viability leading to diverse neurological syndromes (De Gendt et al., 2011). 
Analysing its RNA expression level could help to form a better understanding of the βIII 
tubulin protein changes described in chapter three.   
The mRNA level of TUBB3 relative to GAPDH was significantly reduced upon N2a cell 
exposure to 10 µM CPF (p= 0.0237) and CPO (p= 0.0355) (Figure 5.7, panel A1). The 
pattern was similar when the expression was calculated relative to Rsp18 with CPF, CPO 
having a significant effect apparent at an even lower concentration of 3 µM (p=0.051) and 
10 µM (p= 0.003) (Figure 5.7, panel B1). PSP exposure also caused a significant drop in 
TUBB3 RNA expression level normalised with either GAPDH (Figure 5.7, panel A2) or 
Rps18 (Figure 5.7, panel B2). 
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Figure 5.7. Relative expression of TUBB3 mRNA in differentiating N2a cells after 
CPF, CPO and PSP exposure as determined by quantitative PCR. 
N2a cells were induced to differentiate for 24 h incubation without (0) or with 1, 3 and 10 µM 
concentrations of CPF, CPO or PSP. Data were analysed using one-way ANOVA with Sidak post-
hoc test comparing treatments to the (0) control. The normalization of data to the first 
housekeeping gene GAPDH is shown in panel A, whereas the normalisation to the second 
housekeeping gene Rps18 is shown in panel B. Expression values are relative to the non-OP-treated 
control ± SEM. Data presented are an average of four independent experiments, and all samples 
were amplified in triplicates. Asterisks indicate changes that are statistically different from the non-
OP-treated controls (*p ˂ 0.05) or (**p ˂ 0.01).  
5.3.3.3 Microtubule-Associated Protein Tau (MAPT) 
The main function of protein Tau, which is expressed by the MAPT gene, is to modulate 
the stability of axonal microtubules by Tau phosphorylation at Ser262 and Ser356. 
Furthermore, Tau plays an important role in maintaining the cytoskeletal structure of 
neurons. Abnormalities in its protein expression levels have been linked to 
neurodegenerative disease (Mietelska-Porowska et al., 2014). Therefore, studying its RNA 
expression was of some importance as it would reflect the integrity of the neuronal cells 
and could help to explain the Tau protein changes observed in chapter 3.   
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CPF and CPO did not alter the RNA expression level of MAPT normalised with either 
GAPDH (Figure 5.8, panel A1) or Rsp18 (Figure 5.8, panel B1). However, PSP at              
a concentration of 3 and 10 µM induced a significant drop in its RNA expression 
independently of the housekeeping gene used for the normalisation (Figure 5.8, panel A2 
and panel B2). 
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Figure 5. 8.  Relative expression of MAPT (Tau) mRNA in differentiating N2a cells 
after CPF, CPO and PSP exposure as determined by quantitative PCR.  
N2a cells were induced to differentiate for 24 h incubation without (0) or with 1, 3 and 10 µM 
concentrations of CPF, CPO or PSP. Data were analysed using one-way ANOVA with Sidak post-
hoc test comparing treatments to the (0) control. The normalization of data to the first 
housekeeping gene GAPDH is shown in panel A, whereas the normalisation to the second 
housekeeping gene Rps18 is shown in panel B. Expression values are relative to the non-OP-treated 
control ± SEM. Data presented are an average of four independent experiments, and all samples 
were amplified in triplicates. Asterisks indicate changes that are statistically different from the non-
OP-treated controls (**p ˂ 0.01).  
5.3.3.4 Neurofilament Heavy Chain (NEFH) 
Studies on NEFH-null mice have showed that NF-H, encoded by the NEFH gene, plays an 
important role in determining the physical dimensions of axons and its role extends to 
maintaining a normal axonal conduction velocity (Yuan et al., 2012). Understanding how 
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it behaves at the gene level when exposed to the OPs would help to further explain the 
changes observed in NFH protein levels in neural cells that underlie alterations in 
morphology following exposure to sub lethal concentrations of OPs.  
When cells were exposed to 3 and 10 µM CPO, the relative RNA expression of NEFH was 
significantly decreased. These data were produced by normalizing either to GAPDH 
(Figure 5.9, panel A1) or Rps18 (Figure 5.9, panel B1) and there was very little difference 
between the two sets. By contrast, CPF (Figure 5.9, panel A1) and PSP (Figure 5.9, panel 
A2 and B2) did not induce any significant effects on NEFH expression.  
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Figure 5. 9. Relative expression of NEFH mRNA in differentiating N2a cells after 
CPF, CPO and PSP exposure as determined by quantitative PCR.  
N2a cells were induced to differentiate for 24 h incubation without (0) or with 1, 3 and 10 µM 
concentrations of CPF, CPO or PSP. Data were analysed using one-way ANOVA with Sidak post-
hoc test comparing treatments to the (0) control. The normalization of data to the first 
housekeeping gene GAPDH is shown in panel A, whereas the normalisation to the second 
housekeeping gene Rps18 is shown in panel B. Expression values are relative to the non-OP-treated 
control ± SEM. Data presented are an average of four independent experiments, and all samples 
were amplified in triplicates. Asterisks indicate changes that are statistically different from the non-
OP-treated controls (*p ˂ 0.05) or (**p ˂ 0.01).  
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5.3.3.5 Growth Associated Protein 43 (GAP43). 
Like NEFH, GAP43 has a role in the maintenance of axons particularly during CNS 
development. Null mutation of GAP43 is lethal and causes death within days after birth as 
a consequent of defects in axon path finding (Routtenberg et al., 2000). GAP43 plays an 
important role in differentiating neurons as it is a component of the centrosome (Shen et 
al., 2008). Its central role makes understanding the effect of the organophosphates on its 
expression level crucial.  
The same trends were observed in the mRNA expression level of GAP43 when normalised 
relative to both GAPDH and Rps18. Exposure to a concentration of 10 µM of CPF caused 
a significant reduction in its relative expression (Figure 5.10, panel A1 and B1).                
A reduction was observed at even lower concentrations of PSP: there was a significant 
reduction in its relative expression when cells were exposed to 3 µM as well as at 10 µM 
(Figure 5.10, panel A2 and B2). CPO did not exhibit any significant effects on GAP43 
mRNA expression level compared with the non OP-treated control (Figure 5.10, panel A1 
and B1).   
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Figure 5. 10. Relative expression of GAP43 mRNA in differentiating N2a cells after 
CPF, CPO and PSP exposure as determined by quantitative PCR.  
N2a cells were induced to differentiate for 24 h incubation without (0) or with 1, 3 and 10 µM 
concentrations of CPF, CPO or PSP. Data were analysed using one-way ANOVA with Sidak post-
hoc test comparing treatments to the (0) control. The normalization of data to the first 
housekeeping gene GAPDH is shown in panel A, whereas the normalisation to the second 
housekeeping gene Rps18 is shown in panel B. Expression values are relative to the non-OP-treated 
control ± SEM. Data presented are an average of four independent experiments, and all samples 
were amplified in triplicates. Asterisks indicate changes that are statistically different from the non-
OP-treated controls (*p ˂ 0.05).  
5.3.4 Effect of CPF, CPO and PSP on GFAP expression in differentiating C6 cells.  
As mentioned previously in section (1.11.4), GFAP plays an important role in providing 
structural support in astrocytes. It also maintains important processes in the central nervous 
system including cell communication and blood brain barrier function. As such, studying 
the gene expression pattern of GFAP was of particular interest in order to determine 
whether this could be involved in the GFAP protein changes detected in the Western blots 
shown in chapter 3. 
Normalizing to GAPDH or to Rps18 produced comparable results. CPF, CPO as well as 
PSP treatments all caused switching off the gene as high significant decrease in GFAP 
Results               Chapter 5 
159 
 
RNA expression level that ranged between 4 to 10 fold upon cell exposure to levels as low 
as 1μM and as high as 10 µM (Figure 5.11, panelA1-B2). 
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Figure 5. 11. Relative expression of GFAP mRNA in differentiating C6 cells after 
CPF, CPO and PSP exposure as determined by quantitative PCR. 
C6 cells were induced to differentiate for 24 h incubation without (0) or with 1, 3 and 10 µM 
concentrations of CPF, CPO or PSP. Data were analysed using one-way ANOVA with Sidak post-
hoc test comparing treatments to the (0) control. The normalization of data to the first 
housekeeping gene GAPDH is shown in panel A, whereas the normalisation to the second 
housekeeping gene Rps18 is shown in panel B. Expression values are relative to the non-OP-treated 
control ± SEM. Data presented are an average of four independent experiments, and all samples 
were amplified in triplicates. Asterisks indicate changes that are statistically different from the non-
OP-treated controls (*p ˂ 0.05) or (***p ˂ 0.001).  
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Table 5.2. Summary of OP effects on neural marker gene expression relative to GAPDH 
Cells 
OPs CPF CPO PSP 
Conc. (µM) 1 3 10 1 3 10 1 3 10 
N2a 
MAP2 ns 
-1.3 
(0.017) 
-1.34 
(0.014) 
ns ns 
-1.2 
(0.018) 
ns ns 
-1.23 
(0.018) 
TUBB3 ns ns 
-1.25 
(0.02) 
ns ns 
-1.2 
(0.03) 
ns 
-1.8 
(0.003) 
-2.5 
(0.002) 
MAPT ns ns ns ns ns ns ns 
-1.7 
(0.012) 
-1.9 
(0.005) 
NEFH ns ns ns ns 
-1.2 
(0.05) 
-1.8 
(0.003) 
ns ns ns 
GAP43 ns ns 
-1.32 
(0.04) 
ns ns ns ns 
-1.26 
(0.01) 
-1.27 
(0.01) 
C6 GFAP 
-8.8 
(0.0001) 
-9.5 
(0.0001) 
-8.4 
(0.0001) 
-1.5 
(0.02) 
-3.9 
(0.0003) 
-7.7 
(0.0001) 
-5.9 
(0.0001) 
-18.8 
(0.0001) 
-37.8 
(0.0001) 
Value are expressed as fold change relative to the control (0) with the p-value in the parenthesis. CPF; Chlorpyrifos, CPO; Chlorpyrifos oxon, PSP; Phenyl saligenin 
phosphate, MAP2; Microtubule-associated protein 2, TUBB3; Tubulin beta-3 chain, MAPT; Microtubule-associated proteinTau, NEFH; Neurofilament heavy chain, 
GAP43; Growth associated protein 43, GFAP; Glial fibrillary acidic protein. 
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5.3.5 Histone deacetylase (HDAC) activity upon exposure to CPF, CPO and PSP in 
differentiating neuronal cells.  
Our qPCR results showed that the OP compounds can indeed significantly decrease the 
mRNA levels of some key genes involved in neuronal development (qPCR data are 
summarised in Table 5.2).  Whilst it cannot be discounted that these compounds could 
affect RNA stability, leading to its decrease, an interesting possibility is that they could 
modulate gene expression through the regulation of transcription. This would mean that a 
series of transcription factors and chromatin remodelling complexes are specifically 
recruited to the promoter region of these genes. Once there, these complexes would be 
altering transcription rates by favouring DNA and/or histone modifications. And the 
acetylation and deacetylation of histones is one of the most widely studied changes 
controlling this process. In order to determine whether alterations in histone modifications 
could be involved in the genotoxic effects observed for the OPs studied in the current 
work, the analysis of HDAC activity was performed. As the genes studied exhibited 
reduced expression after exposure to CPF, CPO and PSP, and in general terms histone 
deacetylation is linked to transcriptional repression, it was felt that the HDAC activity 
could provide an insight to the mechanisms underlying the transcriptional changes 
observed.  As such, the activity of HDAC was analysed using a colorimetric assay. 
HDAC activity was measured in nuclear extracts prepared from differentiating N2a cells 
that were exposed to 1, 3 and 10 µM concentrations of CPF, CPO or PSP for 24 h. All 
three OPs caused a concentration dependent increase in the HDAC activity at 
concentrations of 1, 3 and 10 µM (Figure 5.12, panel A and B). 
 
 
 
 
 
 
 
Results   Chapter 5 
162 
 
0 1 3
1
0 0 1 3
1
0
0 .0
0 .1
0 .2
0 .3
O P  c o n c e n tra t io n  (µ M )
O
D
4
0
5
 n
m
a
b
s
o
r
b
a
n
c
e
C P F C P O
* * *
* * *
* * * * * *
* * *
A
* * *
0 1 3
1
0
0 .0
0 .1
0 .2
0 .3
P S P  c o n c e n tra t io n  (µ M )
O
D
4
0
5
 n
m
a
b
s
o
r
b
a
n
c
e
* * *
* * *
* * *
B
 
Figure 5.12. Effects of CPF, CPO and PSP on HDAC activity in differentiating N2a 
cells.  
N2a cells were induced to differentiate for 24 h either without (0) or with 1, 3 and 10 µM 
concentrations of A. CPF and CPO or B. PSP. Data are presented as mean of the total HDAC 
activity of the non-OP-treated control ± SEM (from three independent experiments). Differences 
among different groups were determined by one way-ANOVA with Sidak post-hoc test comparing 
treatments to the (0) control. Asterisks indicate changes that are statistically different from the non-
OP-treated controls (***p ˂ 0.001).  
The experiment was also performed on nuclei prepared from differentiating C6 cells that 
were exposed or not to a concentration of 1, 3 and 10 µM of CPF, CPO or PSP for 24 h. 
The data were identical to those obtained for the N2a cells, where all three 
organophosphates caused statistically significant linear increases in the HDAC activity at 
concentrations of 1, 3 and 10 µM (Figure 5.13, panel A and B). 
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Figure 5.13. Effects of CPF, CPO and PSP on total HDAC activity differentiating C6 
cells . 
C6 cells were induced to differentiate for 24 h either without (0) or with 1, 3 and 10 µM 
concentrations of A. CPF and CPO or B. PSP. Data are presented as mean of the total HDAC 
activity of the non-OP-treated control ± SEM (from three independent experiments). Differences 
among different groups were determined by one way-ANOVA with Sidak post-hoc test comparing 
treatments to the (0) control. Asterisks indicate changes that are statistically different from the non-
OP-treated controls (***p ˂ 0.001).  
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5.4 Discussion  
The previous chapter investigated the effects of CPF, CPO and PSP on the expression 
levels of neural cell differentiation cytoskeletal and associated regulatory proteins (MAP 2, 
βIII tubulin, Tau, NFH, GAP-43, and GFAP), in differentiating mouse N2a neuroblastoma 
cells and C6 glioma cells, and the results showed that the OPs selected influenced the 
expression levels of the proteins investigated, suggesting they may be important in the 
neurotoxic effects produced by OPs.  
As we had observed significant changes in protein expression, this chapter investigated the 
genotoxic effect of CPF, CPO and PSP on the expression level of selected cytoskeletal 
genes in differentiating N2a neuroblastoma and C6 cell lines. There is some evidence that 
OPs can cause genotoxic effects; for example, studies into long-term effects of OPs have 
suggested that occupational exposure is linked to increased reports of cancers such as non-
Hodgkin’s lymphoma (Dreiher et al., 2005), and observations that CPF can bind to DNA 
and produce DNA adducts have led to increased concerns about CPF genotoxic risk in 
humans (Li et al., 2015), but the actual effect of OPs at the genetic level is yet to be fully 
elucidated. Studies have shown that measuring changes to genetic material, such as DNA 
damage, can be a suitable measure of the genotoxic properties of OPs (Kornuta et al., 
1996), and genotoxicity may also affect key structural genes, which could then be linked to 
the changes observed at the protein level.  
The aim of this chapter was to examine the effect of CPF, CPO, and PSP exposure on the 
expression level of selected cytoskeletal genes in differentiating N2a neuroblastoma and 
C6 cell lines. To achieve these aims, quantitative RT-PCR analysis of the RNA expression 
levels for the key proteins GAP43, MAP2, MAPT, NFH, TUBB3, and GFAP were 
measured after exposure to 1, 3 and 10 µM CPF, CPO, and PSP, and normalised to the 
reference genes GAPDH and Rps18. To investigate if there were any significant effects due 
to epigenetic changes, a colorimetric test was used to evaluate HDAC activity. 
The first stage of these experiments was the investigation of the specificity of the primer 
pairs designed to detect the selected genes. The primers were used in a PCR to amplify the 
targeted amplicon using cDNA from mouse and rat brain tissues as positive control, and 
then, using mitotic and differentiated N2a and C6 cell lysates. The results showed a single 
defined band at the expected size, and after excision and sequencing, all the PCR products 
were in a 100 % alignment with their corresponding gene of interest. These results 
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suggested the primers were suitable for use in detecting changes in gene expression after 
treatment with the selected OPs.  
In order to understand gene expression in RNA samples, the selection of at least one 
‘housekeeping’ gene is required. This is a gene whose expression does not change with the 
treatments and can be used to normalize the results. In this study, both GAPDH and Rps18 
gene expression was analysed as possible reference genes: they were both stable and 
presented with similar expression patterns. However, GAPDH had a lower coefficient of 
variance which meant higher stability, thus the results normalized to GAPDH have been 
used for the discussion (Table 5.2).  
The results for the mRNA expression in the N2a cells showed that, as with the results for 
protein expression, there were no significant differences seen following exposure to 1 µM 
of any of the OPs. However, the MAP2 results showed a significant reduction in expression 
after exposure to 3 and 10 µM CPF, 10 µM CPO, and 10 µM PSP. By comparing these 
results to those of the protein expression (Chapter 4), the data show the same pattern of 
reduced expression, which also agree with protein expression results of in vivo studies 
(Abou-Donia, 1993; Prendergast et al., 2007; Ruiz-Muñoz et al., 2011). As there is a good 
correlation between the mRNA levels and protein expression, these results suggest that the 
reduced protein levels are at least partly due to changes in gene expression.  
The results for RNA expression for βIII tubulin (TUBB3) normalised to GAPDH in N2a 
cells showed there was a significant reduction after exposure to 10 µM CPF, CPO and 
PSP, and 3 µM PSP. This is similar to the results for the protein levels, where there were 
significant reductions in expression after treatment with 10 µM of all the OPs, the only 
difference being there were no significant changes seen at 3 µM PSP. These results agree 
with previous studies, which show a reduction in tubulin protein expression after OP 
exposure (Sachana et al., 2008; Sachana et al., 2014), and would suggest the lower protein 
expression is driven by an altered gene expression. 
The results for the mRNA expression for Tau (MAPT) normalised to GAPDH in N2a cells 
showed a significant reduction after exposure to 3 and 10 µM PSP, but not after treatment 
with any of the other OPs. These results are slightly different to those for the protein 
expression; here the treatment with 3 and 10 µM CPF as well as PSP caused a reduction in 
protein expression. As with the results for the protein expression levels, these results are 
different to those published in the literature for protein expression as they found that Tau 
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levels did not change after treatment with other OPs (Sachana et al., 2014). However, it is 
worth remembering that mRNA changes and protein changes do not always correlate. Tau 
turnover is regulated through the proteasome activity and its half-life is 60 h in 
hippocampal neuronal cells (Poppek et al., 2006). Taking this into account, the results 
obtained support a regulation of Tau protein levels through alteration of its proteasomal 
degradation rather than a modification of its gene expression. Changes in gene expression 
detected at 24 h, such as those of PSP treatment, would be detected at protein level only 
hours later than those covered in this study. Furthermore, as CPF treatment seems to 
modify Tau protein levels without affecting its gene expression levels, it would be 
interesting to study if it leads to post-translational modifications of Tau that could explain 
its increased degradation. 
The results for the expression for NFH after normalisation to GAPDH showed a significant 
reduction after cells were exposed to 3 and 10 µM CPO, but no significant changes for the 
other OPs. This is similar to the results for the protein expression levels, but there were 
also reductions in protein expression after treatment with 3 and 10 µM CPF, and 10 µM 
PSP. This suggest that the treatment with CPO caused changes in gene expression which 
resulted in lower protein levels, but the lower protein levels seen after treatment with CPF 
and PSP were probably due to post-translational events. These results are consistent with 
the studies of the effects of OPs on protein levels for NFH in the literature, that have 
showed a reduction in expression of NFH after treatment of N2a cells with 3 µM CPF for 8 
h (Sachana et al., 2001; Sindi et al., 2016), 3 µM CPO for 8 h (Sindi et al., 2016), 1-10 µM 
CPO for 24 h (Flaskos et al., 2011), and 2.5 µM PSP for 24 h (Hargreaves et al., 2006). 
The results for GAP-43 normalised to GAPDH expression show that there was a significant 
reduction in expression after treatment with 10 µM of CPF, 3 µM and 10 µM PSP (p < 
0.05 for all), but no significant differences were observed for CPO. These results have 
some similarities to the results for changes in protein expression; here there was a 
significant reduction in protein expression after exposure to 3 µM CPF and 10 µM of CPF, 
CPO and PSP (p < 0.01), which suggests the reduced protein expression for CPF and PSP 
are a result of an alteration in gene expression, but the changes in protein expression level 
for CPO are not due to changes in mRNA. As with the results for NFH, the results for 
GAP-43 agree well with those in the literature, which reported a reduction in GAP-43 
protein expression in N2a cells after treatment with 3 µM CPF and CPO for 4 h (Sachana 
et al., 2005; Sindi et al., 2016), and 1-10 µM CPO for 24 h (Flaskos et al., 2011).  
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The largest changes in mRNA expression after treatment with OPs were seen for GFAP in 
differentiating C6 cells. The results for RNA expression normalised to GADPH show that 
exposure to all concentrations of all the OPs resulted in a significant reduction in RNA 
expression; 1 µM CPO (p < 0.05), 3 and 10 µM CPO (p ˂ 0.001), 1, 3 and 10 µM CPF (p 
˂ 0.001), and 1, 3 and 10 µM PSP (p ˂ 0.001). This was a greater reduction than what was 
seen at the protein level, but the same trend was observed there: increasing concentrations 
of the OPs resulted in a reduced level of GFAP expression.  
The results for the protein levels showed a significant reduction in expression after 
treatment with 10 µM CPF (p < 0.01), 3 and 10 µM of both CPO and PSP (p < 0.01), 
which suggest the changes in protein are possibly a result of reduced expression levels and 
that the gene expression is more sensitive to the OPs. As with the results for the changes in 
protein expression, the results for the changes in gene levels agree with the different 
studies published in the literature; both in vivo and cell line studies have reported a 
reduction in GFAP after treatment with certain combinations of CPF and DZO (Garcia et 
al., 2002; Sidiropoulou et al., 2009b; Wang and Zhao, 2017).  
Garcia et al. (2001) indicated that CPF disrupted glial development in vivo of C6 glioma of 
the rat, by the disruption of signalling cascades, the inhibition of cell replication, disrupting 
the activity of nuclear transcription factors involved in cell differentiation and increasing 
the levels of reactive oxygen species. The results of the current study also fit with the work 
by Muñoz (2010), who found that 24 h treatment with 10 μM CPO and CPF significantly 
reduced the expression of GFAP in differentiating C6 cells. 
In addition, a study using RT-PCR to detect GFAP mRNA in neuroglia of the zebrafish 
brain to investigate cadmium cytotoxicity after treatment with 1 mg l-1 cadmium chloride 
for 2, 7 and 16 days, found a considerable reduction in GFAP reactivity in the 
subependymal layer, the meninges and the outer surface of blood vessels (Monaco et al., 
2016). The reduced GFAP expression was not due to changes in transcript stability and/or 
transcription, but instead it was due a reduction of protein in the cells or a reduction in the 
number of cells (Monaco et al., 2016). Thus, GFAP may be targetted differently at a 
molecular level by CdCl2.  
In a study of the effect of GFAP knock out, stable transfection of U-251 human 
astrocytoma cells with an antisense GFAP construct caused suppression of GFAP, and this 
resulted in a decreased ability to extend processes in response to neurons and a decrease in 
cell differentiation (Westermark, 1973; Weinstein et al., 1991). Furthermore, GFAP loss 
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could be an important step in glial tumour development, or the reduction in GFAP 
expression may signify the secondary loss of a differentiation marker, both of which are 
important in cancer progression, and can signal progression of the tumour to a more 
malignant and rapidly growing phenotype (Pekny et al., 1998; Wilhelmsson et al., 2003). 
Several studies indicated that many malignant astrocytic tumours are GFAP negative, and 
the majority of high-grade gliomas lose GFAP expression during their development 
(Jacque et al., 1978; Van der Meulen et al., 1978; Jacque et al., 1979; Velasco et al., 1980; 
Tascos et al., 1982). 
Overall, there is a good correlation between the reduced protein levels observed and the 
reduced the RNA expression of some but not all of the markers observed, which suggests 
the cause of the toxicity observed after OP treatment is partly due to genotoxic effects on 
the key genes, but possibly also due to posttranslational effects on gene products, leading 
to the morphological changes observed after OP exposure. The results for the expression of 
these genes agree with the more general studies into the genotoxic effects of OPs; in vivo 
studies in rats and fish have shown that exposure to sub lethal concentrations of CPF can 
cause DNA damage measured by the Comet assay, in a dose- and time- dependent manner 
(Sandhu et al., 2013; Ismail et al., 2014; Muller et al., 2014; Wang et al., 2014).  
Studies have shown that a variety of biological responses can be induced by genotoxic 
stress, including transcriptional activation (Dickinson et al., 2004). Histone acetylation is 
one of the best understood modifications of DNA involved in the epigenetic control of 
gene expression, and there is a correlation between transcription and histone acetylation 
levels. Therefore, having demonstrated that the RNA levels are often changed after OP 
treatments, it is a suitable target to check if OPs induce epigenetic changes (Allfrey et al., 
1964; Witt et al., 2009). Histone deacetylases (HDACs) and histone acetyl transferases 
(HATs) are antagonistic enzymes that regulate gene expression through deacetylation and 
acetylation of histone proteins around which DNA is wrapped inside the eukaryotic cell 
nucleus (Ahmad Ganai et al., 2016). Epigenetic modification of histones is an essential 
principle of how neurons regulate transcriptional responses and adapt to environmental 
signals (Cho and Cavalli, 2014). The post-translational modification of histones by histone 
deacetylases (HDACs) and chromatin-modifying enzymes histone acetyltransferases 
(HATs) shapes chromatin to regulate transcriptional profiles during neuronal development. 
The epigenetic control of HDACs and the cellular imbalance between HATs and HDACs 
dictate disease states and has been implicated in loss of memory, muscular dystrophy, 
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autistic disorders and neurodegeneration. Altering gene expression profiles through 
inhibition of HDACs is now emerging as a powerful technique (Ahmad Ganai et al., 2016) 
and epigenetic events have been recently found to play important roles in regulating axon 
regeneration (Ahmad Ganai et al., 2016). This is further supported by evidence that 
abnormal HDACs are involved in different diseases including cancer, suggesting analysing 
HDAC levels in combination with gene expression studies will provide a clearer picture of 
the effects of OPs (Peng et al., 2015). 
Therefore, to further investigate the genotoxic effects of the selected OPs, and to determine 
if epigenetic changes were involved in these changes, the analysis of HDAC activity in the 
nuclear extracts of differentiating N2a and C6 cells after treatment with CPF, CPO and 
PSP for 24 h was carried out using a colorimetric assay. The results showed that there was 
a significant increase in HDAC activity for all the concentrations of the different OPs, in 
both cell lines, which occurred in a dose-dependent manner.  
The down regulation of gene expression mediated by the up regulating of HDAC activity 
found in this study is comparable to the published study on the HDAC inhibitor 
Trichostatin-A, which was found to induce the expression of GAP43, a neural marker for 
axonal regeneration. It should be noted however, that proteins other than histones can be 
modulated by acetylation of specific lysine residues. Therefore, HDACs have the potential 
to have repressive impact on gene expression, restricting transcription factor access to 
monitoring regions (Gregoretti et al., 2004; Haberland et al., 2009). Therefore, the 
increased activity of HDAC can be correlated to the effects observed on the RNA 
expression; increased HDAC activity would result in higher levels of heterochromatin 
meaning less transcription and lower levels of RNA produced. This means that the 
genotoxic effect, when seen in OP toxicity is partly due the effects of OPs on epigenetic 
factors, which then causes the altered RNA and can be related to the altered protein levels 
and other morphological and developmental responses seen in the toxic effects of the OPs.  
In the meantime, HDAC’s function in neurons and the nervous system remains to be fully 
elucidated, which is a major impediment;  hence, understanding the specific gene 
expression patterns alongside the accurate specificity and dosage will open a novel aspect 
in the field and trigger a new wave (Ahmad Ganai et al., 2016). 
Overall, the combined results from the mRNA and HDAC assays provide new information 
on how OPs produce their toxic effects: this occurs in part by altering the expression levels 
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of the genes investigated. Based on these results, the research could be taken forward by 
investigating other key genes using these techniques to help develop a better picture of the 
mechanisms involved in OP toxicity in more relevant human stem cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Chapter 6 
Organophosphate Toxicity in a Human 
Neural Progenitor Stem Cell Model 
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6.1 Introduction 
While the main aim of this thesis is to investigate the toxic effects of CPF, CPO and PSP 
on differentiating mouse and rat neural cell lines, testing the effects of these toxins on cell 
differentiation and evaluating the gene expression in human stem cell models would add  
value to this study and to the field. By using neural progenitor stem cells derived from 
humans, the cellular model will  resemble cells of the developing human nervous system 
neurons in situ more closely, which can lead to more accurate predictions of chemical-
related changes in vivo (Radio and Mundy, 2008).  
The first neural stem cells were isolated from different regions of human embryonic brains 
(Vescovi et al., 1999); however, recent advances have led to the isolation of neural 
progenitor stem cells from adult human particularly from the neocortex region of the 
nervous system (Richardson et al., 2006). This makes human neural progenitor stem cells a 
valuable tool and exciting model for neuroscience research. Using human neural stem cells 
for evaluating xenobiotic toxicity could diminish the level of uncertainty that is associated 
with cells derived from animal models (Donato et al., 2007). 
Previous research using human neural progenitor stem cells was hampered by the short life 
span of stem cell cultures, as well as the limited facilities available to maintain both a 
stable phenotype and genotype across passages (Wright et al., 2006; Donato et al., 2007).  
The development of immortalised human neural progenitor stem cells, achieved by using 
the myc oncogenic transcription factor, overcame these difficulties (Dang et al., 1999; 
Kim, 2004). The cells’ ability to self-renew, generating large numbers of cells, alongside 
their genomic stability is the fundamental core of immortalisation using myc technology. 
These characteristics have allowed the use of these cells for toxicity screening (Klemm and 
Schrattenholz, 2004).  
The ReNcell CX cell line is one example of human immortalised neural progenitor stem 
cell lines that are commercially available (Merck Millipore). They were derived from a 14-
week old human foetal brain cortex and, upon mitogen withdrawal in serum free defined 
medium, they have the ability to differentiate into a mixed population of neurons, 
astrocytes and oligodendrocytes (Donato et al., 2007; Kornblum, 2007). Due to their 
immortalisation with myc oncogene transduction, these cells can self-renew, since they are 
multipotent, in addition to having phenotypic and genetic stability (Donato et al., 2007). 
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Thus, the ReNcell CX cell line is a suitable model for the assessment of neurotoxicity in 
vitro (Breier et al., 2008). Breier et al. (2008) employed ReNcell CX cells in an 
undifferentiated state, using HTS to measure the effects of chemicals such as lead acetate 
and methyl mercury chloride on the proliferation and viability of neural stem cells. 
However, chemical-induced changes in neurite outgrowth in differentiated ReNcell CX 
cells have yet to be studied. Nor have the underlying molecular effects of CPF, CPO and 
PSP been evaluated in differentiating human neural stem cell models.  
Hence, it was of interest to study the potential effects of OPs using a human-relevant cell 
model. Furthermore, there was additional interest in determining whether this human 
neural progenitor stem cell line, which comprises a mixture of neuronal and glial cells at 
early stages of differentiation, was affected by OP compounds in a manner comparable to 
differentiating N2a cells described in chapters 3, 4 and 5.  
To realize this goal, ReNcell CX cells were utilised as a cell model in co-differentiation 
exposure conditions similar to those applied to N2a and C6 cells. Cells were exposed to the 
same concentrations of CPF, CPO and PSP through 24h of differentiation.  
MTT reduction assays were also used to assess the viability of cells after exposure to OP 
compounds. Furthermore, quantitative PCR was used to evaluate the effects of the OP 
compounds and to confirm the mRNA expression of the mature neural stem cell markers, 
including βIII-tubulin, NF-H and GFAP. Finally, a histone deacetylation assay was carried 
out to further study the molecular mechanism underlying the genotoxic effects of the OPs 
of interest in differentiating ReNcell CX cells. The study of both gene expression a histone 
modification would be a valuable addition to the field of OP toxicity, as this study is the 
first to tackle these aspects particularly in the ReNcell CX cell model. 
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6.2 Results 
6.2.1 Cell viability in the presence of organophosphates   
A 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay 
was used to assess the cells’ viability upon exposure to toxins. ReNcell CX cells were 
differentiated for 24 h (as described in section 2.2.2) with simultaneous exposure to 1, 3 
and 10 μM CPF, CPO or PSP. A slight but significant decrease (P= 0.017) in MTT 
reduction was observed with 1µM CPO. The decrease was slightly more pronounced at 3 
and 10 µM CPO (P= 0.008 and P= 0.006, respectively) (Figure.6.1, panel B). On the other 
hand, exposure to the same concentrations of CPF and PSP did not have any significant 
effect on MTT reduction. 
In order to monitor any morphological changes,ReNcell CX cells line were assessed after 
24 h exposure to different concentrations of CPF, CPO and PSP. Cells were incubated in 
the absence (0) or presence (1, 3 or 10) µM of CPF, CPO and PSP. They were then fixed 
and stained with Coomassie Brilliant Blue dyes (Figure 6.2). There were differences in the 
morphological changes in cells exposed to varying concentrations of CPF, CPO and PSP 
after 24 h. The proportion of cells exhibiting decreased with increasing concentrations  of 
OPs, it was which difficult to determine changes using Coomassie blue stain, as there was 
no obvious change in cell density of the stained monolayerswas.  
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Figure  Effects of CPF (A), CPO (B) and PSP (C) on MTT reduction in 
differentiating ReNcell CX cells. ReNcell CX cells were exposed to 
different concentrations 1,3 and 10 μM of toxins after 24h of 
induction of cell differentiation, the levels of MTT reduction were 
measured to evaluate cell viability. Results are expressed as a 
mean percentage of the corresponding untreated control   SEM 
from five separate experiments. Statistical significance of data was 
analysed using one way ANOVA. (*p<0.05, **p<0.01).  
h24CX cells after  ReNcellC. PSP in  
h24A. CPF in ReNcell CX cells after  
h24B. CPO in ReNcell CX cells after  
 
 
Figure 6.1. Effects of CPF (A), CPO (B) and PSP (C) on MTT reduction in 
differentiating ReNcell CX cells. 
ReNcell CX cells were exposed to different concentrations (1,3 and 10 μM) of OPs during 24 h of 
induction of cell differentiation, the levels of MTT reduction were measured to evaluate cell 
viability. Results are expressed as a mean percentage of the corresponding untreated control ± SEM 
from five separate experiments. Statistical significance of data was analysed using one way 
ANOVA with Sidak post-hoc test comparing treatments to the (0) control (*p<0.05, **p<0.01).  
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Figure 6.2. Effects of CPF, CPO or PSP on the morphology of differentiating ReNcell 
CX cells.  
ReNcell CX cells were induced to differentiate for 24 h in the presence or absence of 1,3,10 µM 
CPF, CPO or PSP, as described in Materials and Methods. Shown are images of typical fields of 
cells viewed by phase contrast microscopy after 24 h differentiation by using an inverted light 
microscope following methanol fixation and staining with Coomassie blue. Bar represents 15 µm. 
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6.2.2 Primer validation 
The designed primer pairs’ specificities were tested prior to running the experiments. 
ReNcell CX cell total RNA was extracted and reversed transcribed to cDNA. The primers 
were used to amplify targeted amplicon in the constructed cDNA by conventional PCR.  
Figure.6.3 illustrates the primers’ specificities and table.6.1 shows the conditions that 
achieved the best amplification results. The amplified bands in Figure.6.3 were excised and 
the amplified products were eluted and sequenced then ‘blasted’ against the genome of 
Homo sapiens. The sequenced PCR products were in a 100% alignment with only their 
corresponding gene of interest (Appendix 8.9, 8.10), accession numbers are listed in 
table.6.1.     
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Table 6.1. Primer sequences and standardised PCR optimisation protocols for the amplification of specific neural markers genes 
Gene Variants Primer Sequence (5’ to 3’) Annealing Tm (C⁰) Product size 
TUBB3 1. Isoform 1 NM_006086.3 
2. Isoform 2NM_001197181.1  
Forward ATTTCATCTTTGGTCAGAGTGGGGCC  65 121 
Reverse CAGTCGCAGTTTTCACACTCCTTCC  
NEFH NM_021076.3  Forward ACTCCCCAAAATTCCCTCTGTGTCC  61 121 
 Reverse TTGGGTCTCCTCTGTCTGTTCCTCC  
GFAP 1. Variant 1 NM_002055.4 
2. Variant 2 NM_001131019.2 
3. Variant 3 NM_001242376.1 
Forward CAGAAGCTCCAGGATGAAACCAACC 63 119 
Reverse GACTCAATCTTCCTCTCCAGATCCAGACG 
GFAP; Glial fibrillary acidic protein, NEFH; Neurofilament heavy chain, TUBB3; Tubulin βIII chain, and Tm; Melting temperature. 
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A B C 
 
Figure 6.3. Confirmation of PCR for genes of interest in mitotic and differentiating 
ReNcell CX cells. 
A- β III tubulin (TUBB3), B- NEFH, C-GFAP. RNA was obtained from mitotic (M) and 
differentiating (D) human stem cell and reverse transcribed into cDNA and analysed by PCR. Non-
template controls were used as negative controls (C). Bands were visualised after electrophoretic 
separation in a 1.5% (w/v) agarose gel stained with SyberSafe. Amplified products are presented as 
a single defined band at size of approximately 100 base-pairs (bp). 
6.2.3 Effect of CPF, CPO and PSP on neuronal markers in ReNcell CX cell line. 
The mRNA expression level of neuronal markers including TUBB3, NEFH and GFAP was 
measured in differentiated ReNcell CX cells that were exposed to 1, 3 and 10 µM 
concentrations of CPF, CPO and PSP.  
Since the expression of neural marker genes in mammalian cell lines of the previous 
chapter were relative to glyceraldehyde 3-phosphate dehydrogenase (GAPDH), the same 
housekeeping gene was selected as reference gene in the gene expression analysis of 
differentiating ReNcell CX cells. 
6.2.3.1 Tubulin beta-3 chain (TUBB3). 
TUBB3 mRNA expression level relative to GAPDH was significantly reduced upon cells’ 
exposure to 1 (p= 0.0303), 3 (p= 0.0340) and 10 µM (p= 0.0070) CPF with 10 µM causing 
the most significant effect. A concentration of 3 µM (p= 0.0005) of CPO caused the most 
significant reduction in TUBB3 mRNA levels. This reduction was also high at                    
a concentration of 10 µM (p= 0.0019) (Figure 6.4, panel A1). PSP exposure did not cause   
a significant effect until a concentration of 10 µM (p= 0.0074), where the expression 
dropped in comparison to the control (Figure 6.4, panel A2).  
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Figure 6.4. Expression of TUBB3 mRNA in differentiating ReNcell CX cells after 
CPF, CPO and PSP exposure, as determined by quantitative qPCR.  
ReNcell CX cells were induced to differentiate for 24 h with incubation without (0) or with 1, 3 
and 10 µM concentrations of CPF, CPO or PSP. Data were analysed using one-way ANOVA with 
Sidak post-hoc test comparing treatments to the (0) control. The normalization of data was to the 
housekeeping gene GAPDH. Expression values are relative to the non-OP-treated control ± SEM. 
Data presented are an average of four independent experiments, and all samples were amplified in 
triplicate. Asterisks indicate changes that are statistically different from the non-OP-treated controls 
(*p ˂ 0.05, **p ˂ 0.01, or ***p ˂ 0.001).  
6.2.3.2 Neurofilament heavy chain (NEFH) 
CPF did not cause a significant effect on NEFH’s mRNA expression levels. On the other 
hand, CPO caused a significant drop in its expression at a concentration of 3(p= 0.0031) 
and 10 (p= 0.0054) µM (Figure 6.5, panel A1). 
Low concentration of PSP (1 µM) elevated NEFH mRNA expression slightly but not 
significantly compared to the control; however, this effect was linearly reduced with 
increased PSP concentration but only significant at a concentration of 10 µM (p= 0.0140) 
(Figure 6.5, panel A2). 
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Figure 6. 5. Expression of NEFH mRNA in differentiating ReNcell CX cells after 
CPF, CPO and PSP exposure as determined by quantitative qPCR.  
ReNcell CX cells were induced to differentiate for 24 h with incubation without (0) or with 1, 3 
and 10 µM concentrations of CPF, CPO or PSP for 24 h. Data were analysed using one-way 
ANOVA with Sidak post-hoc test comparing treatments to the (0) control. The normalization of 
data was to the housekeeping gene GAPDH. Expression values are relative to the non-OP-treated 
control ± SEM. Data presented are an average of four independent experiments, and all samples 
were amplified in triplicate. Asterisks indicate changes that are statistically different from the non-
OP-treated controls (**p ˂ 0.01).  
6.2.4 Glial fibrillary acidic protein (GFAP)  
Exposing the cells to 1 µM (p=0.0433) and 3 µM (p=0.0374) concentrations of CPF 
resulted in significant decreases in GFAP mRNA expression levelsn to approximately 50 
% of control values. Higher CPF levels of 10 µM (p=0.0125) caused a drop in its 
expression to approximately 25 % of the corresponding control value (Figure 6.6, panel 
A1). CPO’s effect was only significantly observed at a concentration of 10 µM (p=0.0051), 
where it caused an almost 50 % drop inGFAP expression (Figure 6.6, panel A1). Exposure 
to a concentration of 3 µM (p=0.0123) and 10 µM (p=0.0074) of PSP caused a similar 
effect to CPF exposure; it decreased GFAP’s mRNA expression by more than half of the 
control value (Figure 6.6, panel A2). 
Data of OPs genotoxicity on ReNcell CX cells are summarised in table 6.2.  
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Figure 6.6. Expression of GFAP mRNA in differentiating ReNcell CX cells after CPF, 
CPO and PSP exposure as determined by quantitative qPCR.  
ReNcell CX cells were induced to differentiate for 24 h with incubation without (0) or with 1, 3 
and 10 µM concentrations of CPF, CPO or PSP for 24 h. Data were analysed using one-way 
ANOVA with Sidak post-hoc test comparing treatments to the (0) control. The normalization of 
data was to the housekeeping gene GAPDH. Expressions values are relative to the non-OP-treated 
control ± SEM. Data presented are an average of four independent experiments, and all samples 
were amplified in triplicate. Asterisks indicate changes that are statistically different from the non-
OP-treated controls (*p ˂ 0.05) or (**p ˂ 0.01).  
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Table 6.2. Summary of OP effects on human neural marker genes relative to GAPDH 
Cells 
OPs CPF CPO PSP 
Conc. (µM) 1 3 10 1 3 10 1 3 10 
ReNcell CX 
TUBB3 -1.4 
(0.03) 
-1.4 
(0.034) 
-1.8 
(0.007) 
ns -1.7 
(0.0005) 
-1.4 
(0.0019) 
ns ns -1.3 
(0.0074) 
NEFH ns ns ns ns -1.4 
(0.0031) 
-1.3 
(0.0054) 
ns ns -1.4 
(0.014) 
GFAP -1.8 
(0.043) 
-1.9 
(0.037) 
-2.8 
(0.012) 
ns ns -1.6 
(0.0051) 
ns -2.4 
(0.01) 
-3.03 
(0.007) 
Value are expressed as fold change relative to the control (0) with the p-value in the parentheses, CPF; Chlorpyrifos, CPO; Chlorpyrifos oxon, PSP; Phenyl saligenin 
phosphate, TUBB3; Tubulin beta-3 chain, NEFH; Neurofilament heavy chain, GFAP; Glial fibrillary acidic protein. 
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6.2.5 Histone deacetylases (HDAC) activity upon exposure to CPF, CPO and PSP in 
differentiating RenCellCX cells.  
HDAC activity was measured in differentiating ReNcell CX cells that were exposed to 1, 3 
and 10 µM concentrations of CPF, CPO or PSP for 24 h. While different concentrations of 
both CPF, CPO (Figure 6.7, panel A) and PSP (Figure 6.7, panel B) exposure caused 
changes in HDAC activity relative to the non OP-treated control, a concentration of 3 µM 
and 10 µM (p<0.05) of CPF, CPO and PSP (Figure 6.7, panel A) significantly increased its 
activity.  
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Figure 6.7. Effects of CPF, CPO and PSP on HDAC activity in differentiating ReNcell 
CX cells. 
ReNcell CX cells were induced to differentiate for 24 h with incubation without (0) or with 1, 3 
and 10 µM concentrations of CPF, CPO (panel A) or PSP (panel B). Data are presented as mean of 
the total HDAC activity ± SEM (from three independent experiments). The significance of 
differences among different groups was determined by one way-ANOVA with Sidak post-hoc test 
comparing treatments to the (0) control. Asterisks indicate changes that are statistically different 
from the non-OP-treated controls (*p ˂ 0.05).  
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6.3 Discussion  
The previous chapters in this thesis have shown that in the N2a and C6 cell lines, the 
selected OPs (CPF, CPO and PSP) at sub-cytotoxic doses (1, 3 and 10 µM) can cause 
morphological changes to neurite outgrowth without cell death (Chapter 3), which can be 
linked to changes in the levels of selected cytoskeletal and associated regulatory proteins 
(MAP 2, Tau, βIII tubulin, GAP-43, NFH and GFAP) (Chapter 4), and in turn this can be 
related to genotoxic effects from reduced mRNA expression of key genes (MAP2, MAPT, 
TUBB3, NEFH, GAP43 and GFAP) and epigenetic changes measured by HDAC activity 
(Chapter 5). 
The use of cell lines can provide a good insight into the effects of the OPs on individual 
cell types, but they do not provide information as to how the different cell types are 
affected in the presence of the other cell types; therefore a different system needs to be 
used to allow the interaction of these cell types to be observed. One such way of doing this 
is to use a stem cell line, such as ReNcell CX cells. These cells can be induced to 
differentiate to form a co-culture of different glial and neuronal cell types, which means 
they offer advantages over the C6 and N2a cell lines as the dendrites and axons formed by 
ReNcell CX cells have similar complex interactions to those found in developing human 
neural cells (Bal-Price et al., 2008; Radio and Mundy, 2008). ReNcell CX cells have 
previously been used in toxicology studies. For example, proliferation and viability assays 
were used in a high throughput methodology approach to assess 16 compounds, including 
several that were known to cause developmental neurotoxicity, and the study found this 
cell line could successfully be used to detect changes in proliferation that were not linked 
to changes in cell viability (Breier et al., 2008). Further high throughput toxicity screening 
studies in ReNcell CX cells have involved using the ToxCast Phase I library of 309 
chemicals, initially at a dose of 40 µM, then in the range 1 nM–40 µM, in a study that 
measured proliferation and cytotoxicity compared to the rat PC12 cell line (Radio et al., 
2015). The results showed that ReNcell CX cells detected activity in 126 (41 %) of the 
chemicals with 63 chemicals selectively inhibiting proliferation, and the PC12 cells 
detected 46 (15 %) chemicals, with similar results between the different doses investigated, 
highlighting the sensitivity and suitability of the ReNcell CX cell type for this type of 
study (Radio et al., 2015). 
The aims of this chapter were to study the effects of the selected OPs (CPF, CPO and PSP) 
on a human-relevant cell model to investigate if similar results were obtained as in the N2a 
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and C6 cell lines. Identical conditions to the cell line studies (1, 3 and 10 µM CPF, CPO 
and PSP) were used to treat the differentiating ReNcell CX cells for 24 h before cell 
viability was measured using MTT reduction assay, and quantitative PCR was used to 
measure mRNA expression of key markers (TUBB3, NEFH and GFAP), and epigenetic 
changes were measured by HDAC activity assays.  
The results of the MTT assay showed that CPO had a slight inhibitory effect on MTT 
reduction, with a significantly lower level observed after 24 h treatment with 1, 3 and 10 
µM CPO, yet there were no significant differences for the other OPs. This suggests that 
there are some differences between the ReNcell CX cells and the N2a and C6 cell types, in 
that the ReNcell CX are more sensitive to reduced metabolic activity following CPO 
exposure than are the rodent cell lines. Further work would help to determine if this 
reflects an effect of CPO on metabolic activity of ReNCell CX cells only, or reduced cell 
proliferation and viability. 
The next step in investigating the effects of the OPs in ReNcell CX cells was to check the 
specificity of the primer pairs designed to detect βIII tubulin (TUBB3), NEFH and GFAP. 
The primers were used in PCR to amplify the target amplicon in cDNA reverse transcribed 
from ReNcell CX cells total RNA, and the results produced single defined band of the 
expected size. After excision and sequencing, all the PCR products were in a 100 % 
alignment with their corresponding Homo sapiens gene of interest, suggesting the primers 
were suitable for use in detecting changes in the expression of their target genes after 
treatment with the selected OPs.  
The results for the mRNA expression levels show that all of the markers were reduced by 
at least one concentration of the selected OPs, which is similar to the results from the N2a 
and C6 cell lines. The results for βIII tubulin (TUBB3), show that, when normalised to 
GAPDH, there was a significant reduction in mRNA levels after treatment with 1, 3 and 10 
µM CPF; 3 and 10 µM CPO, and 10 µM PSP. This has some similarities to the results in 
the N2a cells, as 10 µM CPF, CPO and PSP all caused a reduction in mRNA in the N2a 
cells, but 3 µM PSP also caused a reduction in mRNA. This suggests that βIII tubulin 
mRNA in the ReNcell CX cells is more sensitive to CPF and CPO than in it is the N2a 
cells.  
The results for NEFH, when compared to the relevant controls, showed there was a highly 
significant reduction in mRNA levels after treatment with 3 and 10 µM CPO and 10 µM 
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PSP. This was similar to the results for the N2a cell line, which showed a reduction after 
CPO treatment, except that in N2a cells there was no significant difference after PSP 
treatment. This suggests that in the ReNcell CX cells the production of NEFH mRNA is 
more sensitive to PSP than it is in N2a cells. 
The results for GFAP mRNA levels in ReNCell CX cells, after correction to GAPDH 
levels, show there was a significant reduction after treatment with 1, 3 and 10 µM CPF, 3 
and 10 µM PSP, and 10 µM CPO. These results are similar to those for GFAP in C6 cells, 
except that the C6 cells showed a slightly higher sensitivity, as all the concentrations of all 
3 OPs produced a significant reduction in mRNA levels. 
These results can be compared to those of a previous study that used ReNcell CX cells to 
investigate the changes in multi-parameters of neurite outgrowth using high throughput 
analysis for βIII tubulin, pNFH and GFAP, and protein levels for βIII tubulin and pNFH 
using ELISA after 8 h exposure to 1-10 µM CPF and CPO (Sindi, 2015).  
In order to further investigate if the changes in mRNA were due to epigenetic factors, 
HDAC activity was monitored in the ReNcell CX cells after treatment with the selected 
OPs. The results indicated that there was a significant increase in HDAC activity after 
treatment with 3 and 10 µM CPF. Despite, the increase was also statistically significant 
with CPO and PSP exposure and, the significance with rodent cell lines were much higher 
than human ReNcell CX cells. It may be that in a mixed population of cells (e.g. 
differentiating ReNCell CX cells) not all sub-populations of cells (e.g. neurons, glia and 
undifferentiated stem cells) are similarly affected in terms of their HDAC activity by OP 
exposure, thus making a significant increase in HDAC activity more difficult to detect. In 
this respect, further work at longer exposure times in this cell model would be worthwhile. 
It could also be that, as suggested by Sindi (2015) some OPs (e.g. CPO) may be detoxified 
in the ReNCell system. The observed diversity could also be partly due to the distinct 
origins of the cells. For example, N2a cells are derived from the mouse C1300 tumour 
(neuroblastoma) (Klebe and Ruddle, 1969), C6 cells are derived a rat glial tumour (Benda 
et al., 1968) and ReNcell CX cells were produced from human foetal cortex (Donato et al., 
2007).  
Nevertheless, the trends revealed in this chapter are similar of those observed in the N2a 
and C6 cells, where there were statistically significant, dose-dependent increases in HDAC 
activity after treatment with all concentrations of the OP . Increased HDAC activity could 
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result in higher levels of heterochromatin and less transcription. In addition, my findings  
are in agreement with the study of Ahmad Ganai et al. (2016) in which HDAC inhibitors 
were found to play protective as well as toxic roles in cells, as it would show wheter 
HDAC upregulation alone was responsible for the changes in mRNA levels observed. 
The ReNcell CX results are similar to some other studies in the literature; for example 
sulforophane, an organo-sulphur compound, has been shown to inhibit HDAC activity in 
human prostate cancer cell lines and colon cancer cell lines, resulting in increased 
expression of key inflammatory markers (Myzak et al., 2004; 2005). Overall, the current 
work and the above mentioned studies suggest histone acetylation may be one of the key 
epigenetic changes in neuronal cells during the development of neurotoxicity.  
Taken together, these findings could be explained by the fact that N2a and C6 cells are 
monocultures, whereas ReNcell CX cells are a co-culture of neuronal and glial cells, which 
might influence the outcome. For example, glial cells produce and secrete neurotrophins 
such as glial derived neurotrophic factor (Lin, 1996). In a study by the host research group, 
it was found that conditioned medium from glial cells, and specifically GDNF, protected 
against the neurite outgrowth inhibitory effect of diazinon in differentiating N2a cells 
(Harris et al., 2009a). Moreover, the protective effect was found to involve attenuation of 
the ability of diazinon exposure to reduce the protein levels of NF-H, as detected by 
densitometric analysis of Western blots probed with the monoclonal antibody N52. It 
would be interesting to determine whether comparable effects were observed at the mRNA 
level.  
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7.1 General Discussion 
OPs, have been widely used as pesticides, and in industrial applications, as their 
use increased it became apparent that these compounds caused neurotoxicity with 
the effects seen depending on the dose, age and route of exposure to the OP. 
Although there are extensive studies highlighting the fact that OPs can cause 
effects on AChE inhibition, which is the primary acute toxicity target for many of 
them, there are several other cellular proteins that are proposed targets for OP 
neurotoxicity, including cytoskeletal proteins, axon growth associated proteins and 
other proteins involved in cell signalling pathways (Flaskos, 2014). Some 
developmental processes of the nervous system are controlled by the neuronal 
cytoskeleton, including proliferation, cell migration, differentiation, 
morphogenesis, neurite outgrowth, elongation of axons, branching of dendrites, 
steering of growth cones, and also apoptosis (Hargreaves, 1997; Flaskos, 2014). 
Hence, the disruption of cytoskeletal proteins can result in serious neural 
development damage (Flaskos, 2014). Therefore, further studies needed to focus on 
identifying non-cholinergic targets of OPs, in order to clarify the molecular 
mechanisms involved in OP-induced toxicity. 
Based on previous studies showing that sub-lethal concentrations of CPF and CPO 
in differentiating mouse N2a neuroblastoma cells inhibited axon outgrowth and 
disrupted the cytoskeleton (Sachana et al., 2001; Sindi et al., 2016), the overall 
aims of this thesis were to investigate the effects of sub-cytotoxic concentrations 
(1, 3 and 10 µM) of CPF, CPO and PSP on differentiating N2a, C6 and ReNcell 
CX cell lines in terms of cell viability, neurite outgrowth, effects on expression of 
cytoskeletal proteins, expression of genes encoding key cytoskeletal proteins, and 
epigenetic regulation of gene expression.  
The initial investigations of this thesis involved confirming previous reports of the 
toxicity of the selected OPs using MTT reduction assays and Trypan blue 
exclusion for cell viability, and the effects on neurite outgrowth using a manual 
Coomassie Brilliant Blue assay in differentiating N2a and C6 cells (Sachana et al., 
2001; Hargreaves et al., 2006; Sachana et al., 2008; Flaskos et al., 2011; Sindi, 
2015). Having confirmed previous results using these approaches, a strong basis 
was established for the development of a high throughput screen for multiple 
parameters of neurite outgrowth using differentiating cell monolayers that were 
General discussion   Chapter 7 
189 
 
fixed and stained by indirect immunofluorescence with antibodies against NFH 
and β III tubulin in N2a cells, and GFAP in C6 cells. In this respect, indirect 
immunofluorescence showed good staining for all the antibodies selected, with 
differences visible after some of the treatments, suggesting these antigens were 
suitable markers for use in this study. 
The development of high throughput platforms has enabled researchers to evaluate 
and quantify the neurotoxin exposure effects in a variety of neural cell lines. The 
observation that 10 μM CPO reduced cell body area in differentiating C6 cells 
stained for GFAP after 24 h exposure, is consistent with previous high throughput 
screening studies in which C6 cells differentiated for 24 h before exposure to 10 
μM CPO for 8 h exhibited reduced cell body area (Sindi, 2015), indicating that one 
effect of CPO was to induce C6 cells to become more compact. The observed 
reduction in antibody staining intensity for βIII tubulin, NFH and GFAP after 
treatment with the OPs could be related to reduce neurite length, and is different to 
the results of previous studies where no changes in staining intensity were 
observed for these cell types (Sindi, 2015). One reason for these differences could 
be the longer exposure time (24 h) in the current study compared to the work of 
Sindi (2015) and the fact that the latter involved the use of pre-differentiated cells 
as opposed to treatment throughout the course of differentiation in the present 
work. 
The results for the neurite outgrowth markers in the high content assay were 
similar to the Coomassie blue staining results, as they both indicate reductions in 
neurite outgrowth due to treatment with the higher concentrations of all three OPs 
used, which agrees with previous studies that have shown neurite outgrowth 
impairment in N2a cells after treatment for up to 8h from the point of induction of 
differentiation with 3 µM CPF (Sachana et al., 2001; Sachana et al., 2005). A 
similar concentration dependent response was observed after treatment with CPO 
for 24 h (Flaskos et al., 2011). After 24 h treatment with PSP, there was no 
significant effect on cell shape but a concentration dependent reduction in neurite 
outgrowth in differentiating N2a cells (Hargreaves et al., 2006; Flaskos et al., 
2006). The results were also consistent with previous studies in differentiating glial 
cells which found an inhibitory effect on extension outgrowth following 24 h 
exposure to 1-10 µM CPF and CPO in C6 cells (Sachana et al., 2008).  
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PSP reduced the percentage of cells with significant outgrowth for all markers; for 
anti-βIII tubulin it also caused a significant reduction in maximum and average 
neurite length/cell (with a greater significant difference than for CPF). For anti- 
NFH it significantly reduced maximum neurite length and average neurite 
length/cell. For anti-GFAP it significantly reduced average neurite length/cell 
which were also affected by CPF but to a lesser extent. These results suggest PSP 
can affect all the markers investigated with a different response for each marker, 
and indicate that axon-like process are most sensitive to PSP, causing disruption of 
neurofilaments, and that in differentiating neuronal cells PSP caused reduced 
neurite outgrowth associated with neuronal degeneration and modification of 
axonal morphology, which are critical events in both neural development and in 
the induction of OPIDN as mentioned in the literature (Flaskos et al., 1994; Ehrich 
and Jortner, 2001; Hargreaves et al., 2006). 
CPO treatment produced the largest inhibitory effect in anti-NFH positive (axon-
like) neurites for the percentage of cells with significant outgrowth, maximum 
neurite length/cell, and had a similar effect to PSP on the average neurite 
length/cell, and in anti-GFAP staining for maximal neurite length/cell, it had          
a greater effect than PSP on average neurite length/cell. The fact that CPO 
produced a significant effect on NFH and GFAP suggests it has a relatively potent 
inhibitory effect on axon-like neurites and glial extensions, which in agreement 
with previous studies which have shown CPO was more potent than CPF following 
24 h exposure in pre-differentiated rat PC12 pheochromocytoma cells, and in co-
differentiated N2a cells, causing inhibited neurite outgrowth, and a reduction in 
axonal length in embryonic derived primary cultures of sensory and sympathetic 
neurons (Das and Badone, 1999; Howard et al., 2005; Yang et al., 2008). These 
results also correlate with studies that have shown CPO can cause a reduction in 
NFH levels in vitro (Flaskos et al., 2011), that CPO can bind tubulin and disrupt 
polymerisation in bovine brain MT in vitro (Grigoryan and Lockridge, 2009), and 
disrupt the neurofilament network after 24 h treatment with non-cytotoxic neurite 
inhibitory concentrations of CPO (Flaskos et al., 2011). The morphological 
changes observed after treatment with CPO occur at similar concentrations found 
in vivo in developing humans (Gupta, 1995; Ostrea et al., 2002; Pelkonen et al., 
2006) and therefore can be linked to the developmental neurotoxicity observed 
(Bramanti et al., 2010; Liu et al., 2012). 
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CPF caused significant reductions for βIII tubulin in average neurite length/cell; 
for NFH in the percentage of cells with significant outgrowth; and in GFAP for 
maximal neurite length. CPF caused reduced levels of NFH and can be linked to 
the ability of CPF to inhibit protein and DNA synthesis. These findings correlate 
with previous studies (Song et al., 1998; Sachana et al., 2003; 2005; Flaskos et al., 
2007).  
The reduction in βIII tubulin and NFH after treatment with CPF, CPO and PSP 
could indicate a disruption in the neuronal MT network, and changes, or                 
a breakdown, in the NF networks, which would result in reduced axon stability 
(Sindi, 2015). The effects on neurite length depend on the OP and dose used, 
which can easily be measured via the sensitive high content throughput assay, and 
these axon extensions play a key role in connecting single and multiple neurons 
(Hjorth et al., 2014).  
Based on the preliminary data and the high content analysis, further investigations 
into how CPF, CPO and PSP exert their effects were planned to investigate if the 
changes in neurite outgrowth observed were due to changes in expression of neural 
cell differentiation cytoskeletal and associated regulatory proteins, to help to 
elucidate the mechanism of action of these OPs more fully. Protein expression for 
MAP 2, βIII tubulin, Tau, NFH, GAP-43 and GFAP, were analysed by quantitative 
Western blotting and cell ELISA approaches. Studies have shown that proteins, 
such as NFs and MTs, involved in the neuronal cytoskeletal are key endogenous 
factors that control normal axonal and neurite outgrowth, neuro-stability and 
neurodevelopment (Cambray-Deakin, 1991). Previous studies have shown that 
disruption of the axonal cytoskeleton by OPs is associated with changes in 
neuronal cell morphology (Lee and Cleveland, 1994).  
The investigation of the effect of the OPs on the selected proteins in N2a and C6 
cells showed that the OPs did influence protein expression, with a reduction in 
levels seen for all proteins with at least one OP treatment, but there were no 
significant differences produced with 1 µM of any of the OPs, which is different to 
the morphological results where some of the OPs did cause an effect at this 
concentration. The levels of protein expression were also investigated by cell 
ELISA, which produced decreased expression after OP treatment with some 
similarities to the results of the Western blots, with differences appearing in 
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sensitivity for some of the markers investigated and the OPs that produced a 
response.  
In that there were reductions in the protein levels of βIII tubulin, NFH, GAP-43 
and GFAP after treatment with at least one concentration of PSP, CPO and CPF 
seen in both sets of data. This suggests that the morphological changes observed 
could be linked to reduce cytoskeletal protein expression levels after treatment 
with the different OPs, which helps to explain how these OPs produce the 
neurotoxic effects observed.  
The data obtained in this study may reflect the potential impacts of CPF and CPO 
on memory, since information acquisition and memory storage in the mammalian 
nervous system which are mainly dependent on changes in the synapses and their 
protein contents. Increased levels of GAP43 are vital for axonal outgrowth and 
neuronal connectivity by facilitating the formation of new synapses. GAP43 plays 
an essential role in synaptic transmission and plasticity (Holtmaat et al., 1995). It 
has been validated that decreased levels of GAP43 were associated with memory 
impairment in vivo (Rekart et al., 2005). Therefore, the protein changes observed 
in the current thesis could have induced structural and functional alterations in 
synaptic plasticity, which represents a cellular mechanism of memory and learning 
processes (Mansuy and Shenolikar, 2006). Thus, the cytoskeletal disruption 
observed in cell lines of the current study following OP exposure could reflect       
a potential to induce cognitive deficits and memory disorders related with aging, 
dementias or neurodegenerative disease. 
The obtained findings for GFAP in the C6 cells are also similar to those previously 
published, as 24 h treatment with the organophosphorothioate pesticide DZO 
caused a decrease in GFAP expression (Sidiropoulou et al., 2009b). The findings 
in this study did produce some differences to those previously published, in that 
earlier studies found no significant differences in expression for MAP2 after 
treatment with CPF and CPO in C6 cells, which may be due to the cell type used; 
and no effect on Tau or NFH of 24 h treatment of differentiating N2a cells with 
DZO, which highlights the possible differences in OP specificity (Sachana et al., 
2008; Sachana et al., 2014). 
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As the results of the investigations into the effects of the selected OPs on 
morphological features correlated with the results from the investigations into the 
changes in expression of the selected cytoskeletal and associated regulatory 
proteins, the next step in this thesis was to examine if the reductions in expressed 
protein could be linked to reduced mRNA levels, which would indicate if the OPs 
caused a genotoxic effect, or whether they were only acting at the protein level. 
Based on the protein expression results, the key genes MAP2, TUBB3, MAPT, 
GAP-43, NEFH and GFAP , which encode those proteins, were measured after 24 
h exposure to CPF, CPO, and PSP (1, 3 and 10 µM), and normalised to the 
reference gene GAPDH in differentiating N2a neuroblastoma and C6 cell lines by 
qPCR analysis of the mRNA expression. To further investigate the actual 
mechanism of any genotoxicity of these OPs, any significant effects due to 
epigenetic changes were measured using a colorimetric test to evaluate HDAC 
activity. 
After the initial tests confirmed that the primer pairs amplified the correct genes 
and GAPDH was stably present in the samples, the actual changes in mRNA after 
treatment with the OPs for 24 h were investigated. The results for the N2a cell line 
showed that the OPs did affect mRNA levels, but there were no significant 
differences after treatment with 1 µM of any of the OPs, which correlates with 
their effects at the protein level from the Western blot results. In the N2a cell line 
mRNA changes for MAP 2 and TUBB3 correlate well with the reduced protein 
expression observed in this thesis and the literature from either in vivo studies of 
MAP 2 (Abou-Donia, 1993; Prendergast et al., 2007; Ruiz-Muñoz et al., 2011), or 
in vitro studies for βIII tubulin (Sachana et al., 2008; Sachana et al., 2014), which 
would suggest that the reduced protein levels are due to changes in gene 
expression. The N2a cell line mRNA results for MAPT, NEFH and GAP-43 show 
some similarities to the protein level results from this thesis.  
According to the important roles of glial cell as mentioned in section 1.1.2, any 
damage to glial cells and their extensions can severely impede nerve cell function 
and genesis or alter the integrity of these barriers, which would change the brain 
micro-environment and affect complex nervous system activity. Astrocytes are a 
sub set of glial cells and the primary component of the cytoskeletal intermediate 
filaments (IFs) in these cells is GFAP (Pekny et al., 1999). Studies have shown 
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that GFAP can be substituted by other IF proteins in most situations;  however, if 
IFs are absent in astrocytes, then this can lead to prolonged and impaired healing 
following injury to the central nervous system (Eliasson et al., 1999). In the current 
study, we determined that exposure to CPF, CPO and PSP caused reduced 
expression of GFAP possibly due to switching off the gene. Indeed, the largest 
changes in mRNA expression were observed for GFAP, as a significant reduction 
in expression was observed after treatment with all concentrations of all the OPs. 
However, the GFAP mRNA changes were much greater than those for protein 
expression, but they both followed a concentration-dependent trend. These protein 
and mRNA results correlate with the literature results that have shown in vivo or in 
vitro reductions in GFAP protein after treatment with CPF, DZO, and CPO (Garcia 
et al., 2002; Sidiropoulou et al., 2009b; Muñoz, 2010; Wang and Zhao, 2017). 
Studies on GFAP-/- mice have shown there were generally no gross structural CNS, 
behavioural, or neurologic abnormalities, with astrocytes found in a normal 
distribution. However, there were changes in myelination, which could lead to 
reduced contact between myelin sheaths and astrocytes, or oligodendrocytes and 
astrocytes. This highlights the importance of GFAP in brain development (Gomi et 
al., 1995; Pekny et al., 1995; Shibuki et al., 1996; Liedtke et al., 1996). 
Normally, IFs are depolymerized before cell division, and this process is 
controlled, in part, by phosphorylation (Ku et al., 1996). Studies have shown that 
some of the kinases that are involved in cell cycle regulation, such as cell-division 
cycle 2 (cdc2) and protein kinase C, also play a key role in IF phosphorylation 
(Inagaki et al., 1990; Dalton, 1992; Yong, 1992; Tsujimura et al., 1994). This 
means that, if the IFs are absent, then there may be an increased availability of 
these cell cycle kinases to act on their usual substrates that are involved in the cell 
cycle, which can result in increased proliferation of cells. This is supported by 
studies that have shown that cultured cells without GFAP, or within astrocytoma 
that contain both GFAP-positive and GFAP-negative cells, the GFAP-negative 
fraction have a higher proliferation rate than cells that are GFAP positive, and 
GFAP negative astrocytes were often found to be a less-mature, blastic and more 
aggressive cell state (Hara et al., 1991; Weinstein et al., 1991; Kajiwara et al., 
1992; Rutka et al., 1994; Pekny et al., 1998; Lee et al., 2005). This is evident in 
glioblastoma multiforme, which is the most malignant and common form of 
glioma; it is highly invasive with rapid growth and low GFAP expression, whereas 
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high expression of GFAP is associated with low-grade astrocytomas (Lee et al., 
2005). Also, primary cultures of GFAP-/- astrocytes have been shown to produce a 
higher final cell saturation density (Pekny et al., 1998). However, in vivo, the loss 
of GFAP does not appear to produce an increase in the transformability of 
astrocytes (Weinstein et al., 1991; Rutka et al., 1994; Pekny et al., 1998). 
The mRNA results showed there were reductions in mRNA levels after treatment 
with the some of the selected OPs; therefore, to determine if epigenetic changes 
were involved, the nuclear extracts of differentiating N2a and C6 cells treated with 
CPF, CPO and PSP for 24 h were analysed for HDAC activity using a colorimetric 
assay. One of the key epigenetic gene regulation mechanisms in mammals is the 
control of histone acetylation; this process is carefully balanced by the activity of 
histone acetyl transferases (HATs) to increase histone acetylation, which is 
involved in the regulation of gene transcription. It is linked to the activity of 
histone deacetylase (HDAC), which induce histone hypoacetylation, causing gene 
silencing (Gallinari, 2007; Ropero and Esteller, 2007). HDACs have also been 
shown to regulate gene expression in other ways; they can join with nuclear 
receptors to form corepressor complexes in the absence of a ligand, or they can 
interact directly with transcription factors, including the retinoblastoma protein 
(Rb), p53, TFIIE, NF-kB, Stat3, and E2f, to regulate the expression of a large 
number of genes (Robertson et al., 2000; Lin et al., 2006; Gallinari, 2007).  
Studies have shown HDAC1 and HDAC2 are involved with transcription factors, 
and play a role in transcriptional repression regulated by Rb (Robertson et al., 
2000). Tumour development has been linked to mutations and altered expression 
of HDAC controlling genes, as changes in these genes can affect the transcription 
of genes that are important in apoptosis, cell-cycle regulation, and cell 
proliferation, which are all important in regulating crucial cellular functions 
(Gallinari, 2007; Ropero and Esteller, 2007). The activities of HDACs are tightly 
regulated through many mechanisms as they are vital cellular regulators, including 
modulation of deacetylase activity by protein-protein interactions, recruitment of 
different co-repressor complexes, and by post-translational modifications 
(Gallinari, 2007). HDACs are not only involved in histone deacetylation, they can 
also cause the deacetylation of other non-histone proteins as well as regulation of 
transcription and other biological processes. For example, HDAC1 has been shown 
to deacetylate p53 (the tumour suppressor) in vitro and in vivo which can be 
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important in cancer (Juan et al., 2000; Luo et al., 2000; Gallinari, 2007). Under 
stress conditions, p53 is usually phosphorylated and acetylated, with the acetylated 
p53 lysine residues overlapping with the ubiquitination site; acetylation increases 
protein activation and stability, which is important in permanent cell-division 
arrest, cell death and checkpoints in the cell-division cycle (Juan et al., 2000; Luo 
et al., 2000). Due to these roles, HDAC inhibitors are currently being designed and 
studied as a potential therapy for the treatment of cancer (Ropero and Esteller, 
2007).  
The findings of the current work showed that there was a significant, dose-
dependent increase in HDAC activity in both cell lines for all 3 concentrations of 
the 3 OPs, which would result in higher levels of heterochromatin meaning less 
transcription and lower levels of mRNA produced, and this can be linked to the 
reduced mRNA expression observed for some of the selected markers. Thus, 
HDACs have repressive effect on gene expression through restricting transcription 
factor access to monitoring regions (Gregoretti et al., 2004; Haberland et al., 
2009).  
There are some differences between the mRNA levels and the HDAC results; all 
the OPs caused changes in HDAC activity, but only some of the OPs affected the 
mRNA levels of the markers investigated, which suggests that the OPs do affect 
epigenetic factors and thereby cause the genotoxic effects observed, but the 
changes in the mRNA may not be solely due to the effects on HDAC.  
Overall, for the markers that matched for changes in mRNA and protein 
expression, the results suggest that the changes in protein were due at least partly 
to genotoxic effects, which could be due the effects of OPs on epigenetic factors, 
and that these changes produced the morphological differences observed, which 
provides new information about how OPs produce their toxic effects. 
Based on the results in the N2a and C6 cell lines, experiments were designed to 
investigate if similar effects of the OPs could be detected in the stem cell line 
ReNcell CX. The individual cell lines have provided a good insight into how the 
selected OPs affect cell viability, protein expression, mRNA and HDAC activity, 
but they don’t allow the interactions of the different neural cell types to be 
examined, whereas ReNcell CX cells can be induced to differentiate to form a co-
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culture of different glial and neuronal cell types, allowing the effects of the OPs to 
be studied in a more human-relevant system.  
Interestingly, after 24 h treatment, all concentrations of CPO lowered MTT 
reduction in the ReNcell CX cells, whereas there were no differences in this 
parameter for the N2a and C6 cells, which suggests the ReNcell CX cells are more 
sensitive than N2a or C6 cells to CPO. Whether or not this represents a metabolic 
effect rather than an effect on cell viability requires further investigation. 
After confirming the specificity of the human specific primers, mRNA expression 
for TUBB3, NEFH and GFAP was investigated in this human neural progenitor 
stem cell line. The OPs’ impact on neural markers genes share some similarities 
with the N2a and C6 cells, with TUBB3 in the ReNcell CX cells being more 
sensitive to CPF and CPO and less sensitive to PSP than in the N2a cells. On the 
other hand, NEFH in the ReNcell CX cells was more sensitive to PSP than it was 
in the N2a cells, and GFAP in C6 cells was more sensitive to all the OPs than it 
was the ReNcell CX cells. This suggests that the co-culture reacts differently in 
terms of the response of the individual cell types. A study of the cellular 
composition of the differentiating stem cell population would help to establish the 
extent to which the cells are differentiating at this time point in the human cell 
model, as undifferentiated stem cells may respond differently to establish rodent 
cell lines with predominantly one cell type. It may also be that different exposure 
and differentiation conditions are required to simulate a similar state of 
differentiation in RenCell CX cells as that attained by C6 and N2a cells. 
As there was evidence of changes in epigenetic factors in the N2a and C6 cells, the 
activity of HDAC was also investigated in differentiating ReNcell CX cells. The 
data obtained suggest that HDAC activity was increased with increasing the OP 
concentration but that the differences were not statistically significant in the human 
model.  This suggests that in the rodent cell lines there was a general decrease in 
transcription which resulted in reduced levels of mRNA.  The weaker effect in 
RenCell CX cells may reflect the complexity of the stem cell model, which 
requires investigation under a wider range of experimental conditions as discussed 
above. 
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7.2 Conclusions 
In conclusion the data reported in this thesis have established that: 
- Sub-lethal concentrations of CPF, CPO and CPF inhibit the outgrowth of 
neurites in differentiating N2a, C6 and RenCellCX cells; 
- Neurite inhibitory effects are associated with reduced levels of key 
cytoskeleton proteins in the axons and dendrites of differentiating N2a cells 
and of the intermediate filament protein GFAP in differentiating C6  cells; 
- Changes in mRNA levels account at least in part for changes in protein 
expression; 
- Inhibition of HDAC activity may contribute to the genotoxic effect of  OPs 
with known developmental neurotoxicity; 
- Similar changes in mRNA levels for βII tubulin, NF-H and GFAP were 
confirmed in a more human relevant model; 
- Thus, the OPs tested not only act through inhibition of AChE to produce 
neurotoxicity, but they also act through suppression of key cytoskeletal 
protein expression via genotoxic effects. The combination of the cell types 
in the ReNcell CX cell line provides a more human relevant response to the 
OPs as the two cell types can interact, and therefore this cell line is suitable 
for use in further studies to help elucidate the mechanisms of how OPs 
cause neurotoxicity (Figure 7.1).  
7.3 Future work  
Overall the work presented in this thesis that has shown the selected OPs can 
produce a neurotoxic effect, involving disruption of cytoskeletal proteins/genes 
that are important in neural development. The results also confirm that AChE 
inhibition is not the only way that OPs produce a neurotoxic effect. To further 
enhance these results, there are several areas that could be considered for future 
work: 
▪ Two Two-dimensional PAGE and MALDI-TOF mass spectrometry could be 
used after exposure to sub-cytotoxic concentrations of CPF, CPO and PSP, as 
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this would help identify the further changes in protein expression and identify 
any interacting proteins.  
▪ The levels of DNA damage after treatment with sub-cytotoxic concentrations 
of CPF, CPO and PSP could be determined using the Comet assay, as this 
would help to clarify the genotoxic effects of these OPs by combining these 
results with the changes in mRNA levels and epigenetic results. 
▪ It would also be of interest to investigate the ability of these OPs at sub-
cytotoxic concentrations to alter histone acetylation using anti-acetylated 
histone antibodies or to cause changes in other epigenetic factors, such as DNA 
methylation.  
▪ It would be interesting to analyse the promoter regions of those genes whose 
mRNA changes in the presence of OPs - to see if all those genes are controlled 
by the same transcription factors (as a possible mechanism: OP modifies 
transcription factor activity and, therefore, all genes dependent on that 
transcription factor are affected).   
▪ Studies have shown that about 5 % of CPF is converted to CPO in humans 
(Eyer et al., 2009; therefore the effects on neurite outgrowth of exposure to a 
mixture of CPF at a similar concentration to that used in this study with a much 
smaller amount of CPO, for example using a ratio of 1:20 CPO:CPF, together 
with longer exposure times merits investigation.  
▪ Longer differentiation times could be applied to achieve a more comprehensive 
model of developmental toxicity. Extending the exposure time with lower 
concentrations or using repeat exposures could also have an effect on the extent 
of neurotoxicity both in vitro and in vivo. 
▪ Similar approaches could also be used in N2a, C6 or ReNcell CX cells to 
investigate the effects of CPF, CPO and PSP on other neural markers such as 
(e.g. cofilin), which regulate microfilament dynamics in neural development , 
as such targets were found to be affected by diazinon exposure in previous 
work (Harris et al., 2009). 
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▪ Further studies could be carried out in the ReNcell CX cells by using the high 
throughput analysis system described in this thesis. The system could be 
optimised for other important biomarkers, such as choline acetyl transferase to 
detect changes in cholinergic neurons, tyrosine hydroxylase to detect changes 
in dopaminergic neurons, and myelin basic proteins to detect changes in 
oligodendrocytes exposure to CPF, CPO and PSP, and in comparison to non-
differentiated neural stem cells identified from monolayers counter-stained 
with anti-nestin antibodies.  
▪ Further studies could be performed on the mechanisms of “ switching off ” of 
GFAP expression or the level of regulations of transcription factors after OPs 
exposure on various of neural developmental models.  
▪ Further studies are also desirable with co-cultures or 3D culture models to 
enhance cell-cell interactions to simulate in vivo tissue organisation more 
closely. 
 
Figure 7.1. Schematic diagram of common CPF, CPO and PSP impacts on 
neural cells. 
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Synopsis of PhD thesis 
 
 
 
 
 
 
The objectives  
their associated gene expression ) 3proteins, expression of cytoskeletal 2) disruption of neurite outgrowth, 1) Evaluate the effects of the selected OPs on: 
ed gene expression changes by analysing histone deacetylation in cell models using to investigate the molecular mechanism(s) involved in alter 4)levels, and 
.N2a, C6 and ReNcell CX cell linesdifferentiating  
 
 
▪ What are the impacts of CPF, CPO or PSP on mammalian cell 
lines and human stem cells? 
▪ Are the alterations in proteins expression of neural markers 
associated with genotoxic effects of OPs?  
▪ Could OPs cause epigenetic impacts on the tested cell lines?  
▪ Are these changes responsible for the morphological 
differences or neurodegenerative effects? 
▪ OPs have been widely used as pesticides and in industrial 
applications.  
▪ These compounds caused neurotoxicity with the effects seen 
depending on the dose, age and route of exposure to the OP. 
▪ Sub-lethal concentrations of CPF, CPO and PSP inhibited 
axon outgrowth, disrupted the cytoskeleton in differentiating 
mouse N2a neuroblastoma cells.  
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Figure 8.1. Dose estimation of the effects of CPF,CPO and PSP on MTT reduction in 
differentiating N2a cells after 24 h.  
N2a cells were induced to different concentrations (1.53, 3.125, 6.25, 12.5, 25 µΜ) of CPF (panel 
A), CPO (panel B) and PSP (panel C), of induction of cell differentiation, and the levels of MTT 
reduction were measured to evaluate cell viability. Results are expressed as a mean percentage of 
the corresponding untreated control ± SEM from five separate experiments. Statistical significance 
of data was analysed using one way ANOVA. When an SEM bar is not apparent, the error is 
smaller than the symbol size (*p<0.05, ***p<0.001). 
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Figure 8.2. Dose estimation of the effects of CPF,CPO and PSP on MTT reduction in 
differentiating C6 cells after 24 h.  
C6 cells were induced to different concentrations (1.53, 3.125, 6.25, 12.5, 25 µΜ) of CPF (panel 
A), CPO (panel B) and PSP (panel C), of induction of cell differentiation, and the levels of MTT 
reduction were measured to evaluate cell viability. Results are expressed as a mean percentage of 
the corresponding untreated control ± SEM from five separate experiments. Statistical significance 
of data was analysed using one way ANOVA. When an SEM bar is not apparent, the error is 
smaller than the symbol size (*p<0.05, ***p<0.001). 
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Figure 8.3. Electropherogram data for MAP2 (panel A), TUBB3 (panel B), MAPT 
(panel C), NEFH (panel D) and GAP43 (panel E) PCR sequenced product in N2a cell 
lines.  
The bases represented by N (nucleotides) were replaced by the specific bases identified by coloured 
peaks (A) Adenine (Green), (G) Guanine (Black), (T) Thymine (Red), (C) Cytosine (Blue). 
 
Appendix     
232 
 
 
Figure 8.4. Electropherogram data for GFAP PCR sequenced product in C6 cell 
lines.  
The bases represented by N (nucleotides) were replaced by the specific bases identified by coloured 
peaks (A) Adenine (Green), (G) Guanine (Black), (T) Thymine (Red), (C) Cytosine (Blue). 
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B
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Figure 8.5. Sequences alignments.  
Examples of alignments matching cDNA and sequencing data for the genes in N2a cell lines: 
MAP2 (panel A), TUBB3 (panel B), MAPT (panel C), NEFH (panel D) and GAP43 (panel E).  
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Figure 8.6. Sequences alignments.  
Example of alignments matching between cDNA and sequencing data for GFAP in C6 cell line.  
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Figure 8.7. Electropherogram data for NEFM (panel A) and NEFL (panel B) PCR 
sequenced product in N2a cell lines.  
The bases represented by N (nucleotides) were replaced by the specific bases identified by coloured 
peaks (A) Adenine (Green), (G) Guanine (Black), (T) Thymine (Red), (C) Cytosine (Blue). 
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Figure 8.8. Sequences alignments. 
Example of alignments matching between cDNA and sequencing data for the genes in N2a cell 
lines: NEFM (panel A) and NEFL (panel B). 
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Figure 8. 1. Electropherogram data for TUBB3 (panel A), NEFH (panel B) and GFAP 
(panel C) PCR sequenced product in human ReNCells CX cell lines.  
The bases represented by N (nucleotides) were replaced by the specific bases identified by coloured 
peaks (A) Adenine (Green), (G) Guanine (Black), (T) Thymine (Red), (C) Cytosine (Blue). 
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Figure 8. 2. Sequences alignments. 
The alignments matching between cDNA and sequencing data for the genes in RenCells CX cell 
lines: TUBB3 (panel A), NEFH (panel B), GFAP (panel C).  
 
 
